Herbicide resistant plants

By introducing mutations at specific sites on the PPO enzyme, its resistance to herbicides is enhanced, solving the problem of herbicides affecting both crops and weeds in existing technologies, and enabling selective use of herbicides and control of weeds.

CN121002047APending Publication Date: 2025-11-21SYNGENTA CROP PROTECITON AG
View PDF 149 Cites 0 Cited by

Patent Information

Application Number
CN202480026770.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-04-19
Filing Date
2024-04-18
Publication Date
2025-11-21

AI Technical Summary

Technical Problem

Existing herbicides target the non-specific inhibition of PPO enzymes, resulting in simultaneous effects on crops and unwanted vegetation, making it difficult to effectively control weeds without damaging crops.

Method used

Plants resistant to PPO enzymes were prepared by introducing mutations at specific amino acid positions of PPO enzymes to enhance the enzyme's resistance to PPO inhibitory compounds. Undesirable vegetation was then controlled by applying PPO inhibitory compounds.

Benefits of technology

It achieves crop resistance to herbicides, effectively controls weeds without affecting crops, and improves the selective application effect of herbicides.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121002047A_ABST
    Figure CN121002047A_ABST
Patent Text Reader

Abstract

The present invention relates to modified protoporphyrinogen oxidase (PPO) or functional fragments thereof having increased resistance to PPO inhibiting compounds, plants or parts thereof comprising these modified PPO enzymes, uses thereof and methods of using these plants or parts thereof to control undesirable vegetation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to modified protoporphyrinogen oxidases (PPOs) having one or more mutations at specific amino acid positions that increase the enzyme's resistance to compounds that inhibit PPO, such as herbicides. The invention further relates to plants or portions thereof comprising modified PPO enzymes, methods for preparing such plants, and methods for controlling undesirable vegetation near said plants. Background Technology

[0002] This invention relates to the production of herbicide-resistant modified PPO enzymes, and to plants containing said enzymes.

[0003] Protoporphyrinogen oxidase (PPO) (EC 1.3.3.4) is a highly conserved eukaryotic enzyme that converts protoporphyrinogen IX to protoporphyrin IX. PPO is a flavoprotein located in the inner mitochondrial membrane that catalyzes the removal of six hydrogens (four from methylene bridges and two from cyclic nitrogen) to form protoporphyrin-IX. This involves a three-step, six-electron flavin-adenine dinucleotide-dependent oxidation that consumes molecular oxygen. It is crucial for mitochondrial heme function.

[0004] Herbicides of particular interest in agriculture include those that inhibit PPO enzymes, known as PPO-inhibiting herbicides. Given that heme function is crucial for plant survival, heme has been identified as a weeding target. Recently, effective herbicidal compounds that inhibit PPO enzymes have been developed. When exposed to plants, these herbicides cause cell death and ultimately lead to plant death. Industrially, herbicides are used in agriculture to remove unwanted vegetation, such as weeds from cultivated crops. However, non-specific herbicides that target essential pathways (such as those targeting heme synthesis) will affect both crops and unwanted vegetation, making them difficult to use without damaging valuable crops. Therefore, to use these herbicides effectively, it is desirable to protect crop plants, making them resistant to the herbicidal compounds. Herbicide-resistant plants can then be exposed to the herbicides without being affected, while non-resistant unwanted vegetation is affected and controlled.

[0005] Agricultural crop production often utilizes transgenic traits produced using biotechnological methods. A heterologous gene (also known as a transgene) can be introduced into a plant to produce a transgenic trait. Expression of the transgene in the plant confers traits such as herbicide tolerance. Herbicide tolerance allows the plant to grow, while non-tolerant weed species are eradicated through exposure to the herbicide. Examples of transgenic herbicide tolerance traits include glyphosate tolerance, glufosinate tolerance, and dicamba tolerance. With the increasing number of weed species resistant to commonly used herbicides, new herbicides and accompanying new herbicide tolerance traits are needed in the field. Given the various herbicides that target PPO that have been developed, there is a need to develop traits that confer tolerance to herbicides that inhibit PPO, which would be particularly useful in crops.

[0006] The present invention aims to solve one or more of the above-mentioned problems in the art. Summary of the Invention

[0007] According to a first aspect of the invention, a modified protoporphyrinogen oxidase (PPO) or a functional fragment thereof is provided, wherein the modified protoporphyrinogen oxidase or the functional fragment thereof contains at least one mutation at one or more amino acid residues selected from residues 362, 365 and / or 479 of SEQ ID NO:1 or their corresponding residues.

[0008] In a second aspect of the invention, a modified protoporphyrinogen oxidase (PPO) or a functional fragment thereof is provided, wherein the modified protoporphyrinogen oxidase or the functional fragment thereof comprises mutations at amino acid residues 305 and 426 or their corresponding residues of SEQ ID NO:1, wherein the mutation at amino acid residue 305 or its corresponding residue is a substitution to leucine (305L), and wherein the mutation at amino acid residue 426 or its corresponding residue is a substitution to valine (426V). In some embodiments, referring to SEQ ID NO:1 or its corresponding residues, the modified PPO enzyme comprises substitutions to S305L and Y426V. In some embodiments, referring to SEQ ID NO:2 or its corresponding residues, the modified PPO enzyme comprises substitutions to T305L and Y426V. In some embodiments, the modified PPO enzyme comprises or consists of the amino acid sequence according to SEQ ID NO:125. In some embodiments, the modified PPO enzyme comprises or consists of the amino acid sequence according to SEQ ID NO:139.

[0009] According to a third aspect of the invention, a nucleic acid is provided comprising a polynucleotide encoding a modified PPO enzyme or a functional fragment thereof according to the first or second aspect.

[0010] According to a fourth aspect of the invention, a recombinant vector comprising nucleic acids according to the third aspect is provided.

[0011] According to a fifth aspect of the invention, a plant or a portion thereof is provided, the plant or the portion thereof comprising a modified PPO enzyme or a functional fragment thereof according to the first or second aspect, a nucleic acid according to the third aspect, or a recombinant vector according to the fourth aspect.

[0012] According to a sixth aspect of the invention, a method for producing a plant or a portion thereof according to a fifth aspect is provided, the method comprising: modifying the plant or a portion thereof to contain a PPO enzyme according to a first or second aspect.

[0013] According to a seventh aspect of the invention, a method is provided for controlling undesirable vegetation in the vicinity of a plant or part thereof according to the fifth aspect or at a location where a plant grows according to the fifth aspect, the method comprising applying an effective amount of at least one compound that inhibits PPO enzyme to the undesirable vegetation, plant or part thereof, and / or location, and / or optionally planting seeds at the location, wherein the seeds are capable of producing a plant according to the fifth aspect.

[0014] The invention will now be further described in the following heading section, and features under any given section may be adapted in any combination to any embodiment or aspect. Detailed Implementation

[0015] Modified PPO enzyme

[0016] This invention relates primarily to modified protoporphyrinogen oxidases (PPOs) that exhibit increased resistance to compounds such as herbicides compared to wild-type or control PPO enzymes.

[0017] As used herein, references to “PPO enzyme” or “modified PPO enzyme” and their amino acid sequences also refer to and are intended to encompass isolated polynucleotides encoding such enzymes. The terms “modified polynucleotide,” “mutated polynucleotide,” “mutated polypeptide,” or “modified polypeptide” refer to polynucleotides or polypeptides that have been altered through artificial intervention. Such “mutated polynucleotide,” “modified polynucleotide,” “mutated polypeptide,” or “modified polypeptide” have a sequence that differs from the sequence of the corresponding unmutated or unmodified polynucleotide or polypeptide (e.g., wild-type or naturally occurring polynucleotide or polypeptide) by at least one nucleotide or amino acid. In some instances, the mutated or modified polynucleotide contains alterations caused by a guiding polynucleotide / Cas endonuclease system as disclosed herein.

[0018] Protoporphyrinogen oxidase (PPO) is a key enzyme in the biosynthesis of protoporphyrin IX. PPO catalyzes the final common step in the biosynthesis of chlorophyll and heme, namely, the oxidation of protoporphyrinogen IX to protoporphyrin IX (Matringe et al. 1989. Biochem. 1. [Biochemistry 1] 260: 231). Inhibition of protoporphyrinogen oxidase is the mechanism of action of several commercial herbicides, including nitrophenyl ethers such as trifluralin and flufenacet, and pyrimidinide such as flufenacet and pyrimisulfuron. Visible symptoms of treatment are wilting and drying. The damage is caused by the inhibition of protoporphyrinogen oxidase in the tetrapyrrole biosynthetic pathway, leading to the accumulation of protoporphyrin IX in plant cells. In plants, it is encoded by two nuclear-localized homologous genes (PPOX1 and PPOX2). PPOX1 targets plastids only, providing protoporphyrin for heme and chlorophyll synthesis, while PPOX2 has been found in the plastid membrane and mitochondria of spinach. However, tobacco PPOX2 appears to be a mitochondrial protein only.

[0019] Suitablely, PPO enzymes have been modified to suitably increase enzyme activity within the plant or its parts. Suitablely, the plant may have been modified to contain modified PPO enzymes that, when compared with unmodified (suitably wild-type) PPO enzymes, suitably have increased activity within the plant or its parts.

[0020] Suitable, the activity of the modified PPO enzyme is increased to the point that it provides the plant with an increased level of resistance to compounds that inhibit PPO enzyme activity relative to the unmodified enzyme or the control enzyme.

[0021] Suitable, the activity of the modified PPO enzyme is increased to the point that it provides the plant with an increased level of resistance to compounds that inhibit PPO enzyme activity relative to the unmodified enzyme or the control enzyme.

[0022] Suitablely, when exposed to compounds that inhibit PPO enzyme activity, the activity of the modified PPO enzyme increases to a level that is at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, or at least 150% higher than its activity in unmodified or control plants.

[0023] Appropriately, the increase in enzyme activity can be measured by enzyme assays, which appropriately measure the consumption of substrate or the production of product over time in an in vitro environment. Such assays can be spectrophotometric, fluorescence-based, calorimetric, chemiluminescent, light scattering, or microscale thermophoresis.

[0024] Suitablely, the modified PPO enzyme contains one or more modifications, suitablely one or more mutations. Suitablely, the one or more mutations are selected from deletions, insertions, substitutions, etc. A mutation is any substitution, deletion, or insertion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more amino acids.

[0025] The modified PPO enzyme can be a modified PPO1 enzyme.

[0026] The modified PPO enzyme may include at least one amino acid modification at any one of amino acid positions 362, 365 and / or 479 of SEQ ID NO:1 or at the corresponding residue.

[0027] Suitablely, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with the amino acid sequence of SEQ ID NO: 1, 2, 4-151, 153-302, or 305-336, respectively. Suitablely, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the amino acid sequence of SEQ ID NO: 1, 2, 4-151, 153-302, or 305-336, respectively. Suitably, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or 100% identity with the amino acid sequence of SEQ ID NO: 37-39, 58, 59, 97-99, 118, 119, 125-137, 139-151, 188-190, 209, 210, 248-250, 269, 270, 277-288 or 291-302. Suitablely, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the amino acid sequences of SEQ ID NO: 37-39, 58, 59, 97-99, 118, 119, 125-137, 139-151, 188-190, 209, 210, 248-250, 269, 270, 277-288, or 291-302, respectively.

[0028] Suitably, the modified PPO enzyme may contain the components corresponding to SEQ ID NO: 58, 59, 126, 127, 130, 131, 132, 134, 136, 137, 209, 210, 277, 278, 281, 282, 283, 285, 287, 288, 118, 119, 140, 141, 144, 145, 146, 148, 150, 151, 269, 270, 291, 292, 295, 296, 297, 299, 301, or 302, respectively. The amino acid sequence has an amino acid sequence or functional fragment of at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or 100% identity. Suitably, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof that is at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequences of SEQ ID NO: 58, 59, 126, 127, 130, 131, 132, 134, 136, 137, 209, 210, 277, 278, 281, 282, 283, 285, 287, 288, 118, 119, 140, 141, 144, 145, 146, 148, 150, 151, 269, 270, 291, 292, 295, 296, 297, 299, 301, or 302.

[0029] Suitablely, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or 100% identity with the amino acid sequence of SEQ ID NO: 125, 139, 276, 290, 126, 131, 134, 140, 145, 148, 277, 282, 285, 291, 296, or 299, respectively. Suitablely, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the amino acid sequence of SEQ ID NO: 125, 139, 276, 290, 126, 131, 134, 140, 145, 148, 277, 282, 285, 291, 296, or 299, respectively.

[0030] Suitablely, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or 100% identity with the amino acid sequence of SEQ ID NO: 125, 126, 127, 131, 132, 134, 276, 277, 278, 282, 283, 285, 139, 140, 141, 145, 146, 148, 290, 291, 292, 296, 297, or 299, respectively. Suitablely, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the amino acid sequence of SEQ ID NO: 125, 126, 127, 131, 132, 134, 276, 277, 278, 282, 283, 285, 139, 140, 141, 145, 146, 148, 290, 291, 292, 296, 297, or 299, respectively. Suitablely, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or 100% identity with the amino acid sequence of SEQ ID NO: 125, 131, 134, 139, 145, 148, 276, 282, 285, 290, 296 or 299, respectively. Suitablely, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the amino acid sequence of SEQ ID NO: 125, 131, 134, 139, 145, 148, 276, 282, 285, 290, 296, or 299, respectively.

[0031] Suitably, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity or 100% identity with the amino acid sequence of SEQ ID NO: 125, 139, 276, or 290, respectively. Suitably, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the amino acid sequence of SEQ ID NO: 125, 139, 276, or 290, respectively.

[0032] Suitably, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity or 100% identity with the amino acid sequence of SEQ ID NO: 131, 145, 282, or 296, respectively. Suitably, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the amino acid sequence of SEQ ID NO: 131, 145, 282, or 296, respectively.

[0033] Suitably, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity or 100% identity with the amino acid sequence of SEQ ID NO: 126, 140, 277, or 291. Suitably, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the amino acid sequence of SEQ ID NO: 126, 140, 277, or 291.

[0034] Suitably, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity or 100% identity with the amino acid sequence of SEQ ID NO: 134, 148, 285, or 299. Suitably, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the amino acid sequence of SEQ ID NO: 134, 148, 285, or 299.

[0035] Suitably, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity or 100% identity with the amino acid sequence of SEQ ID NO: 132, 283, 146, or 297, respectively. Suitably, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the amino acid sequence of SEQ ID NO: 132, 283, 146, or 297, respectively.

[0036] Suitably, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity or 100% identity with the amino acid sequence of SEQ ID NO: 127, 278, 141, or 292. Suitably, the modified PPO enzyme may comprise an amino acid sequence or a functional fragment thereof having at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the amino acid sequence of SEQ ID NO: 127, 278, 141, or 292.

[0037] In one embodiment, the modified PPO enzyme may be derived from Arabidopsis thaliana. In another embodiment, the modified PPO enzyme may be derived from millet (Setaria italica).

[0038] The modified PPO enzyme of the present invention may contain the amino acid sequence according to SEQ ID NO:1 (Arabidopsis PPO), wherein residues at positions 362, 365 and / or 479 or their corresponding residues have been modified.

[0039] The modified PPO enzyme of the present invention may comprise the amino acid sequence according to SEQ ID NO:2 (millet PPO), wherein positions 360, 363 and / or 477 or their corresponding residues have been modified. Positions 360, 363 and 477 correspond to positions 362, 365 and 479 of SEQ ID NO:1, respectively.

[0040] The modified PPO enzyme of the present invention may comprise the amino acid sequence according to SEQ ID NO:1 (Arabidopsis PPO), wherein residues at positions 305 and / or 426 or their corresponding positions have been modified, suitably leucine and valine, respectively.

[0041] The modified PPO enzyme of the present invention may comprise the amino acid sequence according to SEQ ID NO:2 (millet PPO), wherein residues at positions 303 and / or 424 or their corresponding residues have been modified, suitably leucine and valine, respectively.

[0042] For example, the modified PPO enzyme of the present invention may comprise the amino acid sequence according to SEQ ID NO:1 (Arabidopsis PPO), wherein position 362 has been modified.

[0043] For example, the modified PPO enzyme of the present invention may comprise the amino acid sequence according to SEQ ID NO:1 (Arabidopsis PPO), wherein position 365 has been modified.

[0044] For example, the modified PPO enzyme of the present invention may comprise the amino acid sequence according to SEQ ID NO:1 (Arabidopsis PPO), wherein position 479 has been modified.

[0045] For example, the modified PPO enzyme of the present invention may comprise the amino acid sequence according to SEQ ID NO:2 (millet PPO), wherein position 360 has been modified.

[0046] For example, the modified PPO enzyme of the present invention may comprise the amino acid sequence according to SEQ ID NO:2 (millet PPO), wherein position 363 has been modified.

[0047] For example, the modified PPO enzyme of the present invention may comprise the amino acid sequence according to SEQ ID NO:2 (millet PPO), wherein position 477 has been modified.

[0048] Suitably, the modified PPO of the present invention may comprise an amino acid sequence having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 98%, or at least 99% sequence identity with the amino acid sequence according to SEQ ID NO: 1, wherein at least one of positions 362, 365, and 479, or the corresponding position thereon, has been modified.

[0049] Suitably, the modified PPO of the present invention may comprise an amino acid sequence having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 98%, or at least 99% sequence identity with the amino acid sequence according to SEQ ID NO: 2, wherein at least one of positions 360, 363, and 477, or the corresponding position thereon, has been modified.

[0050] Suitablely, the modified PPO of the present invention may comprise one or more amino acid sequence motifs as listed in Table 27.

[0051] Suitably, position 362 of SEQ ID NO: 1 or its corresponding position may be substituted with cysteine. In some instances, position 362 of SEQ ID NO: 1 or its corresponding position may be substituted with phenylalanine. Suitably, position 360 of SEQ ID NO: 2 or its corresponding position may be substituted with cysteine. In some instances, position 360 of SEQ ID NO: 2 or its corresponding position may be substituted with phenylalanine.

[0052] Suitablely, position 365 of SEQ ID NO: 1 or its corresponding position may be substituted with methionine. In some instances, position 365 of SEQ ID NO: 1 or its corresponding position may be substituted with leucine. Suitablely, position 363 of SEQ ID NO: 2 or its corresponding position may be substituted with methionine. In some instances, position 363 of SEQ ID NO: 2 or its corresponding position may be substituted with leucine.

[0053] Suitablely, position 479 of SEQ ID NO: 1 or its corresponding position may be substituted with methionine. In some instances, position 479 of SEQ ID NO: 1 or its corresponding position may be substituted with asparagine. Suitablely, position 477 of SEQ ID NO: 2 or its corresponding position may be substituted with methionine. In some instances, position 477 of SEQ ID NO: 2 or its corresponding position may be substituted with asparagine.

[0054] In some instances, in addition to those detailed above, the modified PPO of the present invention may also include one or more additional modifications. For example, modifications of any one of amino acid residues 305, 361, 404, 426, 431 and / or 461 of SEQ ID NO: 1, or their corresponding residues.

[0055] Suitablely, residue 305 of SEQ ID NO: 1 or its corresponding residue may be replaced by leucine.

[0056] Suitablely, residue 361 of SEQ ID NO: 1 or its corresponding residue may be substituted with threonine. Suitablely, residue 361 of SEQ ID NO: 1 or its corresponding residue may be substituted with cysteine. Suitablely, residue 361 of SEQ ID NO: 1 or its corresponding residue may be substituted with aspartic acid. Suitablely, residue 361 of SEQ ID NO: 1 or its corresponding residue may be substituted with glutamine.

[0057] Suitablely, residue 404 of SEQ ID NO: 1 or its corresponding residue may be replaced by alanine.

[0058] Suitablely, residue 426 of SEQ ID NO: 1 or its corresponding residue may be substituted with leucine. Suitablely, residue 426 of SEQ ID NO: 1 or its corresponding residue may be substituted with cysteine. Suitablely, residue 426 of SEQ ID NO: 1 or its corresponding residue may be substituted with threonine. Suitablely, residue 426 of SEQ ID NO: 1 or its corresponding residue may be substituted with valine. Suitablely, residue 426 of SEQ ID NO: 1 or its corresponding residue may be substituted with methionine.

[0059] Suitablely, residue 431 of SEQ ID NO: 1 or its corresponding residue may be substituted with phenylalanine. Suitablely, residue 431 of SEQ ID NO: 1 or its corresponding residue may be substituted with alanine. Suitablely, residue 431 of SEQ ID NO: 1 or its corresponding residue may be substituted with arginine.

[0060] Suitablely, residue 461 of SEQ ID NO: 1 or its corresponding residue may be substituted with glutamine.

[0061] For example, modification of any one of amino acid residues 303, 359, 402, 424, 429 and / or 459 of SEQ ID NO: 2, or a corresponding residue thereof.

[0062] Suitablely, residue 303 of SEQ ID NO: 2 or its corresponding residue may be replaced by leucine.

[0063] Suitablely, residue 359 of SEQ ID NO: 2 or its corresponding residue may be substituted with threonine. Suitablely, residue 359 of SEQ ID NO: 2 or its corresponding residue may be substituted with cysteine. Suitablely, residue 359 of SEQ ID NO: 2 or its corresponding residue may be substituted with aspartic acid. Suitablely, residue 359 of SEQ ID NO: 2 or its corresponding residue may be substituted with glutamine.

[0064] Suitable, residue 402 of SEQ ID NO: 2 or its corresponding residue may be replaced by alanine.

[0065] Suitablely, residue 424 of SEQ ID NO: 2 or its corresponding residue may be substituted with leucine. Suitablely, residue 424 of SEQ ID NO: 2 or its corresponding residue may be substituted with cysteine. Suitablely, residue 424 of SEQ ID NO: 2 or its corresponding residue may be substituted with threonine. Suitablely, residue 424 of SEQ ID NO: 2 or its corresponding residue may be substituted with valine. Suitablely, residue 424 of SEQ ID NO: 2 or its corresponding residue may be substituted with methionine.

[0066] Suitablely, residue 429 of SEQ ID NO: 2 or its corresponding residue may be substituted with phenylalanine. Suitablely, residue 429 of SEQ ID NO: 2 or its corresponding residue may be substituted with asparagine.

[0067] Suitable, residue 459 of SEQ ID NO: 2 or its corresponding residue may be substituted with glutamine.

[0068] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 365, 426, and 479 of SEQ ID NO: 1 or at their corresponding residues.

[0069] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 305, 404, 426, 431 and 479 of SEQ ID NO: 1 or at their corresponding residues.

[0070] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 305 and 365 of SEQ ID NO: 1 or at their corresponding residues.

[0071] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 305, 362, and 404 of SEQ ID NO: 1 or their corresponding residues.

[0072] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 305, 361, 365, 431 and 479 of SEQ ID NO: 1 or at their corresponding residues.

[0073] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 305, 426, and 479 of SEQ ID NO: 1 or at their corresponding residues.

[0074] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 426, 461, and 479 of SEQ ID NO: 1 or their corresponding residues.

[0075] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 305, 361, and 365 of SEQ ID NO: 1 or at their corresponding residues.

[0076] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 305, 361, 362, 426 and 479 of SEQ ID NO: 1 or at their corresponding residues.

[0077] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 361 and 365 of SEQ ID NO: 1 or at their corresponding residues.

[0078] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 365, 404, and 479 of SEQ ID NO: 1 or their corresponding residues.

[0079] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 305, 404, and 479 of SEQ ID NO: 1 or their corresponding residues.

[0080] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 305 and 426 of SEQ ID NO: 1 or at their corresponding residues.

[0081] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 363, 424, and 477 of SEQ ID NO: 2 or at their corresponding residues.

[0082] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 303, 402, 424, 429 and 477 of SEQ ID NO: 2 or at their corresponding residues.

[0083] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 303 and 363 of SEQ ID NO: 2 or at their corresponding residues.

[0084] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 303, 360, and 402 of SEQ ID NO: 2 or at their corresponding residues.

[0085] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 303, 359, 363, 429 and 477 of SEQ ID NO: 2 or at their corresponding residues.

[0086] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 303, 424, and 477 of SEQ ID NO: 2 or at their corresponding residues.

[0087] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 424, 459, and 477 of SEQ ID NO: 2 or at their corresponding residues.

[0088] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 303, 359, and 363 of SEQ ID NO: 2 or at their corresponding residues.

[0089] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 303, 359, 360, 424 and 477 of SEQ ID NO: 2 or at their corresponding residues.

[0090] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 359 and 363 of SEQ ID NO: 2 or at their corresponding residues.

[0091] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 363, 402, and 477 of SEQ ID NO: 2 or at their corresponding residues.

[0092] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 303, 402, and 477 of SEQ ID NO: 2 or at their corresponding residues.

[0093] In some instances, the modified PPO enzyme may include modifications at amino acid residue positions 303 and 424 of SEQ ID NO: 2 or at their corresponding residues.

[0094] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 37 (wherein, compared with SEQ ID NO: 1, this amino acid sequence includes the substitution Y362F). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 37. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 37. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 37. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 37.

[0095] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 38 (wherein, compared with SEQ ID NO: 1, this amino acid sequence includes the substitution V365L). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 38. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 38. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 38. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 38.

[0096] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 39 (wherein, compared with SEQ ID NO: 1, this amino acid sequence includes the substitution V365M). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 39. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 39. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 39. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 39.

[0097] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 58 (wherein, compared with SEQ ID NO: 1, this amino acid sequence includes the substitution L479M). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 58. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 58. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 58. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 58.

[0098] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 59 (wherein, compared with SEQ ID NO: 1, this amino acid sequence includes the substitution L479N). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 59. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 59. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 59. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 59.

[0099] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 97 (wherein, compared with SEQ ID NO: 2, this amino acid sequence includes the substitution Y360F). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 97. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 97. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 97. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 97.

[0100] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 98 (wherein, compared with SEQ ID NO: 2, this amino acid sequence includes the substitution V363L). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 98. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 98. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 98. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 98.

[0101] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 99 (wherein, compared with SEQ ID NO: 2, this amino acid sequence includes the substitution V363M). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 99. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 99. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 99. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 99.

[0102] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 118 (wherein, compared with SEQ ID NO: 2, this amino acid sequence includes the substitution V477M). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 118. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 118. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 118. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 118.

[0103] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 119 (wherein, compared with SEQ ID NO: 2, this amino acid sequence includes the substitution V477N). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 119. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 119. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 119. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 119.

[0104] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 125 (wherein, compared with SEQ ID NO: 1, this amino acid sequence includes the substitutions S305L and Y426V). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 125. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 125. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 125. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 125.

[0105] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 126 (wherein, compared with SEQ ID NO: 1, this amino acid sequence includes substitutions V365L, Y426V, and L479N). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 126. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 126. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 126. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 126.

[0106] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 127 (wherein, compared with SEQ ID NO: 1, this amino acid sequence includes substitutions of S305L, G404A, Y426V, T431R, and L479N). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 127. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 127. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 127. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 127.

[0107] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 128 (wherein, compared with SEQ ID NO: 1, this amino acid sequence includes the substitutions S305L and V365M). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 128. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 128. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 128. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 128.

[0108] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 129 (wherein, compared with SEQ ID NO: 1, this amino acid sequence includes substitutions of S305L, Y362F, and G404A). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 129. The modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 129. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 129. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 129.

[0109] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 130 (wherein, compared with SEQ ID NO: 1, this amino acid sequence includes substitutions of S305L, Y361T, V365L, T431R, and L479M). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 130. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 130. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 130. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 130.

[0110] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 131 (wherein, compared with SEQ ID NO: 1, this amino acid sequence includes substitutions S305L, Y426V, and L479M). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 131. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 131. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 131. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 131.

[0111] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 132 (wherein, compared with SEQ ID NO: 1, this amino acid sequence includes substitutions Y426M, T461Q, and L479M). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 132. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 132. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 132. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 132.

[0112] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 133 (wherein, compared with SEQ ID NO: 1, this amino acid sequence includes substitutions of S305L, Y361D, and V365M). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 133. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 133. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 133. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 133.

[0113] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 134 (wherein, compared with SEQ ID NO: 1, this amino acid sequence includes substitutions of S305L, Y361C, Y362F, Y426M, and L479M). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 134. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 134. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 134. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 134.

[0114] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 135 (wherein, compared with SEQ ID NO: 1, this amino acid sequence includes substituted Y361D and V365L). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 135. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 135. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 135. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 135.

[0115] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 136 (wherein, compared with SEQ ID NO: 1, this amino acid sequence includes substitutions V365L, G404A, and L479N). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 136. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 136. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 136. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 136.

[0116] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 137 (wherein, compared with SEQ ID NO: 1, this amino acid sequence includes substitutions S305L, G404A, and L479N). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 137. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 137. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 137. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 137.

[0117] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 138 (wherein, compared with SEQ ID NO: 2, this amino acid sequence includes the substitutions T303L and Y424M). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 138. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 138. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 138. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 138.

[0118] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 139 (wherein, compared with SEQ ID NO: 2, this amino acid sequence includes the substitutions T303L and Y424V). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 139. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 139. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 139. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 139.

[0119] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 140 (wherein, compared with SEQ ID NO: 2, this amino acid sequence includes substitutions of V363L, Y424V, and L477N). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 140. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 140. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 140. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 140.

[0120] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 141 (wherein, compared with SEQ ID NO: 2, this amino acid sequence includes substitutions of T303L, G402A, Y424V, T429R, and L477N). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 141. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 141. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 141. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 141.

[0121] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 142 (wherein, compared with SEQ ID NO: 2, this amino acid sequence includes the substitutions T303L and V363M). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 142. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 142. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 142. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 142.

[0122] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 143 (wherein, compared with SEQ ID NO: 2, this amino acid sequence includes substitutions of T303L, Y360F, and G402A). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 143. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 143. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 143. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 143.

[0123] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 144 (wherein, compared with SEQ ID NO: 2, this amino acid sequence includes substitutions of T303L, Y359T, V363L, T429R, and L477M). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 144. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 144. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 144. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 144.

[0124] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 145 (wherein, compared with SEQ ID NO: 2, this amino acid sequence includes substitutions of T303L, Y424V, and L477M). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 145. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 145. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 145. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 145.

[0125] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 146 (wherein, compared with SEQ ID NO: 2, this amino acid sequence includes substitutions Y424M, V459Q, and L477M). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 146. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 146. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 146. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 146.

[0126] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 147 (wherein, compared with SEQ ID NO: 2, this amino acid sequence includes substitutions of T303L, Y359D, and V363M). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 147. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 147. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 147. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 147.

[0127] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 148 (wherein, compared with SEQ ID NO: 2, this amino acid sequence includes substitutions of T303L, Y359C, Y360F, Y424M, and L477M). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 148. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 148. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 148. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 148.

[0128] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 149 (wherein, compared with SEQ ID NO: 2, this amino acid sequence includes the substitutions Y359D and V363L). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 149. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 149. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 149. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 149.

[0129] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 150 (wherein, compared with SEQ ID NO: 2, this amino acid sequence includes substitutions V363L, G402A, and L477N). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 150. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 150. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 150. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 150.

[0130] Suitably, the modified PPO may have an amino acid sequence having at least 30% sequence identity with SEQ ID NO: 151 (wherein, compared with SEQ ID NO: 2, this amino acid sequence includes substitutions T303L, G402A, and L477N). Suitably, the modified PPO may have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 151. Suitably, the modified PPO may have an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with SEQ ID NO: 151. Suitably, the modified PPO may comprise the amino acid sequence according to SEQ ID NO: 151. Suitably, the modified PPO may consist substantially of the amino acid sequence according to SEQ ID NO: 151.

[0131] In any aspect of the invention as described herein, a PPO enzyme resistant (whether partially or completely) to compounds that inhibit PPO enzyme activity may comprise the same SEQ ID NO disclosed herein. 1 or 2 or any modified PPO (which may also be referred to as the reference sequence) having at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity amino acid.

[0132] In any aspect of this invention, a modified PPO enzyme resistant to compounds that inhibit PPO enzyme activity can be a homolog of any one of SEQ ID NO: 1, 2, 4-151, 153-302, or 305-336. As used herein, “homolog” means a functionally equivalent protein, i.e., having the same enzymatic activity (i.e., acting as a PPO enzyme as defined herein) as an enzyme having the amino acid sequence according to SEQ ID NO 1, 2, 4-151, 153-302, or 305-336, but possibly having a limited number of amino acid substitutions, deletions, insertions, or additions in the amino acid sequence. Homologs need not exhibit the same level of enzymatic activity. Homologs may have a low sequence identity with the PPO enzymes identified herein, for example, at least 20%, at least 25%, at least 30%, at least 35%, or at least 40% or higher sequence identity, but be capable of performing the same enzymatic reactions. Therefore, this invention includes any isotype of PPO enzymes as defined herein and their mutations.

[0133] "Identity" or "percentage identity" refers to the degree of sequence variation between two given nucleic acid or amino acid sequences. For sequence comparison, typically, one sequence serves as a reference sequence to be compared with the test sequence. When using a sequence comparison algorithm, the test and reference sequences are input into the computer (with subsequence coordinates specified if necessary), and the parameters of the sequence comparison algorithm program are specified. The sequence comparison algorithm then calculates the percentage of sequence identity of this or these test sequences relative to the reference sequence based on the specified program parameters. The optimal alignment of sequences for comparison can be achieved, for example, by the local homology algorithm of Smith and Waterman, Adv. Appl. Math. 2: 482 (1981), the homology alignment algorithm of Needleman and Wunsch, J. Mol. Biol. 48:443 (1970), the similarity finding method of Pearson and Lipman, Proc. Nat'l. Acad. Sci. USA 85: 2444 (1988), by the computerized implementation of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package of the Genetics Computer Group at 575 Science Dr., Madison, WI), or by visual inspection. One example of an algorithm suitable for determining sequence identity percentages and sequence similarity is the BLAST algorithm, described in Altschul et al., J. Mol. Biol. [Journal of Molecular Biology] 215: 403-410 (1990). Software for performing BLAST analysis is publicly available from the National Center for Biotechnology Information (NCBI) (on the world-wide web at ncbi.nlm.nih.gov / ). This algorithm involves first identifying high-scoring sequence pairs (HSPs) by recognizing short codewords of length W in the query sequence. These high-scoring sequence pairs match or satisfy a positive threshold score T when compared to codewords of the same length in a database sequence. T is called the nearest neighbor codeword score threshold (Altschul et al., J. Mol. Biol. [Journal of Molecular Biology] 215: 403-410 (1990)).These initial neighboring codeword hits serve as seeds to initiate the search for longer HSPs containing them. These codeword hits are then extended in both directions along each sequence until the cumulative alignment score can increase. For nucleotide sequences, the cumulative score is calculated using parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatched residues; always < 0). For amino acid sequences, a score matrix is ​​used to calculate the cumulative score. Extension of these codeword hits in each direction stops when the cumulative alignment score decreases by an amount X from its maximum value; when the cumulative score tends to 0 or below due to the accumulation of one or more negative score residue alignments; or when the end of either sequence is reached. The parameters W, T, and X of the BLAST algorithm determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses a word length (W) of 11, an expected value (E) of 10, a cutoff of 100, M = 5, N = -4, and two-strand comparisons as default values. For amino acid sequences, the BLASTP program uses a word length (W) of 3, an expected value (E) of 10, and a BLOSUM62 scoring matrix as default values ​​(see Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences] 89: 10915 (1989)). In addition to calculating the percentage of sequence identity, the BLAST algorithm also performs a statistical analysis of similarity between two sequences (see, for example, Karlin and Altschul, Proc. Nat'l. Acad. Sci. USA [Proceedings of the National Academy of Sciences] 90: 5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the minimum sum probability (P(N)), which provides an indication of the probability that a match will occur by chance between two nucleotide or amino acid sequences. For example, if the minimum sum probability in a comparison of the test nucleic acid sequence with a reference nucleic acid sequence is less than approximately 0.1, the test nucleic acid sequence is considered similar to the reference sequence. In one embodiment, it is less than about 0.01, and in another embodiment, it is less than about 0.001.

[0134] Unless otherwise stated, percentage identity as used herein refers to values ​​obtained using the Needleman and Wunsch algorithm ((1970) J. Mol. Biol. [Molecular Biology Journal] 48:443-453) implemented in the EMBOSS Needle alignment tool, using the default matrix file EBLOSUM62 (for proteins) and default parameters (vacancy open = 10, vacancy extension = 0.5, terminal vacancy penalty = false, terminal vacancy open = 10, terminal vacancy extension = 0.5) or DNAfull (for nucleic acids) and default parameters (vacancy open = 10, vacancy extension = 0.5, terminal vacancy penalty = false, terminal vacancy open = 10, terminal vacancy extension = 0.5); or any equivalent procedure thereof. The EMBOSS Needle is available, for example, from EMBL-EBI, at ebi.ac.uk / Tools / psa / emboss_needle / and as stated in the publication: “The EMBL-EBI search and sequence analysis tools APIs in 2019.” Madeira et al., Nucleic Acids Research, June 2019, 47(W1):W636-W641. As used herein, the term “equivalent procedure” refers to any sequence comparison procedure that, for any two sequences in question, produces alignments with the same nucleotide or amino acid residue matches and the same percentage of sequence identity when compared to the corresponding alignments generated by the EMBOSS Needle.

[0135] The PPO enzyme encoded by nucleic acid, or the PPO enzyme of the present invention, can be a functional fragment of the PPO enzyme as described herein. A “functional fragment” refers to a protein fragment that retains the protein’s function. Therefore, the functional fragment of the PPO enzyme is a fragment or part of the PPO protein that can still catalyze the oxidation of the 6-electron of protoporphyrin-IX to form protoporphyrin-IX.

[0136] Mutations as defined herein can be located at positions that 'correspond' to the amino acid positions listed in another PPO enzyme. PPO peptides can be compared by sequence comparison and locating conserved regions corresponding to the listed amino acid positions. The terms "equivalent amino acid" or "corresponding amino acid" refer to amino acids in the target sequence that correspond to those amino acids in the identified reference sequence, typically SEQ ID NO: 1 or 2 of the PPO enzyme. Equivalent amino acids or regions of corresponding amino acids can be determined by comparing amino acid sequences of proteins from different species using alignment programs such as BLAST® or ClustalW. Note that the corresponding position in the target sequence should be determined by comparison with similar positions in a similar reference sequence. If it is necessary to determine the corresponding position in a PPO enzyme lacking the target peptide, the reference PPO sequence should also lack the target peptide. Suitably, in such embodiments, the reference sequence used herein may be SEQ ID NO: 1, 2 (with a transport peptide), 153, or 154 (without a transport peptide). Any amino acid positions listed herein regarding PPO enzyme sequences containing a target peptide still apply to PPO enzyme sequences from the same organism that do not contain the target peptide.

[0137] Geneious is used as a global comparison of free-end vacancies with the following parameters to determine the “corresponding” amino acid position for a given SEQ ID NO: cost matrix Blossum 62, vacancy opening penalty 12, vacancy extension penalty 3, refinement iteration 2; or its equivalent procedure.

[0138] Unless otherwise stated, the “corresponding” amino acid position for a given SEQ ID NO is determined using the EMBOSS Needle default parameters: BLOSUM62; vacancy open 10, vacancy extended 0.5; terminal vacancy open 10 and terminal vacancy extended 0.5, or equivalent procedures thereof. See Madeira et al. (2022) Nucleic Acids Research, July 1, 2022, 50(W1): W276-W279; PMID: 35412617 PMCID: PMC9252731. As used herein, the term “equivalent procedure” refers to any sequence comparison procedure that, for any two sequences in question, produces alignments with the same corresponding nucleotide or amino acid residue matches when compared to the corresponding alignments produced by the procedure provided above.

[0139] Mutations can include deletions, substitutions, or combinations thereof. For example, a mutation can be a conserved or non-conserved amino acid substitution.

[0140] "Conservative amino acid substitution" refers to the interchangeability of residues with similar side chains, and therefore typically involves substituting amino acids in a polypeptide with amino acids within the same or similar amino acid definition class. For example, an amino acid with an aliphatic side chain can be substituted with another aliphatic amino acid, such as alanine, valine, leucine, and isoleucine; an amino acid with a hydroxyl side chain can be substituted with another amino acid with a hydroxyl side chain, such as serine and threonine; an amino acid with an aromatic side chain can be substituted with another amino acid with an aromatic side chain, such as phenylalanine, tyrosine, tryptophan, and histidine; an amino acid with a basic side chain can be substituted with another amino acid with a basic side chain, such as lysine and arginine; an amino acid with an acidic side chain can be substituted with another amino acid with an acidic side chain, such as aspartic acid or glutamic acid; and hydrophobic or hydrophilic amino acids can be substituted with another hydrophobic or hydrophilic amino acid, respectively. Exemplary conservative substitutions are provided below:

[0141]

[0142] "Non-conservative substitution" refers to the substitution of an amino acid in a polypeptide with an amino acid whose side chain characteristics are significantly different. Non-conservative substitution can be performed between amino acids rather than within defined groups and may affect (a) the structure of the peptide backbone in the substituted region (e.g., replacing glycine with proline), (b) charge or hydrophobicity, or (c) the volume of the side chain. For example, exemplary non-conservative substitutions could be the substitution of an acidic amino acid with a basic or aliphatic amino acid; the substitution of an aromatic amino acid with a small amino acid; and the substitution of a hydrophilic amino acid with a hydrophobic amino acid.

[0143] "Deletion" refers to a modification of a peptide by removing one or more amino acids compared to a wild-type or control peptide. Deletions may include the removal of one or more, two or more, or three or more amino acids from the peptide while preserving enzyme activity. Deletions may be continuous or discontinuous.

[0144] Suitably, the modified PPO enzyme may also include a transport peptide suitably located at its N- or C-terminus, and suitably a mitochondrial and / or chloroplast transport peptide. Suitably located at its N-terminus. In one embodiment, the transport peptide is a mitochondrial transport peptide. In one embodiment, the transport peptide is a chloroplast transport peptide. In one embodiment, the transport peptide comprises both a chloroplast transport peptide and a mitochondrial transport peptide.

[0145] Suitablely, such mitochondrial or chloroplast transport peptides are present in wild-type PPO enzymes. Therefore, suitablely, modified PPO enzymes can contain native endogenous mitochondrial or chloroplast transport peptides. Alternatively, the endogenous mitochondrial or chloroplast transport peptides can be replaced by heterologous mitochondrial or chloroplast transport peptides derived from the enzyme or from different PPO enzymes.

[0146] Therefore, suitably, in some embodiments, the modified PPO enzyme can also be modified by adding a sequence. Suitably, modification is performed by adding a sequence to its N- or C-terminus. Suitably, this sequence is a heterotransport peptide. Suitably, the heterotransport peptide is added to the C-terminus of the PPO enzyme. Suitably, the heterotransport peptide is added to the N-terminus of the PPO enzyme.

[0147] Therefore, in one embodiment, the modified PPO enzyme comprises a heterologous transport peptide suitably at its N-terminus, or a heterologous mitochondrial or chloroplast transport peptide suitably. In one embodiment, the transport peptide is a heterologous mitochondrial transport peptide. In one embodiment, the transport peptide is a heterologous chloroplast transport peptide. In one embodiment, the transport peptide is a heterologous dual-targeting chloroplast / mitochondrial transport peptide. Suitably, the heterologous transport peptide is added to the modified PPO enzyme, suitably causing the modified PPO enzyme to be produced as a fusion protein with the heterologous transport peptide.

[0148] Suitablely, the heterologous mitochondrial or chloroplast transport peptide is a plant mitochondrial or chloroplast transport peptide. Suitablely, the heterologous mitochondrial or chloroplast transport peptide may be derived from a heterologous PPO enzyme, suitablely derived from a wild-type heterologous PPO enzyme. Suitablely, the heterologous mitochondrial or chloroplast transport peptide may be derived from a heterologous plant PPO enzyme. Non-limiting examples of transport peptides include those listed in WO2017198859, US 10745712, and US 10563220, each of which is incorporated herein by reference in its entirety.

[0149] Suitable transport peptides can be selected from: MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRC (SEQ ID NO:303); or MVAAAMATAPSAGVPPLRGTRGPARFRIRGVSVRC (SEQ ID NO: 304).

[0150] For example, a modified PPO enzyme may contain a sequence according to any one of SEQ ID NO: 153 to 302 or 321 to 336. Suitably, a modified PPO enzyme may contain a sequence having at least 30% sequence identity with a sequence according to any one of SEQ ID NO: 153 to 302 or 321 to 336. For example, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 98%, or at least 99%. Suitably, such a modified PPO enzyme containing a sequence according to any one of SEQ ID NO: 153 to 302 or 321 to 336 may further contain a transport peptide at its C-terminus or N-terminus, and a transport peptide may be suitably added thereto. Suitably, it may be a mitochondrial transport peptide and / or a chloroplast transport peptide. Suitablely, in either case, it can be a heterotransport peptide.

[0151] Suitablely, the modified PPO enzyme may contain both mitochondrial transport peptides and chloroplast transport peptides. For example, chloroplast and mitochondrial transport peptides as described herein.

[0152] It should be understood that when a reference is made to a sequence including a transport peptide, the specific amino acid positions will differ from the number of amino acids constituting the transport peptide in modified PPO enzymes that do not include the transport peptide. Any references to sequences including transport peptides herein also apply to the corresponding sequences provided herein that do not contain a transport peptide (SEQ ID NO 153-302 or 321-336).

[0153] For example, positions 362, 365, and 479 of SEQ ID NO: 1 (wild-type Arabidopsis PPO containing a naturally occurring transport peptide) would be represented as positions 328, 331, and 445 of SEQ ID NO: 153 (wild-type Arabidopsis PPO without a transport peptide), respectively.

[0154] For example, positions 360, 363, and 477 of SEQ ID NO: 2 (wild-type millet PPO containing naturally occurring transport peptides) would be represented as positions 325, 328, and 442 of SEQ ID NO: 154 (wild-type millet PPO without transport peptides), respectively.

[0155] In some instances, modified PPO enzymes may include one or more additional elements, regions, or domains that improve or facilitate the purification, expression, and / or stability of the modified PPO enzyme. For example, the modified PPO enzymes described herein may include one or more purification tags, detection tags, and / or cleavage sites.

[0156] Detection tags can be amino acid sequences that can be specifically bound to a partner cell or emit a signal to allow detection or visualization of modified PPO enzymes. Examples of detection tags include V5 tags, Xpress tags, myc tags, 6XHis, GST, BioEase tags, capTEV tags, fluorescent tags (e.g., GFP), Lumio tags, HA tags, and FLAG tags.

[0157] Purification tags can be amino acid sequences that, when generated by recombinant methods, can be used to aid in the purification of modified PPO enzymes. For example, a purification tag can allow the modified PPO enzyme to bind to a resin or bead via the purification tag. Examples of purification tags include 6XHis, GST, BioEase tags, and capTEV tags. For instance, the modified PPO enzymes provided herein may include a 6XHis tag (i.e., a tag comprising six histidine residues). Suitably, the modified PPO enzymes provided herein may include a 6XHis tag according to SEQ ID NO: 375.

[0158] A cleavage site is an amino acid sequence that can be cleaved or shortened by a specific cleaving enzyme, such as a protease. Cleavage sites allow for simplified removal of any tags that may be included. Cleavage can occur after purification and before the recombinant protein is transferred to the host. For example, the cleavage site can be placed adjacent to the tag, allowing for tag cleavage using a protease. Examples of cleavage sites include the tobacco etch virus (TEV) cleavage site, the enterokinase (EK) cleavage site, the HRV3C site, and the factor Xa site. Suitably, the modified PPO enzymes provided herein may include a TEV site. For example, the TEV site according to SEQ ID NO: 376. In some instances, the modified PPO enzymes provided herein include a His-tag and a TEV site as defined in SEQ ID NO: 377 or 378.

[0159] Combined resistance and / or other target traits

[0160] The plant or a portion thereof of the present invention may also be modified to include additional target traits. In one embodiment, the additional target trait increases resistance to different compounds that inhibit different plant metabolic processes. Suitably, the plant or a portion thereof of the present invention may also be modified to include increased resistance to compounds that inhibit plant metabolic processes (other than those involving PPO enzymes). Suitably, this can be considered as an 'addition' of resistance. Suitably, in the plant of the present invention, resistance to compounds that inhibit PPO enzymes can be additive with resistance to another compound that inhibits a different enzyme or metabolic pathway. Thus, suitably, the plant or a portion thereof exhibits the trait of resistance to a second compound.

[0161] Suitably, the plant or a portion thereof of the present invention may also be modified to include increased resistance to compounds that inhibit plant enzymes different from PPO. Suitably, the plant or a portion thereof of the present invention may also be modified to include increased resistance to compounds that inhibit essential plant metabolic processes. By inhibiting plant metabolic processes, this can mean inhibiting one or more enzymes involved in plant metabolic processes. Suitably, the plant or a portion thereof of the present invention may also be modified to include increased resistance to compounds that target different essential plant enzymes and metabolic processes, rather than compounds that target PPO enzymes.

[0162] Suitably, the plant or its parts may contain additional modified enzymes, and suitably, the plant or its parts have been modified to increase its resistance to compounds that inhibit plant enzymes different from PPO. Suitably, such compounds are herbicides. Suitably, the plant or its parts may contain increased resistance to a herbicide that inhibits PPO enzyme activity and increased resistance to another herbicide, suitably, which inhibits a different plant metabolic process. Thus, suitably, the plant or its parts exhibit the trait of resistance to a second herbicide.

[0163] Therefore, the modified PPO enzymes and their variants provided herein can be superimposed with one or more other modified enzymes that confer desired traits, such as insect, disease, or herbicide resistance, or other desired agronomic traits, including but not limited to traits associated with: high oil content; traits associated with increased protein content and increased digestibility; balanced amino acid content; improved drought resistance; altered maturity and / or flowering time; and high energy content. Such traits can refer to characteristics of seed and non-seed plant tissues, or characteristics of food or feed prepared from plants or seeds possessing such traits.

[0164] As used herein, gene or trait "superposition" encompasses combining desired genes or traits into a transgenic plant line. Superposition can include the introduction of a desired transgenic trait, a trait resulting from genome editing, or a desired natural trait. Additional polynucleotides (such as those encoding modified PPO enzymes as described herein) can be introduced through a variety of methods, including transgenic means, through breeding, targeted integration via a genome editing system, or introduction via genome editing. As one method, plant breeders superimpose transgenic traits (referred to as "breeding superposition") by crossing parents (each possessing the desired trait) and then identifying offspring with both desired traits. Another way to superimpose genes is to transfer two or more genes into the plant's cell nucleus simultaneously with transformation. In examples, the two or more genes may be transferred via different expression cassettes or via a common expression cassette. Another way to superimpose genes is to retransform a transgenic plant containing the desired trait with another target gene conferring another desired trait, thereby providing progeny transgenic plants containing the trait combination. Such methods can include, for example, random integration techniques or targeted integration via gene editing systems such as CRISPR or megnucleases. For example, gene stacking can be used to combine two different insect resistance traits, two different herbicide resistance traits, two different agronomic performance traits, an insect resistance trait combined with a disease resistance trait, a herbicide resistance trait (e.g., Bt11), or an agronomic performance trait. The use of selective markers in addition to the target gene is also considered gene stacking. In embodiments, offspring or progeny plants with the desired combination of traits are identified by using genetic or molecular markers, including but not limited to SNPs, QTLs, primers or probes targeting genes or transgenes associated with the desired trait, promoters, microRNAs, siRNAs, mRNAs, dsRNAs, transcriptomic profiles, and methylation patterns.

[0165] In some embodiments, the polynucleotides or vectors disclosed herein may include additional coding sequences for one or more target polypeptides or double-stranded RNA molecules (dsRNAs) for agronomic traits whose primary beneficiaries are seed companies, growers, or grain processors. The target polypeptide can be any polypeptide encoded by a target nucleotide sequence, such as an enzyme. Non-limiting examples suitable for producing target polypeptides in plants include those polypeptides that produce agronomically important traits (such as modified enzymes conferring these traits), such as herbicide resistance (sometimes also called "herbicide tolerance"), disease resistance, viral resistance, bacterial pathogen resistance, insect resistance, nematode resistance, or fungal resistance. See, for example, U.S. Patent Nos. 5,569,823; 5,304,730; 5,495,071; 6,329,504; and 6,337,431. Polypeptides can also be traits that enhance plant vigor or yield (including traits that allow plants to grow under different temperatures, soil conditions, and levels of sunlight and precipitation), or traits that allow identification of plants exhibiting the desired trait (e.g., selective markers, seed coat color, relative maturity groups, etc.). Different target peptides and methods for introducing these peptides into plants are described, for example, in U.S. Patent Nos. 4,761,373; 4,769,061; 4,810,648; 4,940,835; 4,975,374; 5,013,659; 5,162,602; 5,276,268; 5,304,730; 5,495,071; 5,554,798; 5,561,236; 5,569,823; 5,767,366; 5,879,903, 5,928,937; 6,084,155; 6,329,504 and 6,337,431; and U.S. Patent Publication No. 2001 / 0016956.

[0166] Suitably, the additional target polypeptide to be superimposed on the modified PPO enzyme provided herein may comprise any known target polypeptide or modified enzyme in the art, which has been modified to increase resistance to known compounds that inhibit plant metabolic processes. Suitably, such compounds are herbicides. Thus, suitably, the additional target polypeptide or modified enzyme may provide additional herbicide resistance traits, suitably by providing increased herbicide resistance. Suitably, the plant or a part thereof may comprise the modified PPO enzyme and an additional enzyme, the modified PPO enzyme providing increased resistance to herbicides that inhibit PPO, and the additional enzyme providing increased resistance to another herbicide (suitably which inhibits a different plant metabolic process).

[0167] In some embodiments, the target polypeptides superimposed on the modified PPO enzymes provided herein may be suitable, in some embodiments, to confer resistance / tolerance to herbicides (such as imidazolinones or sulfonylureas) that inhibit growth points or meristems. Exemplary polynucleotides for mutant ALS and AHAS enzymes in this classification number are described, for example, in U.S. Patent Nos. 5,767,366 and 5,928,937. U.S. Patent Nos. 4,761,373 and 5,013,659 relate to plants resistant to various imidazolinone or sulfonylurea herbicides. U.S. Patent No. 4,975,374 relates to plant cells and plants containing nucleic acids encoding modified glutamine synthase (GS) that resist the inhibitory effects of herbicides known to inhibit GS (e.g., glufosinate and methionine sulfoximine). U.S. Patent No. 5,162,602 discloses plants resistant to the inhibitory effects of cyclohexanedione and aryloxyphenoxypropionic acid herbicides. This resistance is conferred by a modified acetyl-CoA carboxylase (ACC enzyme). Other herbicide tolerance traits conferred by ACC enzyme inhibitors can be found in WO 2014144951, WO 2017138986, WO 2018205995, WO 2021088601, WO 2011028836, and WO2011028833.

[0168] In some embodiments, the target polypeptide superimposed on the modified PPO enzyme provided herein is also suitable for this disclosure, conferring resistance to glyphosate. See, for example, U.S. Patent Nos. 4,940,835 and 4,769,061. U.S. Patent No. 5,554,798 discloses a glyphosate-resistant transgenic corn plant conferred by a modified 5-enolpyruvate-3-phosphate (EPSP) synthase gene. Polynucleotides encoding resistance to phosphoryl compounds such as glufosinate or glufosinate, and pyridoxypropionic acid or phenoxypropionic acid and cyclohexanone are also suitable. See, European Patent Application No. 0242 246. See also U.S. Patent Nos. 5,879,903, 5,276,268, and 5,561,236.

[0169] Additional herbicide tolerance traits that may be superimposed on the modified PPO disclosed herein include PPO tolerance traits, including, for example, one or more of the PPO traits listed in US 20190062777, US 10370677, US 11124803, WO 2017217793, WO 2020251313, US10392630, US 10378023, WO 2016099153, WO 2019117579, WO 2019117578, and US 10100329, each of which is incorporated herein by reference in its entirety. HPPD tolerance traits include: WO 2009144079, US 8642748, EP 2453012, WO 2013026740, US 9078446, US 10793872, US10508089, US 10400249, US 10597674, WO 2018119364, WO 2018119361, US 11180770, US20200157086, US 20210147866, US 11279944, US 202000331866, WO 2019227036, WO2019227028, WO 2022115296, WO Those disclosed in 2011068567, and Maeda et al. (2019) Science, Vol. 365, No. 6451, pp. 393-396, are incorporated herein by reference in their entirety. ACC enzyme tolerance traits include: US 20120284812, US 20120284853, US 20160108423, US20160244780, US 20160264990, US 20170275645, US 20210153448, US 10696975 B2, US10370678, CN 109082416, US 10694694, US 20170265469, and US 20170231225, each of which is incorporated herein by reference. Dicamba tolerance traits include, for example, RE45048 or US 7884262. Various traits that confer tolerance to AOPP herbicides, phenoxy acid herbicides, and / or pyridyloxy acid herbicides include, for example, US 10174337, US8278505, WO 05107437, WO 11022469, US 10023874, and US 2019241903 (and other traits therein), each of which is incorporated herein by reference.Other desired herbicide tolerance traits include glucosyltransferase peptides as listed in 2018213022 or solanesyl diphosphate synthase peptides as listed in WO 2020236790, BIO3-BIO1 and / or BioA enzymes as described in European patent application EP 23154964.3, each of which is incorporated herein by reference in its entirety.

[0170] Other suitable polynucleotides include those conferring resistance to photosynthetic inhibitory herbicides such as triazine and phenyl cyanide (nitrile hydrolases), see U.S. Patent No. 4,810,648. Additional suitable polynucleotides encoding herbicide resistance include those encoding resistance to 2,2-dichloropropionic acid, quizalofop-P-ethyl, pyrifluquinazon, imidazolinone herbicides, sulfonylurea herbicides, triazolopyrimidine herbicides, mesotriazine herbicides, and bromosulfuron-methyl. Also suitable are polynucleotides encoding modified enzymes conferring resistance to the original enzyme, or polynucleotides providing enhanced resistance to plant diseases; enhanced tolerance to adverse environmental conditions (abiotic stresses) including, but not limited to, drought, excessive cold, excessive heat, or excessively high soil salinity or extreme acidity or alkalinity; and alterations in plant structure or development, including alterations in developmental timing. See, for example, U.S. Patent Publication No. 2001 / 0016956 and U.S. Patent No. 6,084,155.

[0171] Disease resistance proteins (such as enzymes) can increase resistance to a variety of plant diseases, including rust, including but not limited to one or more resistance genes listed below: WO 2019103918; WO202100878; WO 2021022022; WO2021260673; WO 2022173659; WO 2022159341; WO 2021154632 A1; WO 2021022026; WO2021022101; US ​​20220135997; US 10842097; or WO 2022140257; each of these documents is incorporated herein by reference in its entirety. In other embodiments, the modified PPO enzymes described herein, or their active variants or fragments, are superimposed on the natural trait that confers disease resistance. For example, various regions, loci, or resistance genes listed in WO 2009079729, US 9091681, WO 2010009404, WO2017222827, WO 2021000878, WO 2021022026, WO 2021022101, WO 2021154632, and WO2022173659 (each of which is incorporated herein by reference in its entirety) can be used to introduce the desired trait. Disease resistance proteins and / or natural traits that increase resistance to various plant diseases, including NCLB, include, for example, US 8921646, US 2021000059, US 10858668, US 20200199610, WO 2022 / 013268, WO 2022 / 013268, US 9040772, US 10897862, and EP 3839073, each of which is incorporated herein by reference.

[0172] Other suitable polynucleotides include those encoding insecticidal polypeptides (such as insecticidal enzymes). These polypeptides can be produced in amounts sufficient to control, for example, insect pests (i.e., insect control levels). It should be recognized that the amount of insecticidal polypeptides necessary for controlling insects or other pests produced in plants can vary depending on the cultivar, the type of pest, environmental factors, etc. Polynucleotides that can be used for resistance to other insects or pests include, for example, those encoding toxins identified in Bacillus organisms. Polynucleotides containing nucleotide sequences encoding the Cry protein from several subspecies of Bacillus thuringiensis (Bt) have been cloned, and these recombinant clones have been found to be toxic to lepidopteran, dipteran, and / or coleopteran insect larvae. Examples of such Bt insecticidal proteins include Cry proteins such as Cry1Aa, Cry1Ab, Cry1Ac, Cry1B, Cry1C, Cry1D, Cry1Ea, Cry1Fa, Cry3A, Cry9A, Cry9B, Cry9C, etc., as well as vegetative insecticidal proteins such as Vip1, Vip2, Vip3, etc. A complete list of Bt-derived proteins can be found in the Bacillus thuringiensis toxin nomenclature database maintained by the University of Sussex on the World Wide Web (see also Crickmore et al. (1998) Microbiol. Mol. Biol. Rev. [Review of Microbial Molecular Biology] 62:807-813).

[0173] In the embodiments, the additional polypeptides are insecticidal polypeptides (such as enzymes) derived from non-Bt sources, including but not limited to: α-amylase, peroxidase, cholesterol oxidase, potato glycoprotein, protease, protease inhibitor, urease, α-amylase inhibitor, porogenin, chitinase, lectin, engineered antibodies or antibody fragments, Bacillus cereus insecticidal proteins, pathogenic bacilli species (such as X. nematophila or X. bovienii) insecticidal proteins, luminescent bacilli species (such as P. luminescens or P. asymobiotica) insecticidal proteins, brevispore species (such as B. laterosporous) insecticidal proteins, Lysinibacillus spp. species (such as L. sphearicus) insecticidal proteins, and Chromobacterium species (such as C. subtsugae or C. Insecticidal proteins from species of the genus *Pscinae* (e.g., *Yersinia entomophaga*), species of the genus *Bacillus* (e.g., *P. propylaea*), species of the genus *Clostridium* (e.g., *C. bifermentans*), and species of the genus *Pseudomonasspp.* (e.g., *P. fluorescens*) containing both insecticidal proteins and lignin.

[0174] In some embodiments, additional polypeptides or enzymes are resistance proteins (such as enzymes) that confer increased resistance to pathogens, such as increased resistance to any of the following pathogens: soybean cyst nematode, bacterial pustule, root-knot nematode, soybean gray spot, Phytophthora, brown stem rot, nematodes, Asian soybean rust, smut, Erythrophagus dispora, Asteraceae powdery mildew, wheat powdery mildew, Cucurbita monomecium, Cucumber powdery mildew, Pythium cerevisiae, Gracilaria gracilis, Pea spores, Rice blast fungus, Rice blast fungus, Rhizoctonia solani, Soybean Phytophthora, Wheat aphid, Tobacco whitefly, Corn aphid, Reticulated slug, Sugarcane borer, Wheat aphid, Peach aphid, Sclerotinia sclerotiorum, Common bean scab, or North American soybean sudden death syndrome pathogen. Exemplary polynucleotides encoding proteins conferring increased pathogen resistance that can be superimposed on the modified PPO enzyme of the present invention include polynucleotides encoding proteins (such as enzymes) conferring increased ASR resistance, as described below in: U.S. Patent Publication No. US 20200354739 and PCT Publications WO 2019103918, WO 2021154632 A1, WO 2021022022, WO 2021022026, WO 2021022101, WO 2021260673, and WO 2021263249, each of which is incorporated herein by reference in its entirety.

[0175] Suitable peptides for production in plants further include those that improve or otherwise facilitate the conversion of harvested plants or plant parts into commercially useful products (including, for example, increased or altered carbohydrate content or distribution, improved fermentation characteristics, increased oil content, increased protein content, improved digestibility, and increased nutrient content (e.g., increased phytosterol content, increased tocopherol content, increased sterol content, or increased vitamin content)). Target peptides also include, for example, those that result in or contribute to a reduction in the content of unwanted components (e.g., phytic acid, or enzymes that degrade sugars) in harvested crops. "Resulting in" or "contributing to" means that such a target peptide can directly or indirectly contribute to the presence of the target trait (e.g., by increasing cellulose degradation through the use of heterologous cellulase). Any such peptide can be superimposed with the modified PPO enzyme of the present invention.

[0176] In some embodiments, the polypeptide contributes to improved digestibility of food or feed. Xylanases are hemicellulose-degrading enzymes that improve the breakdown of plant cell walls, leading to better utilization of these phytonutrients by animals. This results in improved growth rates and feed conversion. Similarly, the viscosity of feeds containing xylan can be reduced. Heterogeneous production of xylanases within plant cells can also promote the conversion of lignocellulose into fermentable sugars for industrial processing. Many xylanases from fungal and bacterial microorganisms have been identified and characterized (see, for example, U.S. Patent No. 5,437,992; Coughlin et al. (1993) "Proceedings of the Second TRICEL Symposium on Trichoderma reesei Cellulases and Other Hydrolases" Espoo; Souminen and Reinikainen (1993) Foundation for Biotechnical and Industrial Fermentation Research 8:125-135; U.S. Patent Publication No. 2005 / 0208178; and PCT Publication No. WO 03 / 16654). Specifically, three specific xylanases (XYL-I, XYL-II, and XYL-III) have been identified in *Trichoderma reesei* (Tenkanen et al. (1992) *Enzyme Microb. Technol.* 14:566; Torronen et al. (1992) *Bio / Technology* 10:1461; and Xu et al. (1998) *Appl. Microbiol. Biotechnol.* 49:718). Any such polypeptide can be superimposed on the modified PPO enzyme of this invention.

[0177] In other embodiments, the polypeptides useful to this disclosure may be polysaccharide-degrading enzymes. Plants of this disclosure that produce such enzymes would be useful for generating fermentation feedstocks, for example, for bioprocessing. In some embodiments, enzymes that can be used in fermentation processes include α-amylase, protease, amylopectinase, isoamylase, cellulase, hemicellulase, xylanase, cyclodextrin glycosyltransferase, lipase, phytase, laccase, oxidase, esterase, cutinase, granular starch hydrolase, and other glucosylases. Polysaccharide-degrading enzymes include: starch-degrading enzymes such as α-amylase (EC 3.2.1.1) and glucuronidase (EC 3.2.1.131); exo-1,4-α-D-glucanases such as amylase and glucosylamylase (EC 3.2.1.3), β-amylase (EC 3.2.1.2), α-glucosidase (EC 3.2.1.20), and other exoamylases; starch debranching enzymes, such as a) isoamylase (EC 3.2.1.68) and amylopectin (EC 3.2.1.41); b) cellulases such as exo-1,4-3-cellobiose hydrolase (EC 3.2.1.91), exo-1,3-β-D-glucanase (EC 3.2.1.39), and β-glucosidase (EC 3.2.1.21); c) L-arabinases, such as endo-1,5-α-L-arabinase (EC 3.2.1.99) and α-arabinosidase (EC 3.2.1.55); d) galactanases, such as endo-1,4-β-D-galactanase (EC 3.2.1.89), endo-1,3-β-D-galactanase (EC 3.2.1.90), α-galactosidase (EC 3.2.1.22), and β-galactosidase (EC 3.2.1.23); e) mannanases, such as endo-1,4-β-D-mannanase (EC 3.2.1.78), β-mannosidase (EC 3.2.1.25), and α-mannosidase (EC 3.2.1.24); f) Xylanases, such as endo-1,4-β-xylanase (EC 3.2.1.8), β-D-xylosidase (EC 3.2.1.37), 1,3-β-D-xylanase, etc.; and g) other enzymes such as α-L-fucosidase (EC 3.2.1.51), α-L-rhamnosidase (EC 3.2.1.40), fructanase (EC 3.2.1.65), inulinase (EC 3.2.1.7), etc. In one embodiment, the α-amylase is the synthetic α-amylase Amy797E described in U.S. Patent No. 8,093,453 (incorporated herein by reference in its entirety). Any such polypeptide can be superimposed on the modified PPO enzyme of the present invention.

[0178] Other enzymes that can be used with this disclosure include proteases, such as fungal and bacterial proteases. Fungal proteases include, but are not limited to, those obtained from the genera *Aspergillus*, *Trichoderma*, *Mucor*, and *Rhizopus*, such as *Aspergillus niger*, *Aspergillus awamori*, *Aspergillus oryzae*, and *M. miehei*. In some embodiments, the polypeptide of this disclosure may be cellobiose hydrolase (CBH) (EC 3.2.1.91). In one embodiment, the cellobiose hydrolase may be CBH1 or CBH2. Any such polypeptide may be superimposed with the modified PPO enzyme of the present invention.

[0179] Other enzymes that may be used in this disclosure include, but are not limited to, hemicellulases such as mannanase and arabinofuranase (EC 3.2.1.55); ligninases; lipases (e.g., EC 3.1.1.3), glucose oxidase, pectinase, xylanase, transglucosidase, α1,6-glucosidase (e.g., EC 3.2.1.20); esterases such as ferulic acid esterase (EC 3.1.1.73) and acetylxylan esterase (EC 3.1.1.72); and keratinases (e.g., EC 3.1.1.74). Any such polypeptide may be superimposed on the modified PPO enzyme of the present invention.

[0180] In other embodiments, the modified PPO enzyme described herein may be superimposed with a polynucleotide encoding a polypeptide that increases protein content and / or alters seed composition and / or fatty acid content. Such sequences include, but are not limited to, those disclosed in PCT applications PCT / CN 2022 / 075977 and PCT / CN 2022 / 075982 (both filed February 11, 2022), WO2021 / 044027, US 2020 / 0131524, and US 2021 / 0403933, each of which is incorporated herein by reference in its entirety.

[0181] In one embodiment, the modified PPO enzyme described herein is superimposed on a modified BIO3-BIO1 and / or BioA enzyme and / or a modified biotin synthesis pathway. Therefore, suitably, the plant or parts thereof described herein contain modified BIO3-BIO1 and / or BioA enzymes. Thus, in one embodiment, an additional modified enzyme is a modified BIO3-BIO1 and / or BioA enzyme.

[0182] Therefore, suitably, the plant or its parts may also be modified to include BIO3-BIO1 and / or BioA enzymes, which provide the plant or its parts with increased resistance relative to unmodified plants to compounds that inhibit BIO3-BIO1 and / or BioA enzymes and / or biotin synthesis pathways. Therefore, suitably, the plant or its parts may be modified to include BIO3-BIO1 and / or BioA enzymes with one or more modifications, which provide the plant or its parts with BIO3-BIO1 and / or BioA resistance traits, suitably by providing increased resistance relative to unmodified plants to compounds that inhibit biotin synthesis, and thus BIO3-BIO1 and / or BioA enzymes. Suitably, the plant or its parts may include recombinant polynucleotides encoding BIO3-BIO1 and / or BioA enzymes with one or more modifications. Suitably, the modification, or each modification, provides the plant with increased resistance to compounds that inhibit BIO3-BIO1 and / or BioA enzymes relative to unmodified plants. Suitably, the modification, or each modification, provides the plant with increased resistance to herbicides that inhibit BIO3-BIO1 and / or BioA enzymes and the biotin synthesis pathway. Suitably, the plant or parts thereof may also be modified to contain BIO3-BIO1 and / or BioA enzymes, as described in European patent application EP 23154964.3, which is incorporated herein by reference.

[0183] Plant or part of it

[0184] The plants included in this invention include both non-GMO and GMO plants.

[0185] "Non-GMO plants" refer to plants that lack recombinant DNA in their genome but contain mutant nucleic acid molecules in their plant cell genome, which has been mutated through artificial intervention using mutagenesis techniques such as chemical mutagenesis, gene editing, or those methods provided herein. Non-GMO plants can encompass plants that have mutant or modified sequences due to natural processes or through the use of gene editing techniques, such as plants containing spontaneous PPO enzymes that provide desired resistance to compounds that inhibit PPO enzyme activity. In certain embodiments, non-GMO plants contain modified PPO enzymes that have been altered through gene editing to include at least one or more of the modifications disclosed herein. Such gene editing modifications will increase the plant's resistance to the target herbicide.

[0186] "Transgenic plant" refers to a plant whose genome contains recombinant DNA. As used herein, when referring to nucleic acids or peptides, "recombinant" indicates that such material has been conceived and produced in the laboratory using one or more techniques in biotechnology, protein design, or protein engineering, such as molecular biology, protein biochemistry, bacterial transformation, plant transformation, site-directed mutagenesis, directed evolution using random mutagenesis, genome editing, gene editing, gene cloning, DNA ligation, DNA synthesis, protein synthesis, and DNA shuffling. This includes, for example, alterations due to human applications of recombinant technologies such as polynucleotide restriction and ligation, polynucleotide overlap extension, or genome insertion or transformation. An open reading frame is recombinant if the nucleotide sequence within an open reading frame of a gene sequence has been removed from its natural environment and cloned into any type of artificial nucleic acid vector. The term recombinant can also refer to an organism possessing recombinant material; for example, a plant containing recombinant nucleic acids can be considered a recombinant plant. Such transgenic plants can be produced by introducing recombinant DNA into the plant genome. When such recombinant DNA is incorporated into the genome of a transgenic plant, the plant's offspring may also contain recombinant DNA. Daughter plants containing at least a portion of the recombinant DNA of at least one ancestral transgenic plant are also transgenic plants.

[0187] As used herein, the term "heterologous" in relation to a polypeptide or polynucleotide sequence refers to a sequence derived, for example, from a cell or organism of a foreign species. Alternatively, if the sequence originates from the same species, it originates from a cell or organism with a different genetic background; or, if it originates from the same genetic background, it has undergone substantial modification from its natural form at its constituent and / or genomic loci through deliberate human intervention. Thus, heterologous sequences exhibit conformations not found in nature.

[0188] The term "spontaneous mutant" refers to a mutant or variant produced by a parental line without the intentional use of a mutagen; that is, they are considered not to have undergone genetic modification (non-transgenic). Spontaneous mutants in plants can also be called bud mutations, bud mutants, or chimeras.

[0189] Suitablely, the plant or part thereof of the present invention is genetically modified. In other embodiments, the plant or part thereof of the present invention is non-genetically modified and contains gene edits that increase the tolerance of the plant or part thereof to the target herbicide.

[0190] Therefore, in one embodiment, the plant or a portion thereof contains a recombinant polynucleotide encoding a modified PPO enzyme. In some embodiments, the plant or a portion thereof contains a polynucleotide encoding a modified or mutated PPO enzyme. Suitably, the polynucleotide encoding the modified PPO enzyme may contain one or more modifications. Therefore, suitably, the polynucleotide may be operable to express a modified PPO enzyme having one or more modifications or mutations. Suitably, the expression of said polynucleotide provides or confers increased resistance to compounds that inhibit PPO enzyme activity to the plant or a portion thereof. Suitably, the modifications in the modified PPO enzyme or each modification provides increased resistance to compounds that inhibit PPO enzyme activity. Suitable PPO modifications are defined herein and may include any one of SEQ ID NO: 1, 2, 4-151, 153-302, and 305-336 or their active variants as described elsewhere herein. For example, such PPO modifications are defined herein and may include any one of SEQ ID NO: 37-39, 58, 59, 97-99, 118, 119, 125-137, 139-151, 188-190, 209, 210, 248-250, 269, 270, 277-288, or 291-302, or their active variants as described elsewhere herein. In certain embodiments, the modified or mutated PPO enzyme is encoded by a recombinant polynucleotide stably integrated into the plant genome. Alternatively, the modified or mutated PPO enzyme is encoded by a polynucleotide (suitably, a gene) that contains non-transgenic modifications (e.g., editing) within the plant genome.

[0191] In one embodiment, the plant or a portion thereof may be modified to include a modified PPO enzyme, wherein the modified PPO enzyme is overexpressed, and wherein the modified PPO enzyme contains one or more mutations provided herein that provide the plant or a portion thereof with resistance to compounds that increase the activity of the PPO enzyme relative to unmodified or control PPO enzymes or the plant. Suitable modified PPOs may include any one of SEQ ID NOs: 1, 2, 4-151, 153-302, and 305-336. For example, modified PPOs may include any one of SEQ ID NOs: 37-39, 58, 59, 97-99, 118, 119, 125-137, 139-151, 188-190, 209, 210, 248-250, 269, 270, 277-288, or 291-302, or their active variants as described elsewhere herein.

[0192] In one embodiment, the plant has been transformed with the recombinant polynucleotide. Suitable transformation methods are described below.

[0193] The transformed parts of plants, transformed plant cells, or transformed plant protoplasts described herein can be regenerated to produce modified plants as described herein.

[0194] When a sufficient number of transformed cells or protoplasts containing recombinant modified PPO enzymes are obtained, the cells can be cultured and regenerated into complete plants. "Regeneration" refers to the process of growing a plant from plant cells (e.g., plant protoplasts or explants). Such regeneration techniques rely on the manipulation of certain plant hormones in the tissue culture growth medium, typically depending on biocidal and / or herbicide markers introduced along with the desired nucleotide sequences. The choice of regeneration steps is not critical. See, for example, Ammirato et al., Handbook of Plant Cell Culture — Crop Species, Macmillan Publ. Co. (1984); Shimamoto et al., Nature 338:274-276 (1989); Fromm, UCLA Symposium on Molecular Strategies for Crop Improvement, April 16-22, 1990, Keystone, Colorado (1990); Vasil et al., Bio / Technology 8:429-434 (1990); Vasil et al., Bio / Technology 10:667-674 (1992); Hayashimoto, Plant Physiol 93:857-863. (1990); and Datta et al., Bio-technology 8:736-740 (1990). Such regeneration techniques are generally described in Klee et al., Ann. Rev. Plant Phys. 38:467-486 (1987).

[0195] This invention can be used for any plant species and its offspring, including but not limited to monocots and dicots.

[0196] Examples of target plant species include, but are not limited to, maize or corn (Zea mays), Brassica sp. (e.g., rapeseed (B. napus), turnip (B. rapa), mustard (B. juncea)) (including those Brassica species that can be used as seed oil sources), alfalfa (Medicagosativa), rice (Oryza sativa), rye (Secale cereale), sorghum (Sorghum bicolor, Sorghum vulgare), millet (e.g., pearl millet (Pennisetumglaucum)), foxtail millet (Panicum miliaceum)), foxtail millet (Setariaitalica)), and sorghum (Eleusine). Coracana, sunflower (Helianthus annuus), safflower (Carthamus tinctorius), wheat (common wheat, durum wheat), soybean (Glycine max), tobacco (Nicotiana tabacum), potato (Solanum tuberosum), peanut (Arachis hypogaea), cotton (Gossypium barbadense, Gossypium hirsutum), sweet potato (Ipomoea batatus), cassava (Manihotesculenta), coffee (Coffea spp.), coconut (Cocos nucifera), pineapple (Ananas comosus), citrus (Citrus spp.), cocoa (Theobroma cacao), tea (Camellia) sinensis), banana (Musa spp. species).Avocado (Persea americana), fig (Ficus casica), guava (Psidium guajava), mango (Mangifera indica), olive (Olea europaea), papaya (Carica papaya), cashew (Anacardium occidentale), macadamia (Macadamia integrifolia), almond (Prunus amygdalus), beet (Betavulgaris), sugarcane (Saccharum spp.), oat (Avena sativa), barley (Hordeum vulgare), vegetables, ornamental plants, and conifers.

[0197] In one embodiment, the plant of the present invention is a crop plant (e.g., sunflower, Brassica species, cotton, sugar, sugar beet, soybean, peanut, alfalfa, safflower, tobacco, corn, rice, wheat, rye, barley, triticale, sorghum, millet, etc.).

[0198] In another embodiment, the plants of the present invention may also include various types of cover crop plants. Exemplary cover crops include, but are not limited to, species of the genus *Brassica* (e.g., African rapeseed (*B. carinata*), European rapeseed, turnip, white mustard (*B. hirta*), mustard greens, black mustard (*B. nigra*)), radish (*Raphanus sativus*)), species of the genus *Capsella* (e.g., capsella flax), pennycress (*Thlaspi arvense*), alfalfa (*Trifolium* species, e.g., crimson clover, red clover, white clover, ground clover), field pea (*Pisum sativum*), species of the genus *Vicia* (e.g., hairy pea, yellow pea, black pea, rescue pea), rye (*Secale cereale*), barley (*Hordeum vulgare*), winter wheat (common wheat), oat (*Avena sativa*), and annual ryegrass (*Lolium*). multiflorum, buckwheat (Fagopyrum esculentum), white mustard, alfalfa (purple alfalfa).

[0199] As used herein, the terms "offspring" and "offspring plant" refer to plants produced from one or more parent plants through asexual or sexual reproduction. Offspring plants can be obtained by cloning or self-pollination of a single parent plant, or by hybridization of two parent plants.

[0200] As used herein, unless otherwise expressly stated, the term "plant" is intended to mean a plant at any developmental stage, and any one or more parts of a plant that can be attached to or separated from the whole plant. Such parts of a plant include, but are not limited to, the seeds, organs, tissues, and cells of a plant, including plant callus, plant clusters, plant protoplasts, and plant cell tissue cultures that can regenerate plants. Examples of specific plant parts include stems, leaves, roots, inflorescences, flowers, florets, fruits, pedicels, stamens, anthers, stigmas, styles, ovaries, petals, sepals, carpels, root tips, root caps, root hairs, leaf hairs, seed hairs, pollen grains, microspores, embryos, ovules, cotyledons, hypocotyls, epicotyls, xylem, phloem, parenchyma, endosperm, accompanying cells, guard cells, and any other known organs, tissues, and cells of a plant. Furthermore, it is recognized that seeds are part of a plant.

[0201] A plant cell is the structural and physiological unit of a plant, containing a protoplast and a cell wall. Plant cells can exist as isolated single cells or cultured cells, or as part of higher-level tissue units such as plant tissues, plant organs, or the whole plant. A plant part is a unique and distinct structured and differentiated portion of a plant, such as a root, stem, leaf, flower bud, or embryo.

[0202] The plants of the present invention, their progeny, or portions thereof express at least one of the modified PPO enzymes disclosed herein. Expression of the enzymes of the present invention, the polynucleotides encoding said enzymes, or expression vectors provides plants with at least partial resistance to compounds that inhibit PPO enzyme activity (such as those herbicides described herein). For example, the plants of the present invention, their progeny, or portions thereof exhibit increased resistance to herbicides that inhibit PPO enzyme activity. This increase in resistance can be determined by comparison with wild-type or control plants as described herein. For example, plants that have not yet been modified to include or express the modified PPO enzymes of the present invention, the polynucleotides encoding said PPO enzymes, or expression vectors.

[0203] Methods for producing modified plants or increasing plant resistance

[0204] This document provides a method for conferring increased resistance of a plant or a portion thereof to compounds that inhibit PPO enzymes (i.e., PPO enzyme activity) by modifying the plant to include a modified PPO enzyme as disclosed herein, which provides the resistance. Suitably, such a method may include (i) a method for producing a modified plant or a portion thereof having increased resistance to compounds that inhibit PPO enzyme activity, and (ii) a method for increasing the resistance of a plant or a portion thereof to compounds that inhibit PPO enzyme activity.

[0205] Suitablely, any method includes the step of modifying the plant or a portion thereof to include a modified PPO enzyme that provides increased resistance.

[0206] Suitablely, modifying a plant may include providing the plant or a portion thereof with a modified PPO enzyme having one or more modifications, wherein the modification or each modification provides increased resistance.

[0207] Suitablely, such a step may include providing the plant or a part thereof with a recombinant polynucleotide encoding a modified PPO enzyme as described herein.

[0208] Suitablely, provision may include introducing a recombinant polynucleotide encoding a modified PPO enzyme as provided herein into a plant or a portion thereof, or introducing the modified PPO protein into a plant or a portion thereof. Suitablely, the modified PPO enzyme may be introduced into a plant or a portion thereof by introducing the polynucleotide of the present invention encoding the modified PPO enzyme. Thus, the plant of the present invention may be referred to as a modified or transgenic plant.

[0209] Suitablely, modified PPO enzymes can be introduced into plants or parts thereof by transforming them with recombinant polynucleotides encoding modified PPO enzymes.

[0210] Suitably, the recombinant polynucleotide may also encode a transport peptide, such as a mitochondrial or chloroplast transport peptide. Suitably as a fusion with a modified PPO enzyme. Thus, suitably, the recombinant polynucleotide may comprise a chimeric polynucleotide encoding a modified PPO as described above, and a transport peptide operatively linked thereto, and a mitochondrial or chloroplast transport peptide operatively linked thereto. Suitable transport peptides are described elsewhere herein.

[0211] Suitablely, the recombinant polynucleotide may be part of an expression construct or contained in an expression vector. Suitablely, the expression construct or vector may contain one or more expression elements (such as promoters), as described elsewhere herein. Thus, suitablely, these methods may include providing, introducing, or transforming a plant or part thereof with an expression construct or expression vector containing a polynucleotide encoding a modified PPO enzyme, suitablely, which may be a recombinant polynucleotide.

[0212] Suitably, these methods may also include the step of inducing recombinant polynucleotide expression to produce the modified PPO enzyme provided herein in a plant or its parts. Suitably, inducing polynucleotide expression may include contacting the plant or its parts with an inducer. Suitably, in such embodiments, the polynucleotide encoding the modified PPO enzyme may be under the control of an inducible promoter, and thus, suitably, the expression construct or vector may contain an inducible promoter operatively linked to the polynucleotide encoding the modified PPO enzyme. Suitable inducible promoters and inducers are well known in the art.

[0213] Alternatively or alternatively, plants can be modified by in situ editing of endogenous genetic material to provide genes expressing modified PPO enzymes that provide increased resistance to compounds that inhibit PPO enzyme activity.

[0214] Suitably, in such embodiments, components of a gene-editing system can be provided to plants for modifying an endogenous gene sequence encoding a PPO enzyme at one or more sites to produce a modified gene sequence encoding a modified PPO enzyme that provides increased resistance to compounds that inhibit PPO enzyme activity. Suitably, plants can be transformed with one or more polynucleotides encoding a gene-editing system for modifying an endogenous gene sequence encoding a PPO enzyme at one or more sites to produce a modified gene sequence encoding a modified PPO enzyme that provides increased resistance to compounds that inhibit PPO enzyme activity. This provides plants or portions thereof expressing a modified PPO enzyme that provides increased resistance to compounds that inhibit PPO enzyme activity.

[0215] Endogenous PPO-encoding gene sequences can be edited in situ using gene editing techniques to provide modified PPO enzymes (such as the modified plants described herein) that exhibit at least partial resistance to compounds that inhibit PPO enzyme activity (such as those described herein). Such genome editing and / or mutagenesis techniques are well known in the art. Similarly, the introduction can be accomplished by any means known in the art, including gene introgression, transgenesis, or site-directed nucleases (SDNs). In particular, modifications to the gene sequence are introduced via site-directed nucleases (SDNs). More specifically, the SDN is selected from meganucleases, zinc fingers, transcription activator-like effector nuclease systems (TALENs), or clustered regularly spaced short palindromic repeat systems (CRISPRs). SDNs are also referred to as “genome editing” or genome editing using engineered nucleases (GEENs). This is a type of genetic engineering in which engineered nucleases that produce site-specific double-strand breaks (DSBs) at desired locations in the genome are used to insert, delete, or replace DNA in the genome of an organism. Targeted mutations ('editing') are achieved by repairing induced double-strand breaks through non-homologous end joining (NHEJ) or homologous recombination (HR). Specifically, SDNs can include technologies such as megnucleases, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) (Feng et al. 2013 Cell Res. 23, 1229-1232; Sander and Joung Nat. Biotechnol. 32, 347-355 2014), and clustered regularly spaced short palindromic repeats (CRISPR-Cas) systems. Gene editing can also be achieved via SDN-2. SDN-2 is similar to SDN but also provides a small nucleotide template complementary to the break region. The template contains one or more sequence modifications to genomic DNA, incorporating said modifications to produce a mutation in the target gene. In one embodiment, the gene editing system can include a CRISPR-Cas system.

[0216] As used herein, the term "guide RNA" or "gRNA" generally refers to an RNA molecule (or group of total RNA molecules) that can bind to CRISPR system effectors (such as Cas or Cpf1 proteins) and help target the Cas or Cpf1 protein to a specific location within a target polynucleotide (e.g., DNA). The guide RNA of this invention can be an engineered single RNA molecule (sgRNA), wherein, for example, sgRNA comprises a crRNA segment and optionally a tracrRNA segment. The guide RNA of this invention can also be a dual-guide system, wherein the crRNA and tracrRNA molecules are physically distinct molecules that then interact to form a double strand for recruiting CRISPR system effectors (such as Cas9) and for targeting that protein to a target polynucleotide.

[0217] As used herein, the term "crRNA" or "crRNA segment" refers to an RNA molecule or portion thereof that comprises a polynucleotide targeting guide sequence, a stem sequence involved in protein binding, and optionally a 3'-overhang sequence. The polynucleotide targeting guide sequence is a nucleic acid sequence complementary to a sequence in the target DNA (e.g., a gene encoding a PPO enzyme). This polynucleotide targeting guide sequence is also called the "prespacer sequence." In other words, the polynucleotide targeting guide sequence of the crRNA molecule interacts with the target DNA in a sequence-specific manner via hybridization (i.e., base pairing). Therefore, the nucleotide sequence of the polynucleotide targeting guide sequence of the crRNA molecule can vary and determines the location within the target DNA where the guiding RNA and target DNA will interact.

[0218] The polynucleotide targeting guide sequence of the crRNA molecule can be modified (e.g., through genetic engineering) to hybridize with any desired sequence within the target DNA. The polynucleotide targeting guide sequence of the crRNA molecule of the present invention can have a length from about 12 nucleotides to about 100 nucleotides. For example, the polynucleotide targeting guide sequence of crRNA can have the following lengths: from about 12 nucleotides (nt) to about 80 nt, from about 12 nt to about 50 nt, from about 12 nt to about 40 nt, from about 12 nt to about 30 nt, from about 12 nt to about 25 nt, from about 12 nt to about 20 nt, or from about 12 nt to about 19 nt. For example, the polynucleotide targeting guide sequence of crRNA can have a length from about 17 nt to about 27 nt.

[0219] For example, the polynucleotide targeting guide sequence of crRNA can have the following lengths: from about 19 nt to about 20 nt, from about 19 nt to about 25 nt, from about 19 nt to about 30 nt, from about 19 nt to about 35 nt, from about 19 nt to about 40 nt, from about 19 nt to about 45 nt, from about 19 nt to about 50 nt, from about 19 nt to about 60 nt, from about 19 nt to about 70 nt, from about 19 nt to about 80 nt, from about 19 nt to about 90 nt. The lengths of the crRNA polynucleotide targeting guide sequence can range from 0 nt, from about 19 nt to about 100 nt, from about 20 nt to about 25 nt, from about 20 nt to about 30 nt, from about 20 nt to about 35 nt, from about 20 nt to about 40 nt, from about 20 nt to about 45 nt, from about 20 nt to about 50 nt, from about 20 nt to about 60 nt, from about 20 nt to about 70 nt, from about 20 nt to about 80 nt, from about 20 nt to about 90 nt, or from about 20 nt to about 100 nt. The nucleotide sequence of the crRNA polynucleotide targeting guide sequence can have a length of at least about 12 nt. In some embodiments, the length of the crRNA polynucleotide targeting guide sequence is 20 nucleotides. In some embodiments, the length of the crRNA polynucleotide targeting guide sequence is 19 nucleotides.

[0220] The present invention also provides a guide RNA comprising engineered crRNA, wherein the crRNA contains a bait RNA segment capable of hybridizing with a genomic target sequence. This engineered crRNA can be a physically distinct molecule, as in a dual-guide system.

[0221] As used herein, the term "tracrRNA" or "tracrRNA segment" refers to an RNA molecule or a portion thereof that includes a protein-binding segment (e.g., a protein-binding segment capable of interacting with a CRISPR-associated protein, such as Cas9). This invention also provides guide RNA comprising engineered tracrRNA, wherein the tracrRNA further comprises a decoy RNA segment capable of binding to a donor DNA molecule. The engineered tracrRNA can be a physically distinct molecule (e.g., in a dual-guide system) or can be a segment of an sgRNA molecule.

[0222] The guide RNA, whether as sgRNA or as two or more RNA molecules, does not contain tracrRNA because some CRISPR-related nucleases (such as Cpfl (also known as CaSL2a)) are known in the art to not require tracrRNA due to their RNA-mediated endonuclease activity (Qi et al., (2013), Cell, 152: 1173-1183; Zetsche et al., (2015), Cell, 163: 759-771). Such a guide RNA of the present invention may contain crRNA, wherein the decoy RNA is operatively linked to the 5' or 3' end of the crRNA. Cpfl also possesses RNase activity against its homologous pre-crRNA (Fonfara et al., (2016), Nature, doi.org / 10.1038 / naturel7945).

[0223] The guide RNA of this invention may comprise multiple crRNAs, wherein Cpfl possesses mature crRNA. Each of these crRNAs may be operatively linked to a bait RNA. At least one of these crRNAs may be operatively linked to a bait RNA. The bait RNA may be target sequence (SOI) specific or a "universal" bait having a corresponding "universal" prey sequence on the donor DNA molecule.

[0224] The present invention also provides a polynucleotide comprising a sequence encoding the guide RNA of the present invention. The polynucleotide may be a DNA or RNA molecule. The polynucleotide molecule may be circular or linear. The polynucleotide may be single-stranded, partially double-stranded, or double-stranded. The polynucleotide may be complexed with at least one polypeptide. The polypeptide may have a nucleic acid recognition domain or a nucleic acid binding domain. The polypeptide may be a shuttle for mediating the delivery of, for example, the polynucleotide, nuclease, and optionally a donor molecule of the present invention. The polypeptide may be a Feldan shuttle (US Patent Publication No. 20160298078, incorporated herein by reference). The polynucleotide may comprise an expression cassette capable of driving polynucleotide expression. The polynucleotide may also comprise additional expression cassettes capable of expressing, for example, nucleases (such as CRISPR-associated nucleases).

[0225] Therefore, suitably, a Cas enzyme, or one or more polynucleotides encoding a Cas enzyme, and a polynucleotide sequence encoding a guide RNA can be provided to the plant or a part thereof for specific transformation as described above. Suitably, the guide RNA is complementary to the PPO gene or its regulatory sequence in the plant or a part thereof. Suitably, the guide RNA is operable to target the Cas enzyme to edit the PPO gene and to provide the plant or a part thereof with increased resistance to compounds that inhibit PPO enzyme activity relative to unmodified plants.

[0226] Alternatively or concurrently, the plant can be modified by providing one or more regulatory RNA sequences to the plant or a part thereof, the regulatory RNA sequences being operable to target genes encoding PPO enzymes or their regulatory sequences. Suitablely, the plant or a part thereof can be transformed with one or more regulatory RNA sequences, the regulatory RNA sequences being operable to target genes encoding PPO enzymes or their regulatory sequences. Suitablely, the regulatory RNA sequence can be complementary to and bind to genes encoding PPO enzymes or their regulatory sequences in the plant or a part thereof, and can provide increased resistance to compounds that inhibit PPO enzyme activity.

[0227] "Transformation" refers to the process of introducing exogenous nucleic acid molecules (such as recombinant polynucleotides) into cells or protoplasts, whereby these exogenous nucleic acid molecules are incorporated into the host cell genome or organelle genome (such as chloroplasts or mitochondria) or are capable of autonomous replication. "Transformed" or "transgenic" refers to cells, tissues, organs, or organisms in which exogenous nucleic acids, such as expression vectors or recombinant nucleic acid molecules, have been introduced. Nucleic acid molecules can be stably integrated into the host genome, or they can exist as extrachromosomal molecules. Such extrachromosomal molecules are capable of autonomous replication. Nucleic acid molecules can also be introduced into the genomes of chloroplasts or mitochondria in plant cells.

[0228] Transformation methods for plant cells or tissues include, but are not limited to, Agrobacterium-mediated transformation and bio-projectile or particle gun-mediated transformation. Suitable plant transformation vectors for Agrobacterium-mediated transformation include elements of tumor-inducing (Ti) plasmids derived from Agrobacterium tumefaciens, such as the right boundary (RB) and left boundary (LB) regions, as disclosed in Herrera-Estrella et al., Nature 303:209 (1983); Bevan, Nucleic Acids Res. 12:8711-8721 (1984); and Klee et al., Bio-Technology 3(7):637-642 (1985). In addition to plant transformation vectors derived from Agrobacterium Ti or root-inducing (Ri) plasmids, alternative methods can be used to insert the nucleic acid molecules of the present invention into plant cells. These methods may involve, but are not limited to, the use of liposomes, electroporation, chemicals that increase the uptake of cell-free DNA, cell-free DNA delivery by bombardment with micro-projectiles, and conversion using viruses or pollen.

[0229] "Transgenic" or "transformed" cells or plants also include the offspring of the cells or plants and the offspring produced from a breeding program that uses "transgenic" plants as parents in a hybridization process, and the offspring produced from the breeding program exhibit altered phenotypes due to the presence of foreign nucleic acid molecules.

[0230] Transgenic plants can be homozygous for the polynucleotide encoding the modified PPO enzyme (i.e., plants containing two added genes encoding the enzyme at the same location on each chromosome pair). Homozygous transgenic plants can be obtained by hybridizing (self-pollinating) independent transgenic plant isolates containing a single added gene, germinating some of the resulting seeds, and transforming the resulting plants with the target gene.

[0231] Breeding plants

[0232] The development or regeneration of transgenic plants containing nucleic acid molecules encoding the recombinant modified PPO enzyme of the present invention is well known in the art. Regenerated plants can be self-pollinated to provide homozygous transgenic plants, as described above. Alternatively, pollen obtained from the regenerated plants can be hybridized with seed-growing plants of important agronomic lines. Conversely, pollen from these important lines can be used to pollinate the regenerated plants.

[0233] The plants with at least partial resistance described herein and their progeny (such as transformed, modified, or transgenic plants as described herein) can be used in methods for preparing plants with at least partial resistance, plants with increased tolerance to compounds that inhibit PPO enzyme activity, and seeds of such plants. Thus, for example, the plants exemplified herein can be used in breeding programs to develop additional plants with at least partial resistance to herbicides, such as commercial varieties of such plants. According to such a method, a first parent plant can be used to hybridize with a second parent plant, wherein at least one of the first or second parent plants contains a modified PPO enzyme as described herein. One application of this process is the production of F1 hybrid plants. Another aspect of this process is that it can be used to develop new parents, double haploids, or inbred lines. For example, plant lines as described herein can be hybridized with any second plant, and the resulting hybrid offspring can be self-crossed and / or cross-crossed with their siblings for about 5 to 7 generations or more, thereby providing a large number of different parent lines. These parent lines can then be hybridized with other lines, and the beneficial characteristics of the resulting hybrid offspring can be analyzed. In this way, novel lines endowed with desired characteristics can be identified. Various breeding methods can be used in these methods, including haploid breeding, pedigree breeding, single-seed propagation, improved single-seed propagation, recurrent selection, and backcrossing.

[0234] Plants and their progeny can exhibit a synergistic rather than an additive effect of tolerance to compounds that inhibit PPO enzyme activity, thus the level of tolerance in plants containing multiple mutations and their progeny is greater than the combined tolerance in plants containing a single modified PPO enzyme.

[0235] Plant lines containing the modified PPO enzyme of this invention can be hybridized naturally or mechanically. Mechanical pollination can be achieved by controlling the type of pollen that can be transferred to the stigma or by manual pollination.

[0236] Any breeding method can be used in the methods of this invention. In one example, the resistant plants of this invention can be bred using a haploid method. In such a method, parents with genetic bases having desired complementary characteristics are hybridized in a simple or complex hybridization manner. Hybridization (or cross-pollination) refers to the transfer of pollen from one plant to another. The hybrid offspring were cultured using techniques known to those skilled in the art, and microspores (immature pollen grains) were isolated and filtered (e.g., Swanson, EB et al., (1987) Plant Cell Reports, 6: 94-97, “Efficient isolation of microspores and the production of microspore-derived embryos in Brassica napus, L.”; and Swanson, EB., (1990) Microspore culture in Brassica, pp. 159-169 in Methods in Molecular Biology, Vol. 6, Plant Cell and Tissue Culture, Humana Press). These microspores exhibited gene segregation. Microspores are cultured in the presence of a suitable AHAS inhibitor herbicide, such as imazapyr (e.g., PURSUIT™) or methoxypromethazine (e.g., SOLO™, BEYOND™, and RAPTOR™), or a 50 / 50 mixture of imazapyr and methoxypromethazine (e.g., ODYSSEY™), which kills microspores lacking the mutant gene responsible for herbicide resistance. Microspores carrying the herbicide resistance gene survive and produce embryos, forming haploid plants. Their chromosomes then double to produce doubled haploids.

[0237] Other breeding methods can also be used according to the present invention. For example, pedigree breeding can be used to improve primarily self-pollinating crops such as Brassica and Canola. Pedigree breeding begins with a cross between two genotypes, each of which may have one or more desired traits that are lacking in or complement the other. If the two original parents do not provide all the desired traits, other parents can be included in the hybridization program. These parents can be crossed in a simple or complex manner to produce simple or complex F1 plants. The F2 population is produced from F1 plants through self-pollination of one or more F1 plants, or through crosses between two F1 plants (i.e., sibling mating). Selection of the best individuals can begin from the F2 generation, and from F3, selection of the best families and the best individuals within the best families can be performed. Repeated testing of families can begin from the F4 generation to improve the effectiveness of selection for traits with low heritability. In the later stages of inbreeding (i.e., F6 and F7), mixtures of the best lines or phenotypic similar lines can be tested as a potential release of new varieties. However, for developing plants with at least partial resistance to improved PPO enzyme inhibitory compounds, the pedigree approach is more time-consuming than the haploid approach because the plants exhibit multigenerational segregation and the recovery of the desired trait is relatively low.

[0238] The Single Seed Subculturing (SSD) program can also be used to breed improved varieties. Strictly speaking, the SSD program involves planting a segregating population, harvesting a sample of one seed from each plant, and then using this single-seed population to propagate the next generation. As the population progresses from F2 to the desired level of inbreeding, the plants in the derived lines will each be traced back to a different F2 individual. Because some seeds fail to germinate or some plants produce at least one seed, the number of plants in the population decreases with each generation. Therefore, when the generations are complete, not all plants initially sampled from the F2 population will be represented by the offspring.

[0239] In a multi-seed process, canola breeders typically harvest one or more pods from each plant in the population and thresh them together to form a batch. A portion of this batch is used to plant the next generation, while the remainder is kept as a reserve. This process is known as modified single-seed propagation or pod batch technology. The multi-seed process has been used to save labor during harvest. Using a machine to thresh the pods is much faster than manually removing one seed from each pod in a single-seed process. The multi-seed process also makes it possible to plant the same number of seeds in each generation of inbred populations. Sufficient seeds are harvested to compensate for plants that did not germinate or produce seeds.

[0240] Backcrossing is used to transfer one or more genes for a simple, highly heritable trait from a source variety or line (donor parent) to another desired variety or inbred line (recurrent parent). After the initial hybridization, individuals with the donor parent phenotype are selected and repeatedly crossed with the recurrent parent (backcross). When the backcrossing is complete, the resulting plants are expected to possess the attributes of the recurrent parent and the desired traits transferred from the donor parent.

[0241] Improved varieties can also be developed through recurrent selection. In this method, a population of genetic variation in heterozygous individuals is identified or created by crossing several different parents. The best plants are selected based on individual superiority, excellent offspring, or excellent combining ability. The selected plants are then crossed to produce new populations, where further selection cycles continue.

[0242] Plants possessing at least partial resistance can be produced by cross-pollinating a first plant with a second plant and allowing a pollen recipient plant (which may be either the first or second plant) to produce seeds from that cross-pollination. The seeds and the progeny plants produced therefrom may have mutations that hybridize into the genomes of the seeds and / or the progeny plants. The pollen recipient plant may be either the first or second plant. The first plant contains a nucleic acid encoding a modified PPO enzyme as disclosed herein. The second plant may be any compatible plant and may contain a second, identical or different, modified PPO enzyme. The first and second enzymes may contain nucleic acids encoding one or more amino acid substitutions, respectively, relative to the wild-type modified PPO enzyme. Seeds or progeny plants produced by hybridization may be selected that contain one or both nucleic acids encoding the modified PPO enzyme.

[0243] When the first and second plants are homozygous for the first and second nucleic acid molecules, respectively, each of the resulting progeny plants contains one copy of each of the first and second nucleic acid molecules, and the selection step can be omitted. When at least one of the first and second plants is heterozygous, progeny plants containing both nucleic acid molecules can be selected, for example, by analyzing the DNA of the progeny plants to identify progeny plants containing both the first and second nucleic acid molecules, or by testing for increased herbicide tolerance in the progeny plants.

[0244] The presence of specific modified PPO nucleic acids or enzymes can be determined by evaluating progeny and / or offspring plants against the nucleic acid molecules of the present invention using any method.

[0245] Therefore, this document also provides a method for selecting plants or parts thereof comprising the modified PPO enzyme of the present invention, or nucleic acid or expression vector encoding the modified PPO enzyme, by exposing plants or parts thereof to an effective amount of a compound that inhibits PPO enzyme activity, wherein the effective amount of the compound is sufficient to prevent or reduce the growth of plants that do not at least comprise the modified PPO enzyme of the present invention, or nucleic acid or expression vector encoding the modified PPO enzyme. Whether the plant has been affected by the compound (e.g., reduced growth or reduced damage) can then be determined by the method described herein. Plants unaffected by the compound can then be selected.

[0246] Methods for determining whether a plant contains the modified PPO enzyme of the present invention, or the nucleic acid or expression vector encoding the modified PPO enzyme, and / or whether the plant is affected by compounds that inhibit PPO enzyme activity include phenotypic assessment, genotypic assessment, or a combination thereof. Compound resistance and other desired traits in progeny plants can be assessed. Resistance to these compounds can be assessed by exposing plants to one or more suitable compounds that inhibit PPO enzyme activity and evaluating the damage. Some traits, such as lodging resistance and plant height, can be assessed by visually inspecting the plant, while early maturity can be assessed by visually inspecting the seeds within the pods (siliques). Other seed traits, such as oil percentage, protein percentage, and total glucosinolates, can be assessed using techniques such as near-infrared spectroscopy and / or liquid chromatography and / or gas chromatography.

[0247] Any genotyping method can be used to identify the plants of the present invention. Genotyping of plants includes the use of techniques such as isoenzyme electrophoresis, restriction fragment length polymorphism (RFLP), random amplified polymorphic DNA (RAPD), arbitrary primer polymerase chain reaction (AP-PCR), allele-specific PCR (AS-PCR), DNA amplified fingerprint (DAF), sequence characteristic amplified region (SCAR), amplified fragment length polymorphism (AFLP), and simple sequence repeats (SSR) (also known as “microsatellites”). Additional compositions and methods for analyzing the plant genotypes provided herein include those disclosed in U.S. Publication Nos. 2004 / 0171027, 2005 / 02080506, and 2005 / 0283858, the entire contents of which are incorporated herein by reference.

[0248] Evaluation and manipulation (through exposure to one or more suitable compounds that inhibit PPO enzyme activity) may continue for several generations. The performance of the new line can be evaluated using objective criteria compared to a control variety. Lines exhibiting the desired combination of traits are either crossed with another line or self-pollinated to produce seeds.

[0249] "DNA sequencing" refers to determining the nucleic acid sequence of a segment of DNA (such as a gene). Standard methods and commercial services are known in the art. Basic methods for DNA sequencing include the Maxam-Gilbert method and chain termination methods. High-throughput technologies have also been developed and can be used in the methods of this invention. These high-throughput technologies include, but are not limited to, massively parallel characterization sequencing (MPSS), Polony sequencing, 454 pyrosequencing, Illumina (Solexa) sequencing, combined probe anchoring synthesis (cPAS), SOLiD sequencing, Ion Torrent semiconductor sequencing, DNA nanosphere sequencing, Heliscope single-molecule sequencing, single-molecule real-time (SMRT) sequencing, and nanopore DNA sequencing.

[0250] Sequencing can be performed using primers capable of binding to the isolated polynucleotides of the present invention. For example, primers complementary to at least a portion of the isolated polynucleotides of the present invention.

[0251] As used herein, the term "primer" refers to an oligonucleotide that, when placed under conditions that induce the synthesis of primer extension products (e.g., in the presence of nucleotides and reagents for polymerization (such as DNA polymerase) and at suitable temperature and pH), can anneal to a polynucleotide target and serve as an initiation site for DNA synthesis. Primers (in some instances extension primers, in others amplification primers) can be single-stranded to achieve maximum efficiency in extension and / or amplification. Primers can be oligodeoxyribonucleotides. Primers are typically long enough to initiate the synthesis of extension and / or amplification products in the presence of reagents for polymerization. The minimum length of a primer can depend on a number of factors, including but not limited to the primer's temperature and composition (A / T versus G / C content). In the case of amplification primers, these amplification primers are typically provided as a pair of bidirectional primers consisting of a forward and a reverse primer, or as a pair of forward primers commonly used in the field of DNA amplification (such as in PCR amplification).

[0252] Therefore, it should be understood that, as used herein, the term "primer" can refer to more than one primer, particularly where there is some ambiguity in the information regarding one or more terminal sequences of the target region to be amplified. Thus, "primer" can include a collection of primer oligonucleotides containing sequences representing possible variations in that sequence, or nucleotides that allow for typical base pairing. Primers can be prepared by any suitable method known in the art. Methods for preparing oligonucleotides with specific sequences are known in the art and include, for example, cloning and restriction of suitable sequences and direct chemical synthesis. Chemical synthesis methods can include, for example, the phosphodiester or triester method, the diethylaminophosphate method, and the solid-phase support method disclosed in U.S. Patent No. 4,458,066.

[0253] If desired, primers can be labeled by incorporating a detectable moiety, such as a spectral, fluorescent, photochemical, biochemical, immunochemical, or chemical moiety. Primers for diagnosing resistance to compounds that inhibit PPO enzyme activity (i.e., those capable of identification or selection based on the presence or absence of the modified PPO enzyme-encoded nucleic acid as described herein) can be generated by any known method. PCR methods are well described in manuals and are known to those skilled in the art. Following PCR amplification, the target polynucleotide can be detected by hybridization with a probe polynucleotide that forms a stable hybrid with the target sequence under stringent to moderately stringent hybridization and washing conditions. Stringent conditions can be used if the probe is expected to be substantially perfectly complementary to the target sequence (i.e., approximately 99% or more).

[0254] If some mismatches are expected, for example, if variant polynucleotides are expected to cause incomplete probe complementarity, the stringency of hybridization can be reduced. In some instances, conditions are chosen to exclude nonspecific / accidental bindings. Conditions affecting hybridization and the selection of conditions for nonspecific bindings are known in the art and described, for example, in Sambrook and Russell (2001), *Molecular Cloning: A Laboratory Manual*, 3rd edition, Cold Spring Harbor Laboratory Press, New York, USA. Generally, lower salt concentrations and higher temperatures for hybridization and / or washing increase the stringency of hybridization conditions.

[0255] seed

[0256] This document also includes seeds capable of producing the plants or parts thereof of the present invention. Suitably, the seeds contain the modified PPO enzyme provided herein, or a polynucleotide or expression vector encoding the modified PPO enzyme provided herein, which provides increased resistance to compounds that inhibit PPO enzyme activity relative to unmodified plants.

[0257] The term "seed" encompasses all kinds of seeds and plant propagules, including but not limited to true seeds, seed tubers, suckers, grains, bulbs, fruits, tubers, cereals, cuttings, and cuttings.

[0258] Seeds can be treated or untreated. For example, seeds can be treated to improve germination, such as by seed priming or by sterilization to prevent seed-borne pathogens. In another instance, seeds can be coated with any available coating to improve, for example, plantability, seed emergence, and protection against seed-borne pathogens. Seed coating can be any form of seed coating, including but not limited to pelleting, film coating, and crusting.

[0259] Seeds can germinate and be used to produce or grow the plant or parts thereof of the present invention. This includes the plant or parts thereof comprising a modified PPO enzyme that provides increased resistance to compounds that inhibit PPO enzyme activity relative to unmodified plants.

[0260] This document also provides containers for containing the seeds of the present invention. The seed container can contain any number, weight, or volume of seeds. For example, the container may contain at least or more than about 10, 25, 50, 75, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, or 5000 seeds. Alternatively, the container may contain at least or more than about 1 ounce, 5 ounces, 10 ounces, 1 pound, 2 pounds, 3 pounds, 4 pounds, 5 pounds, or 1 pound of seeds.

[0261] The container for plant seeds can be any container available in the art. As a non-limiting example, the container can be a box, bag, packet, pouch, roll of tape, bucket, foil, or tube.

[0262] The seeds contained in the container can be treated or untreated. For example, seeds can be treated to improve germination, such as by seed priming or by sterilization to prevent seed-borne pathogens. In another instance, seeds can be coated with any available coating to improve, for example, plantability, seed emergence, and protection against seed-borne pathogens. Seed coating can be any form of seed coating, including but not limited to pelleting, film coating, and crusting.

[0263] At least 10% of the seeds in the container may be seeds of the present invention. For example, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100% of the seeds in the container may be seeds of the present invention.

[0264] The seeds of the present invention can be hybrid seeds produced by a method comprising crossing the first plant of the present invention with a second plant; and obtaining seeds. For example, a plant comprising a modified PPO enzyme, or a polynucleotide or expression vector encoding such a modified PPO enzyme, is crossed with another plant, the modified PPO enzyme providing increased resistance to compounds that inhibit PPO enzyme activity.

[0265] The term "hybrid seed" refers to a seed produced through cross-pollination between two plants. Plants bred from hybrid seeds can have improved agricultural characteristics, such as better yield, greater uniformity, and / or disease resistance. Hybrid seeds do not truly reproduce; that is, seeds produced through self-fertilization of a hybrid plant (plants grown from hybrid seeds) cannot reliably produce the next generation of the same hybrid. Therefore, new hybrid seeds must be produced from parental plant lines with each planting. Since most crop plants possess both male and female organs, hybrid seeds can only be produced by preventing self-pollination of the female parent and allowing or promoting pollination with the desired pollen. There are several methods to prevent self-pollination of the female parent; one method is to mechanically remove the pollen-producing organs before the pollen falls off. Commercial hybrid maize seed production typically involves cultivating desired male and female parent lines, usually in separate rows or plots in isolated fields. Female parent plants are treated to prevent pollen shedding, ensuring pollination of the female is achieved only through the designated male parent, and hybrid seeds are harvested only from the female parent. Hybrid seeds can be single hybrids (e.g., first-generation hybrids between two inbred lines), modified single hybrids (e.g., first-generation hybrids between two inbred lines, one or the other possibly slightly altered by using closely related hybrids), double hybrids (e.g., first-generation hybrids between two single hybrids), three-way hybrids (e.g., first-generation hybrids between a single hybrid and an inbred line), top crosses (e.g., first-generation hybrids of an inbred line and an open-pollinated variety, or a first-generation hybrid of a single-cross line and an open-pollinated variety), or open-pollinated varieties (e.g., plant populations selected according to criteria that may exhibit variation but possess characteristics that distinguish one variety from others).

[0266] As used herein, the term "cross" or "crossed" refers to the fusion of gametes through pollination to produce offspring (e.g., cells, seeds, or plants). This term encompasses both sexual hybridization (one plant being pollinated by another) and self-pollination (self-pollination, such as when pollen and ovules are from the same plant). The term "crossing" refers to the act of fusing gametes via pollination to produce offspring.

[0267] Nucleic acid

[0268] The present invention further provides isolated polynucleotides encoding modified PPO enzymes or fragments thereof as defined in any aspect or embodiment herein. Suitably, these isolated polynucleotides may encode modified PPO enzymes or fragments thereof as defined in any sequence listed herein. Suitably, these isolated polynucleotides may encode any one of SEQ ID NO: 1, 2, 4-151, 153-302, or 305-336. Suitably, these isolated polynucleotides may encode any one of SEQ ID NO: 37-39, 58, 59, 97-99, 118, 119, 125-137, 139-151, 188-190, 209, 210, 248-250, 269, 270, 277-288, or 291-302. Therefore, modified PPO enzymes or functional fragments thereof that can be expressed by such isolated polynucleotides are also provided.

[0269] A “separated” polynucleotide is essentially isolated from other polynucleotide sequences that are normally associated with a polynucleotide, such as from the chromosomal or extrachromosomal DNA of the cell in which the polynucleotide is naturally present. A polynucleotide can be a separated polynucleotide when it contains a transgene or part of a transgene present in the genome of another organism. The term also includes polynucleotides that have been biochemically purified to substantially remove contaminating polynucleotides and other cellular components. A separated polynucleotide essentially does not contain sequences naturally flanking the nucleic acid in the genomic DNA of the organism from which the polynucleotide was derived (i.e., sequences located at the 5' and 3' ends of the polynucleotide) (such as sequences encoding proteins). For example, a separated polynucleotide may contain fewer than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0.1 kb of nucleotide sequences naturally flanking the polynucleotide in the genomic DNA of the cell from which the polynucleotide was derived. The flanking regions of a separated polynucleotide can be natural genomic sequences that control its expression in the cell, such as natural promoters or natural 3' untranslated regions.

[0270] Expression builder and carrier

[0271] Expression constructs and vectors including at least one polynucleotide of the present invention inserted therein can be any construct or vector capable of delivering polynucleotides into a host or host cell and allowing polynucleotide expression to provide a functionally modified PPO enzyme or a fragment thereof as described herein.

[0272] Such constructs or vectors may contain heterologous polynucleotide sequences, i.e., polynucleotide sequences that are not naturally present near the polynucleotides of the present invention and may originate from a species different from the species from which the one or more polynucleotide molecules originate. The construct or vector may be RNA or DNA, may be prokaryotic or eukaryotic, and typically the vector is a virus or plasmid.

[0273] Many vectors suitable for stable transfection of plant cells or the establishment of transgenic plants have been described, for example, in Pouwels et al., Cloning Vectors: A Laboratory Manual, 1985, Supplement 1987; Weissbach and Weissbach, Methods for Plant Molecular Biology, Academic Press, 1989; and Gelvin et al., Plant Molecular Biology Manual, Kluwer Academic Publishers, 1990. Typically, plant expression vectors comprise, for example, one or more clones of plant genes and dominant-selective markers under transcriptional control of 5' and 3' regulatory sequences. For example, the vector could be pBIN 19 (Bevan, Nucl. AcidsRes. (1984)).

[0274] The expression vector of the present invention may include one or more regulatory sequences. For example, the expression vector may contain a promoter regulatory region (e.g., a regulatory region controlling inducible or constitutive, environmental or developmental, or cell or tissue-specific expression), a transcription initiation site, a ribosome binding site, an RNA processing signal, a transcription termination site, and / or a polyadenylation signal. Such a portion of the expression vector may be referred to as an expression construct. The expression construct may include one or more regulatory sequences that function in plants. This thus allows the expression of polynucleotides encoding the modified PPO enzyme of the present invention in plants.

[0275] As used herein, an "expression construct" refers to a nucleic acid sequence (containing a promoter operatively linked to a target polynucleotide, which is operatively linked to a termination signal sequence) capable of directing the expression of a specific nucleic acid sequence in a suitable host cell. It also typically contains the sequence necessary for proper translation of the polynucleotide sequence. An expression construct containing the target polynucleotide can be chimeric, meaning that at least one of its components is heterologous relative to at least one of its other components. An expression construct can also be naturally occurring but already obtained in a recombinant form for heterologous expression. However, typically, the expression construct is heterologous relative to the host, meaning that the specific polynucleotide of the expression cassette is not naturally present in the host cell and must have been introduced into the host cell or its ancestor through a transformation event. Expression of the polynucleotide sequence in the expression construct can be under the control of, for example, a constitutive or inducible promoter that initiates transcription only when the host cell is exposed to a specific external stimulus. In the case of multicellular organisms (such as plants), the promoter can also be tissue- or organ-specific, or developmental stage-specific.

[0276] As used herein, the terms "regulatory element" or "regulatory sequence" refer to nucleic acids capable of regulating the transcription and / or translation of operatively linked polynucleotides. Regulatory elements include, but are not limited to, promoters, enhancers, introns, 5' UTRs, and 3' UTRs.

[0277] The expression cassette may include, in the 5'-3' direction of transcription, a transcription and translation initiation region (e.g., a promoter) that functions in plants, a polynucleotide sequence encoding the modified PPO enzyme of the present invention, and a transcription and translation termination region (e.g., a termination region).

[0278] Any promoter can be used to generate expression constructs as described herein and vectors comprising such expression constructs. For the plant host and / or the polynucleotide sequence encoding the modified PPO of this invention, the promoter can be natural or similar, foreign or heterologous. Additionally, the promoter can be a natural sequence or alternatively synthetic. When a promoter is “foreign” or “heterologous” for the plant host, it means that the promoter has not been found in the natural plant in which it is introduced. When a promoter is “foreign” or “heterologous” for the polynucleotide encoding the modified PPO of this invention, it means that the promoter is not a primary or naturally occurring promoter of the polynucleotide of this invention that can be operatively linked.

[0279] While heterologous promoters may be preferred for expressing the polynucleotide encoding modified PPO of the present invention, natural promoter sequences can be used to prepare expression constructs. Such expression constructs can alter the expression level of the modified PPO enzyme in plants or plant cells. Therefore, the phenotype of the plant or plant cells is altered.

[0280] Any promoter can be used to prepare expression constructs to control the expression of polynucleotides encoding modified PPO, such as constitutive, tissue-preferred, inducible promoters, or other promoters for expression in plants. Constitutive promoters include, for example, the core promoter of the Rsyn7 promoter and other constitutive promoters disclosed in WO 99 / 43 838 and US Patent No. 6,072,050; the core CaMV 35S promoter (Odell et al. (1985) Nature 313:810-812); rice actin (McElroy et al. (1990) Plant Cell 2:163-171); ubiquitin (Christensen et al., (1989) Plant Molecular Biology 12:619-632 and Christensen et al., (1992) Plant Molecular Biology 18:675-689); pEMU (Last et al. (1991) Theor. Appl. Genet. 81). :581-588); MAS (Velten et al. (1984) EMBO J. [Journal of the European Society for Molecular Biology] 3:2723-2730); ALS promoter (US Patent No. 5,659,026), etc. Other constitutive promoters include, for example, US Patent Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597; 5,466,785; 5,399,680; 5,268,463; 5,608,142; and 6,177,611.

[0281] Tissue-biased promoters can be used to guide the expression of the modified PPO enzymes of this invention in specific plant tissues. Such tissue-biased promoters include, but are not limited to, leaf-biased promoters, root-biased promoters, seed-biased promoters, and stem-biased promoters. Tissue-biased promoters include those described in the following literature: Yamamoto et al. (1997) Plant J. 12(2):255-265; Kawamata et al. (1997) Plant Cell Physiol. 38(7):792-803; Hansen et al. (1997) MoI Gen Genet. 254(3):337-343; Russell et al. (1997) Transgenic Res. 6(2):157-168; Rinehart et al. (1996) Plant Physiol. 1 12(3):1331-1341; Van Camp et al. (1996) Plant Physiol. 1 12(2):525-535; Canevascini et al. (1996) Plant Physiol. [Plant Physiology] 112(2): 513-524; Yamamoto et al. (1994) Plant Cell Physiol. 35(5):773-778; Lam (1994) Results Probl. Cell Differ. 20:181-196; Orozco et al. (1993) Plant MoI Biol. 23(6):1129-1138; Matsuoka et al. (1993) Proc. Natl. Acad. Sci. USA 90(20):9586-9590; and Guevara-Garcia et al. (1993) Plant J. 4(3):495-505.

[0282] The expression construct may also include a transcription termination region. When using a transcription termination region, any termination region can be used in the preparation of the expression cassette. For example, the termination region may be natural for the transcription initiation region, natural for the target polynucleotide to which it is operatively linked, natural for the plant host, or derived from another source (i.e., foreign or heterologous to the promoter, the target polynucleotide encoding the modified PPO enzyme, the plant host, or any combination thereof). Examples of termination regions that can be used in the expression constructs and vectors of the present invention include termination regions derived from Agrobacterium tumefaciens Ti-plasmids, such as octopaline synthase and carmine synthase termination regions. See also Guerineau et al. (1991) MoI. Gen. Genet. [Molecular Genetics and General Genetics] 262: 141-144; Sanfacon et al. (1991) Genes Dev. [Genes and Development] 5:141-149; Mogen et al. (1990) Plant Cell 2:1261-1272; Munroe et al. (1990) Gene 91:151-158; Ballas et al. (1989) Nucleic Acids Res. 17:7891-7903; and Joshi et al. (1987) Nucleic Acid Res. 15:9627-9639.

[0283] For example, the expression construct may contain the Tomato Mosaic Virus (TMV) Ω5' leader sequence, and the target gene encoding the modified PPO enzyme is excised using XhoI / KpnI and cloned into pBIN 19, located after the doubly enhanced 35S promoter and before the NOS 3' transcription terminator. A suitable exemplary vector containing such an expression construct is provided herein as SEQ ID NO: 3.

[0284] Polynucleotides can be optimized to enhance expression in transformed plants. That is, polynucleotides encoding modified PPO enzymes can be synthesized using plant-preferred codons to improve expression. See, for example, Campbell and Gowri (1990) Plant Physiol. [Plant Physiology] 92:1-11 for a discussion of host-preferred codon usage patterns. Methods for synthesizing plant-preferred genes are available in the art. See, for example, U.S. Patents 5,380,831 and 5,436,391, and Murray et al. (1989) Nucleic Acids Res. [Nucleic Acids Research] 17:477-498, which are incorporated herein by reference.

[0285] In addition, other sequence modifications can be made to the polynucleotides of the present invention. For example, other sequence modifications known to enhance gene expression in the host cell are also possible. These include the elimination of sequences encoding pseudopolyadenylation signals, exon / intron splicing site signals, transposon-like repeats, and other well-characterized sequences that may be detrimental to gene expression. The GC content of the sequence can also be adjusted to the average level of the target host cell, as calculated by referencing known genes expressed in the host cell. Furthermore, the sequence can be modified to avoid predicted hairpin secondary mRNA structures.

[0286] Other polynucleotide sequences can also be used to prepare the expression constructs of the present invention, for example, to enhance the expression of polynucleotide sequences encoding modified PPO. Such polynucleotide sequences include introns of maize Adhl, intron 1 genes (Callis et al. (1987) Genes and Development 1:1183-1200), and leader sequences (W-sequences) from tobacco mosaic virus (TMV), maize chlorotic mottle virus, and alfalfa mosaic virus (Gallie et al. (1987) Nucleic Acid Res. 15:8693-8711, and Skuzeski et al. (1990) Plant Molecular Biology 15:65-79, 1990). The first intron of the maize shrunken-1 locus has been shown to increase gene expression in chimeric gene constructs. U.S. Patent Nos. 5,424,412 and 5,593,874 disclose the use of specific introns in gene expression constructs, and Gallie et al. ((1994) Plant Physiol. [Plant Physiology] 106:929-939) also showed that introns can be used to regulate gene expression on a tissue-specific basis. Plant cells transformed with such modified expression constructs or vectors can then exhibit overexpression or constitutive expression of the polynucleotides of the present invention.

[0287] The expressive construct can additionally include a 5' leader sequence. Such a leader sequence can enhance the translation. Translational leader sequences are well-known in the field and include: microRNA virus leader sequences, such as the EMCV leader sequence (5' untranslated region of encephalomyocarditis) (Elroy-Stein et al. (1989) Proc. Natl. Acad. ScL USA [Proceedings of the National Academy of Sciences], 86:6126-6130); potato virus Y leader sequences, such as the TEV leader sequence (tobacco etch virus) (Gallie et al. (1995) Gene [Gene] 165(2):233-238), the MDMV leader sequence (corn dwarf mosaic virus) (Virology [Virology] 154:9-20), and human immunoglobulin heavy chain binding protein (BiP) (Macejak et al. (1991) Nature [Nature] 353: 90-94); and the untranslated leader sequence of the coat protein mRNA from alfalfa mosaic virus (AMV RNA 4) (Jobling et al. (1987)). Nature [Nature] 325: 622-625); Tobacco mosaic virus leader sequence (TMV) (Gallie et al. (1989) in Molecular Biology of RNA, edited by Cech (Liss, New York), pp. 237-256); and Maize chlorotic mottle virus leader sequence (MCMV) (Lommel et al. (1991) Virology [Virusology] 81: 382-385). See also, Della-Cioppa et al. (1987) Plant Physiol. [Plant Physiology] 84: 965-968.

[0288] In preparing the expression constructs and expression vectors described herein, various polynucleotides can be manipulated to provide the correct orientation and, where appropriate, the polynucleotide within the correct reading frame. For this purpose, adaptors or linkers can be used to ligate nucleic acid molecules, or other manipulations can be involved to provide convenient restriction sites, remove redundant polynucleotides, remove restriction sites, etc. For this purpose, in vitro mutagenesis, primer repair, restriction, annealing, and re-substitution (e.g., conversion and transversion) can be employed.

[0289] Expression vectors may include additional features. For example, a gRNA promoter regulates the expression of at least one gRNA, such as prOsU3-01, which is the rice U3 promoter for non-coding pol III-dependent transcription. Vectors may similarly include additional features such as selectivity markers, such as phosphog-mannose isomerase (PMI) and antibiotic resistance genes, which can be used to help recover stably transformed plants.

[0290] As used herein, “operably linked” or “operably associated” means that the specified elements are functionally related to each other and are also typically physically related. Therefore, as used herein, the terms “operably linked” or “operably associated” refer to polynucleotides on a single functionally related nucleic acid molecule. Thus, a first polynucleotide sequence or nucleic acid molecule operably linked to a second polynucleotide sequence or nucleic acid molecule refers to a situation where the first polynucleotide sequence or nucleic acid molecule is functionally related to the second polynucleotide sequence or nucleic acid molecule. For example, if a promoter influences the transcription or expression of a polynucleotide sequence or nucleic acid molecule, then the promoter is operably associated with said polynucleotide sequence or nucleic acid molecule. Those skilled in the art will understand that a control sequence (e.g., a promoter) does not need to be adjacent to the polynucleotide sequence or nucleic acid molecule to which it is operably associated, as long as the control sequence functions to guide its expression. Therefore, for example, an untranslated, transcribed sequence may be present between the promoter and the polynucleotide sequence or nucleic acid molecule, and the promoter can still be considered “operably linked” to or “operably associated” with that polynucleotide sequence or nucleic acid molecule.

[0291] Herbicide resistance and application methods

[0292] The plants or portions thereof according to the invention are at least partially resistant to inhibition by compounds that inhibit PPO enzymes (i.e., PPO enzyme activity). The invention further relates to a method for controlling undesirable vegetation growth in a location containing plants in its vicinity with the modified PPO enzymes provided herein, wherein the method comprises applying an effective amount of at least one herbicide that inhibits PPO.

[0293] The term "site" includes soil, seeds, seedlings, fields, greenhouses, cultivated areas, and established vegetation.

[0294] Suitablely, the compound that inhibits PPO enzyme is a herbicide. Therefore, suitablely, the plants of the present invention are resistant to herbicides that inhibit PPO enzyme activity (referred to herein as PPO-inhibiting herbicides), and thus, such plants can be used in methods of applying these herbicides. The herbicide can be applied pre- or post-emergence to the crop plant or undesirable vegetation.

[0295] Plants exhibiting increased resistance to compounds that inhibit PPO enzyme activity (PPO-inhibiting herbicides) may be termed "herbicide-tolerant" or "herbicide-resistant" plants. Such plants are tolerant or at least partially resistant to at least one compound that inhibits PPO enzyme activity at a level that typically kills or inhibits the growth of: normal plants lacking the modified PPO enzyme of the present invention, polynucleotides or expression vectors encoding said enzyme, control plants, or wild-type plants. The term "herbicide" is used herein to mean an active ingredient that kills, controls, or otherwise adversely alters plant growth and is typically used to control undesirable vegetation.

[0296] For example, the plants of the present invention may exhibit at least a 2-fold increase in resistance to compounds that inhibit PPO enzyme activity (such as the inhibitory herbicides described herein). For example, the plants of the present invention may have at least a 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold increase in resistance. In one embodiment, compared to unmodified plants, plants of the present invention comprising at least one of the modified PPO enzymes disclosed herein may exhibit at least a 2-fold increase in resistance to any of the compounds A to E described herein. In one embodiment, compared to unmodified plants, plants of the present invention comprising at least one of the modified PPO enzymes disclosed herein may exhibit at least a 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold increase in resistance to any of the compounds A to E described herein. In one embodiment, compared to control plants, plants of the present invention comprising at least one of the modified PPO enzymes disclosed herein may exhibit at least a 2-fold increase in resistance to any of the compounds A to E described herein. In one embodiment, compared with a control plant, a plant of the present invention comprising at least one of the modified PPO enzymes disclosed herein may exhibit at least a 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold increased resistance to any of the compounds A to E described herein. For example, the control plant may be a plant comprising an alternative modified PPO enzyme to those PPO enzymes of the present invention. For example, a plant comprising a modified PPO having the sequence listed in SEQ ID NO: 124.

[0297] Resistance to compounds that inhibit PPO enzyme activity can be determined by any known method for comparing the growth, damage, or other characteristics of two plants after application of a compound that inhibits PPO enzyme activity. For example, the resistance of the plants of the present invention can be determined by comparing the percentage of damage to the plants after application of a compound that inhibits PPO enzyme activity (such as the herbicide described herein) to wild-type or control plants.

[0298] In the context of this invention, increased resistance to compounds that inhibit PPO enzyme activity (PPO-inhibiting herbicides) refers to a plant modified to contain a modified PPO enzyme, which exhibits improved or increased resistance to compounds that inhibit PPO enzyme activity, relative to an unmodified plant (e.g., wild-type) or a control plant (e.g., a plant containing the PPO enzyme according to SEQ ID NO: 124). Suitably, increased resistance may be due to increased activity of the modified PPO enzyme in the plant compared to the activity of such an enzyme in an unmodified plant when at least one compound known to interfere with PPO enzyme activity in plants is present at a concentration or level known to inhibit wild-type PPO protein activity. Improved resistance means that the plant containing the enzyme and the modified PPO enzyme itself have at least partial resistance to compounds that inhibit PPO enzyme activity (PPO-inhibiting herbicides). When exposed to compounds that inhibit PPO enzyme activity, the PPO enzyme activity of the partially resistant plants of the present invention may still be reduced, for example, by up to 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%. Therefore, suitably, the modified PPO enzyme used in the present invention may be partially resistant, and the enzyme activity of the modified PPO enzyme may still be reduced when exposed to compounds that inhibit PPO enzyme activity. In some embodiments, plants modified to contain the modified PPO enzyme may have complete or near-complete resistance to compounds that inhibit PPO enzyme activity (PPO-inhibiting herbicides). Suitably, the plants may have 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% resistance to compounds that inhibit PPO enzyme activity. Therefore, suitably, when exposed to compounds that inhibit PPO enzyme activity, the enzyme activity of the modified PPO enzyme used in this invention may not be substantially reduced.

[0299] However, when at least one compound known to interfere with PPO enzyme activity is present and the concentration or level of that compound is known to inhibit the activity of wild-type PPO proteins, any reduction in activity is less than the reduction in activity relative to the wild-type enzyme. The observed reduction in activity for partially resistant modified PPO enzymes can be a reduction in activity that has no negative impact on the growth, reproduction, or development of plants containing partially resistant modified PPO enzymes. Furthermore, the activity of such partially resistant modified PPO enzymes may be referred to herein as “herbicide-tolerant” or “herbicide-resistant” enzymes. Plants that are at least partially “resistant” to at least one compound that inhibits PPO enzyme activity rarely exhibit necrosis, lysis, chlorosis, or other damage, even if present, when exposed to that compound at concentrations and rates typically used by agricultural communities to kill unwanted vegetation in the vicinity of the plant (e.g., fields).

[0300] The modified PPO enzymes described herein can be compared with reference, unmodified, or wild-type enzymes (otherwise referred to as control enzymes) or plants containing such enzymes. The term "wild-type" is used to refer to nucleic acid molecules or proteins that can be found in nature and are different from those artificially produced or mutated by humans. Reference or unmodified PPO enzymes may be derived from the same species as the modified enzymes, but do not include any modifications of the invention as described herein. In some embodiments, the reference enzyme may be a wild-type enzyme. However, the use of the terms "unmodified" or "reference" is not intended to necessarily imply that the plant, plant tissue, plant cell, or other host cell lacks any recombinant DNA in its genome and / or does not possess herbicide resistance characteristics different from those disclosed herein. Reference or unmodified PPO enzymes mentioned herein may very well include other mutations or modifications that do not affect resistance to compounds that inhibit PPO enzyme activity. For example, a reference enzyme may include mutations or modifications to improve or alter the expression, translation, or targeting of the control enzyme in a specific tissue, organ, or cell.

[0301] In some instances, the control enzyme (or plant comprising the enzyme) mentioned may be a PPO enzyme that includes alternative modifications to those modifications of the present invention, which increase resistance to compounds that inhibit PPO enzyme activity.

[0302] Wild-type, unmodified reference PPO enzyme can be the enzyme encoded by SEQ ID NO: 1. Wild-type, unmodified reference PPO enzyme can be the PPO enzyme encoded by SEQ ID NO: 2. Reference or control PPO enzyme can be the enzyme encoded by SEQ ID NO: 124.

[0303] Many herbicides that inhibit PPO enzyme activity are known in the art and encompass a diverse range of chemicals. Therefore, those skilled in the art will understand that a broad spectrum of PPO-inhibiting herbicides is of practical use in this invention.

[0304] In one embodiment, the herbicide that inhibits PPO is selected from the group consisting of: flufenacet, cyclopyridaben, cyprodinil, flufenacet (herbicide A), flufenacet, propyzoxystrobin, flufenacet, ethoxyflufenacet, pyrazosulfuron, pyrazosulfuron (herbicide E), metolachlor, flufenacet, trifluralin (herbicide B); compounds disclosed in WO 2016 / 095768, for example, ethyl 3-(2-chloro-4-fluoro-5-(3-methyl-2,6-dioxo-4-trifluoromethyl-3,6-dihydropyrimidin-1(2H)-yl)phenyl)-5-methyl-4,5-dihydroisoxazol-5-carboxylate (herbicide C); WO Compounds described in WO 2017 / 202768, for example, ethyl acetate of 2-[[3-[[3-chloro-5-fluoro-6-[3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]-2-pyridyl]oxy]; compounds disclosed in WO 2020 / 239607, for example, (5S)-3-[2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thio-1,3,5-triazin-1-yl)-4-fluoro-phenyl]-5-methyl-4H-isooxazol-5-carboxylic acid ethyl ester (herbicide D); WO Compounds disclosed in 2021 / 013799, such as pyridin-2-ylmethyl-[(3-(2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenoxy)pyridin-2-yl)oxy]acetate; 2-methoxyethyl-[(3-(2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenoxy)pyridin- 2-(2-yl)oxy]acetate, 2-methoxyethyl-[(3-(2-cyano-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydro-pyrimidin-1(2H)-yl]phenoxy)pyridin-2-yl)oxy]acetate and cyanomethyl-[(3-(2-bromo-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenoxy)pyridin-2-yl)oxy]acetate; WO Compounds disclosed in WO 2021 / 143677, such as methyl 3-[2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1(2H)-pyrimidinyl]-4-fluorophenyl]-3a,4,5,6-tetrahydro-6-methyl-6aH-cyclopentane[d]isoxazole-6a-carboxylate; compounds disclosed in WO 2021 / 175689, such as methyl 2-[2-[2-bromo-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy]phenoxy]-2-methoxy-acetic acid;Compounds disclosed in WO 2022 / 138633, such as (2-ethoxy-2-oxo-ethyl)1-[2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy]cyclopropanecarbamate; and compounds disclosed in WO 2023 / 044364, including, where applicable, enantiomers of said compounds (including mixtures rich in enantiomers) and, where applicable, agrochemically acceptable salts and / or esters of all the foregoing compounds.

[0305] The compound that inhibits PPO enzyme activity can be any combination of one or more such inhibitory compounds, preferably one or more of the compounds listed above. For example, 1, 2, 3, 4, 5 or more inhibitory compounds as described herein.

[0306] The plants of the present invention, including the modified PPO enzyme of the present invention, can be used in methods for controlling undesirable vegetation near the plants. These methods may include applying an effective amount of at least one compound that inhibits PPO enzyme activity (such as those listed above) to the undesirable vegetation and plants.

[0307] Furthermore, plants of the present invention, including the modified PPO enzyme of the present invention, can be used in methods for enhancing plant growth by controlling undesirable vegetation near the plant. These methods may include applying an effective amount of at least one compound that inhibits PPO enzyme activity (such as those listed above) to the undesirable vegetation and the plant.

[0308] Suitably, certain modified PPO enzymes may perform better when used with certain compounds that inhibit PPO enzyme activity. Suitably, certain modified PPO enzymes may provide better resistance to certain compounds that inhibit PPO enzyme activity compared to other compounds that inhibit PPO enzyme activity. Therefore, suitably, certain combinations of PPO modifications and compounds may be best suited for use in the methods of the present invention.

[0309] In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at position 362 or the corresponding residue of SEQ ID NO: 1, and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound D). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at position 362 or the corresponding residue of SEQ ID NO: 1, and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound B). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at position 365 or the corresponding residue of SEQ ID NO: 1, and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound B). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at position 365 or the corresponding residue of SEQ ID NO: 1, and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound E). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at position 479 or the corresponding residue of SEQ ID NO: 1, and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound B). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at position 479 or the corresponding residue of SEQ ID NO: 1, and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound D). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at position 479 or the corresponding residue of SEQ ID NO: 1, and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound E).

[0310] In one embodiment of such a method, the plant of the present invention may comprise a PPO enzyme having a mutation at positions 305 and 426 or their corresponding residues in SEQ ID NO: 1, wherein the mutation at position 305 is S305L and the mutation at position 426 is Y426V or their corresponding residues (i.e., SEQ ID NO 125 or 139), and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound A). In another embodiment of such a method, the plant of the present invention may comprise a PPO enzyme having a mutation at positions 305 and 426 or their corresponding residues in SEQ ID NO: 1, wherein the mutation at position 305 is S305L and the mutation at position 426 is Y426V or their corresponding residues, and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound C). In one embodiment of such a method, the plant of the present invention may comprise a PPO enzyme having a mutation at or above positions 305 and 426 of SEQ ID NO: 1, wherein the mutation at position 305 is S305L and the mutation at position 426 is Y426V or a corresponding residue, and is intended for use with any PPO-inhibiting herbicide disclosed herein, including, for example, compound D. In another embodiment of such a method, the plant of the present invention may comprise a PPO enzyme having a mutation at or above positions 305 and 426 of SEQ ID NO: 1, wherein the mutation at position 305 is S305L and the mutation at position 426 is Y426V or a corresponding residue, and is intended for use with any PPO-inhibiting herbicide disclosed herein, including, for example, compound E.

[0311] In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 365, 426, and 479 of SEQ ID NO: 1 or at the corresponding residues (e.g., SEQ ID NO 126), and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound A). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 365, 426, and 479 of SEQ ID NO: 1 or at the corresponding residues, and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound C). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 365, 426, and 479 of SEQ ID NO: 1 or at the corresponding residues, and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound D). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 365, 426 and 479 of SEQ ID NO: 1 or at the corresponding residues, and may be used in conjunction with any herbicide that inhibits PPO disclosed herein, including, for example, compound E.

[0312] In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme having a mutation at positions 305, 404, 426, 431, and 479 of SEQ ID NO: 1 or at the corresponding residues (e.g., SEQ ID NO 127), and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound A). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme having a mutation at positions 305, 404, 426, 431, and 479 of SEQ ID NO: 1 or at the corresponding residues, and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound C). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme having a mutation at positions 305, 404, 426, 431, and 479 of SEQ ID NO: 1 or at the corresponding residues, and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound D). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme having a mutation at positions 305, 404, 426, 431 and 479 of SEQ ID NO: 1 or at the corresponding residues, and may be used in conjunction with any herbicide that inhibits PPO disclosed herein, including, for example, compound E.

[0313] In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 305 and 365 of SEQ ID NO: 1 or at the corresponding residues (e.g., SEQ ID NO 128), and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound C). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 305 and 365 of SEQ ID NO: 1 or at the corresponding residues, and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound D). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 305 and 365 of SEQ ID NO: 1 or at the corresponding residues, and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound E).

[0314] In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 305, 362, and 404 of SEQ ID NO: 1 or at the corresponding residues (e.g., SEQ ID NO 129), and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound A). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 305, 362, and 404 of SEQ ID NO: 1 or at the corresponding residues, and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound B). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 305, 362, and 404 of SEQ ID NO: 1 or at the corresponding residues, and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound C). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme having a mutation at positions 305, 362, and 404 of SEQ ID NO: 1 or at the corresponding residues, and is intended for use with any PPO-inhibiting herbicide disclosed herein, including, for example, compound D. In another embodiment of such a method, the plant of the present invention may contain a PPO enzyme having a mutation at positions 305, 362, and 404 of SEQ ID NO: 1 or at the corresponding residues, and is intended for use with any PPO-inhibiting herbicide disclosed herein, including, for example, compound E.

[0315] In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme having a mutation at positions 305, 361, 365, 431, and 479 of SEQ ID NO: 1 or at the corresponding residues (e.g., SEQ ID NO 130), and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound A). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme having a mutation at positions 305, 361, 365, 431, and 479 of SEQ ID NO: 1 or at the corresponding residues, and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound B). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme having a mutation at positions 305, 361, 365, 431, and 479 of SEQ ID NO: 1 or at the corresponding residues, and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound D). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme having a mutation at positions 305, 361, 365, 431 and 479 of SEQ ID NO: 1 or at the corresponding residues, and may be used in conjunction with any herbicide that inhibits PPO disclosed herein, including, for example, compound E.

[0316] In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 305, 426, and 479 of SEQ ID NO: 1 or at the corresponding residues (e.g., SEQ ID NO 131), and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound A). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 305, 426, and 479 of SEQ ID NO: 1 or at the corresponding residues, and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound B). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 305, 426, and 479 of SEQ ID NO: 1 or at the corresponding residues, and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound C). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 305, 426, and 479 of SEQ ID NO: 1 or at the corresponding residues, and is intended for use with any PPO-inhibiting herbicide disclosed herein, including, for example, compound D. In another embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 305, 426, and 479 of SEQ ID NO: 1 or at the corresponding residues, and is intended for use with any PPO-inhibiting herbicide disclosed herein, including, for example, compound E.

[0317] In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 426, 461, and 479 of SEQ ID NO: 1 or at the corresponding residues (e.g., SEQ ID NO 132), and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound A). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 426, 461, and 479 of SEQ ID NO: 1 or at the corresponding residues, and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound B). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 426, 461, and 479 of SEQ ID NO: 1 or at the corresponding residues, and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound C). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 426, 461 and 479 of SEQ ID NO: 1 or at the corresponding residues, and may be used in conjunction with any herbicide that inhibits PPO disclosed herein, including, for example, compound E.

[0318] In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 305, 361, and 365 of SEQ ID NO: 1 or at the corresponding residues (e.g., SEQ ID NO 133), and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound A). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 305, 361, and 365 of SEQ ID NO: 1 or at the corresponding residues, and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound B). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 305, 361, and 365 of SEQ ID NO: 1 or at the corresponding residues, and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound C). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme having a mutation at positions 305, 361, and 365 of SEQ ID NO: 1 or at the corresponding residues, and is intended for use with any PPO-inhibiting herbicide disclosed herein, including, for example, compound D. In another embodiment of such a method, the plant of the present invention may contain a PPO enzyme having a mutation at positions 305, 361, and 365 of SEQ ID NO: 1 or at the corresponding residues, and is intended for use with any PPO-inhibiting herbicide disclosed herein, including, for example, compound E.

[0319] In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 305, 361, 362, 426, and 479 of SEQ ID NO: 1 or at the corresponding residues (e.g., SEQ ID NO 134), and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound A). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 305, 361, 362, 426, and 479 of SEQ ID NO: 1 or at the corresponding residues, and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound C). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 305, 361, 362, 426, and 479 of SEQ ID NO: 1 or at the corresponding residues, and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound D). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme having a mutation at positions 305, 361, 362, 426 and 479 of SEQ ID NO: 1 or at the corresponding residues, and may be used in conjunction with any herbicide that inhibits PPO disclosed herein, including, for example, compound E.

[0320] In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 361 and 365 of SEQ ID NO: 1 or at its corresponding residues (e.g., SEQ ID NO 135), and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound C). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 361 and 365 of SEQ ID NO: 1 or at its corresponding residues, and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound B). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 361 and 365 of SEQ ID NO: 1 or at its corresponding residues, and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound D). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 361 and 365 of SEQ ID NO: 1 or at its corresponding residues, and may be used in conjunction with any PPO-inhibiting herbicide disclosed herein (including, for example, compound E).

[0321] In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 365, 404, and 479 of SEQ ID NO: 1 or at the corresponding residues (e.g., SEQ ID NO 136), and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound B). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 365, 404, and 479 of SEQ ID NO: 1 or at the corresponding residues, and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound C). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 365, 404, and 479 of SEQ ID NO: 1 or at the corresponding residues, and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound D). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 365, 404 and 479 of SEQ ID NO: 1 or at the corresponding residues, and may be used in conjunction with any herbicide that inhibits PPO disclosed herein, including, for example, compound E.

[0322] In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 305, 404, and 479 of SEQ ID NO: 1 or at the corresponding residues (e.g., SEQ ID NO 137), and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound A). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 365, 404, and 479 of SEQ ID NO: 1 or at the corresponding residues, and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound B). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme with a mutation at positions 365, 404, and 479 of SEQ ID NO: 1 or at the corresponding residues, and is intended for use with any PPO-inhibiting herbicide disclosed herein (including, for example, compound C). In one embodiment of such a method, the plant of the present invention may contain a PPO enzyme having a mutation at positions 365, 404, and 479 of SEQ ID NO: 1 or at the corresponding residues, and is intended for use with any PPO-inhibiting herbicide disclosed herein, including, for example, compound D. In another embodiment of such a method, the plant of the present invention may contain a PPO enzyme having a mutation at positions 365, 404, and 479 of SEQ ID NO: 1 or at the corresponding residues, and is intended for use with any PPO-inhibiting herbicide disclosed herein, including, for example, compound E.

[0323] Undesirable vegetation can include, for example, dicotyledonous and monocotyledonous weeds. Dicotyledonous weeds include, but are not limited to, the following genera: Mustard, Ligustrum, Galium, Chickweed, Matricaria, Chrysanthemum, Achyranthes, Chenopodium, Nettle, Senecio, Amaranth, Portulaca, Xanthium, Convolvulus, Ipomoea, Polygonum, Sesbania, Ragweed, Thistle, Calendula, Sophora, Solanum, Watercress, Jointed Vegetable, Motherwort, Wild Sesame, Veronica, White Hemp, Trichosanthes, Datura, Viola, Weasel, Poppy, Cornflower, Clover, Ranunculus, and Taraxacum. Monocotyledonous weeds include, but are not limited to, the following genera: barnyard grass, foxtail grass, millet, crabgrass, cogon grass, Kentucky bluegrass, fescue, goosegrass, armgrass, ryegrass, bromegrass, oat, sedge, sorghum, icegrass, bermudagrass, hyacinth, sedge, arrowhead, water chestnut, sedge, paspalum, duckbill grass, bellflower, creeping bentgrass, barnyard grass, and apis.

[0324] Additionally, undesirable vegetation can include, for example, crop plants growing in undesirable locations. For instance, if corn plants are undesirable in a soybean field, then native corn plants in a field primarily composed of soybeans can be considered weeds.

[0325] "Effective amount" or "effective concentration" refers to the amount and concentration of a compound that inhibits PPO enzyme activity (a PPO-inhibiting herbicide) sufficient to kill or inhibit the growth of wild-type plants and / or unwanted plants, plant tissues, plant cells, microspores, or host cells, but not to severely kill or inhibit the growth of plants, parts thereof, plant tissues, plant cells, and seeds having at least partial resistance to the modified PPO described herein. Typically, an effective amount is the amount routinely used in agricultural production systems to kill unwanted target vegetation. Such amounts are known to those skilled in the art or can be readily determined using methods known in the art. Furthermore, it is recognized that an effective amount in an agricultural production system may differ significantly from an effective amount in a plant culture system, such as a microspore culture system. Thus, the amount may be small enough to only delay or inhibit the growth or development of a given weed or unwanted vegetation, or it may be large enough to irreversibly destroy a given weed or unwanted vegetation. Moreover, the amount can be any amount in between.

[0326] The effective amount can be at least 1 gram of active compound per hectare (g ai / ha). For example, compounds that inhibit PPO enzyme activity can be present in quantities of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250. 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500 g active compound per hectare.

[0327] It should be understood that, in the above methods, the compound can be applied to the vicinity of the plant before and / or after crop emergence (so-called "excessive" application).

[0328] "Pre-emergence" refers to the application of the compound to the vicinity of plants of the present invention that have at least partial resistance (e.g., cultivated fields or areas) before the plants have clearly emerged from the soil and / or before seed germination. "Post-emergence" refers to the application of the compound to the vicinity of plants of the present invention that have at least partial resistance after the plants have clearly emerged from the soil. In some cases, the terms "pre-emergence" and "post-emergence" are used to refer to weeds or undesirable vegetation near plants of the present invention that have at least partial resistance; in other cases, these terms are used to refer to crop plants near plants of the present invention that have at least partial resistance. When referring to weeds or undesirable vegetation, these terms may apply only to specific types or species of weeds or undesirable vegetation present or believed to be present in the target area. While any compound that inhibits PPO enzyme activity can be applied in pre-emergence and / or post-emergence treatments, some such compounds are known to be more effective in controlling one or more weeds or undesirable plants when applied pre-emergence or post-emergence. The compound can be applied in a "pre-planting incorporation" manner, which involves incorporating the compound into the soil before planting.

[0329] The application rate of compounds that inhibit PPO enzyme activity can vary within a wide range and depends on soil properties, application method (pre-emergence; post-emergence; seed furrow application; no-till application, etc.), plant, unwanted vegetation to be controlled, major climatic conditions, and other factors governed by application method, application time, and target crop. Compounds that inhibit PPO enzyme activity can be applied at a rate of at least 1 L / ha. For example, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 17 0, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 3 40, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 550 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000 L / ha. In some instances, the compound can be applied at a rate of 200 L / ha.

[0330] The compound is typically applied by spraying, usually using a tractor-mounted sprayer for large areas, but other methods such as dusting (for powders), dripping, or immersion can also be used.

[0331] As discussed elsewhere herein, plants, plant parts, and seeds are provided having the modified PPO provided herein stably incorporated into their genome, as well as additional polynucleotides conferring tolerance to at least one other herbicide, including, for example, herbicides containing glyphosate, glufosinate, HPPD herbicides, etc. Therefore, the application of an effective amount of a PPO-inhibiting herbicide can be combined with the application of other herbicides to which the crop is naturally resistant or to which the crop is resistant by expressing one or more modified herbicide resistance genes.

[0332] The one or more other herbicides, when applied in combination with a PPO-inhibiting herbicide, can be applied sequentially (e.g., successively) or simultaneously without affecting the yield or growth of herbicide-resistant plants. This includes applying the one or more other herbicides according to a schedule based on the application of the PPO-inhibiting herbicide. In simultaneous application, an effective amount of each herbicide is applied to the plant simultaneously (e.g., at the same stage of plant growth, and / or as a component of a herbicide composition comprising the one or more herbicides and the HPPD-inhibiting herbicide). In sequential application, an effective amount of each herbicide is applied to the plant successively.

[0333] According to the present invention, "enhancing plant growth" means improved plant vitality, improved plant quality, improved tolerance to stress factors, and / or improved efficiency of input.

[0334] The invention described herein also relates to a kit comprising a container and instructions for use, the container comprising a compound that inhibits PPO enzyme activity, and the instructions comprising instructions for applying the compound to a plant modified to contain a modified PPO enzyme that provides increased resistance to the compound to the plant or a portion thereof.

[0335] Suitably, the compound can be any of those defined above. Suitably, instructions for applying the compound can include instructions for applying the compound at an effective amount as defined above. Suitably, instructions for applying the compound can include instructions for applying the compound at a specific ratio as described above. Suitably, instructions for applying the compound can include instructions for applying the compound by a specific method, such as by spraying as defined above. Suitably, instructions for applying the compound can include instructions for applying the compound at a specific time (such as before and / or after crop emergence) or during a specific season or month.

[0336] Suitablely, these instructions may also include guidance on preparing the compound so that it can be applied in a desired effective amount and by a desired method. Suitablely, such guidance may include guidance on suitably diluting the compound in a solvent (such as water) to an effective concentration.

[0337] Further provided are compositions comprising the modified PPO enzymes disclosed herein (e.g., any one of SEQ ID NO: 1, 2, 4-151, 153-302 or 305-336 or SEQ ID No: 37-39, 58, 59, 97-99, 118, 119, 125-137, 139-151, 188-190, 209, 210, 248-250, 269, 270, 277-288 or 291-302 or their active variants) and herbicides that inhibit PPO (including, but not limited to, herbicides disclosed herein as herbicides A, B, C, D or E).

[0338] Filtering methods

[0339] Various screening methods are further provided: methods for screening plants with increased resistance to compounds that inhibit PPO enzyme activity, methods for screening modified PPO enzymes containing increased resistance to compounds that inhibit PPO enzyme activity, and methods for screening compounds that inhibit PPO enzyme activity.

[0340] In one aspect of the invention, a method is provided for selecting a plant or organism (including, for example, a prokaryote, such as bacteria) having increased resistance to a compound that inhibits PPO enzyme activity relative to an unmodified plant or organism, the method comprising: (a) providing the plant or organism; (b) optionally mutagenesis of the plant or organism; (c) exposing the plant or organism to an effective amount of the compound that inhibits PPO enzyme activity; and (d) selecting the plant or organism if it exhibits resistance to the compound.

[0341] In one embodiment, the plant may be a plant according to the first aspect of the invention and may include any characteristics of such a plant as defined herein.

[0342] Suitablely, step (b) may include mutagenesis of the plant or organism by any known means such as EMS or other chemical treatment, or by X-ray or other radiation treatment. Suitablely, modification in the PPO gene may be induced, suitablely, one or more mutations.

[0343] Suitably, after step (b), the plant or organism contains one or more modifications to an endogenous or heterologous PPO gene, or one or more mutations in the endogenous or heterologous PPO gene. Suitably, the modified PPO gene may encode a modified PPO enzyme, suitably as described herein. Therefore, suitably, after step (b), the plant or organism may contain a modified PPO enzyme as described herein, suitably having one or more mutations as described herein.

[0344] Suitablely, step (c) includes exposing the plant or organism to an effective amount of the compound as described above. Suitablely, it is determined whether the one or more modifications to the endogenous or heterologous PPO gene produced in step (b) and the resulting modified PPO enzyme confer resistance to the compound.

[0345] Suitablely, if a plant or organism exhibits resistance to a compound, selection of that plant or organism may include, for example, selecting those plants that do not exhibit any PPO deficiency markers. Suitablely, such markers may include stunted growth, wilting, necrosis, discoloration, etc. For organisms (such as bacteria), resistance to a compound may include the ability to grow in the presence of a herbicide.

[0346] A further method for identifying a modified PPO enzyme comprising increased resistance to compounds that inhibit PPO enzyme activity is provided, the method comprising: (a) generating a library of polynucleotides encoding modified PPO; (b) screening a population of resulting polynucleotides encoding modified PPO by expressing each of the polynucleotides in a bacterium, plant, or plant part and exposing the bacterium, plant, or plant part to an effective amount of a compound that inhibits PPO enzyme activity; and (c) selecting polynucleotides encoding modified PPO that provide the bacterium, plant, or plant part with increased resistance to the compound compared to a reference bacterium, plant, or plant part containing a polynucleotide encoding an unmodified or control PPO.

[0347] Suitablely, generating libraries of polynucleotides encoding modified PPO can be performed using any known technique to produce gene libraries containing different modifications (suitably mutations throughout the gene sequence). Suitablely, these methods can be randomized or directed. Such methods may include exposing polynucleotides encoding PPO to mutagens (such as chemicals or radiation), or, for example, performing error-prone PCR on polynucleotides encoding PPO. Other molecular techniques may include DNA shuffling or cross-extension processes on polynucleotides encoding PPO.

[0348] Suitable transformation methods and suitable constructs for expressing polynucleotides encoding PPO are described elsewhere in this document.

[0349] Suitable exposure of bacteria, plants or parts thereof to an effective amount of a compound that inhibits PPO enzyme activity includes using an effective amount of a suitable compound as described above.

[0350] Suitable selection includes choosing polynucleotides encoding modified PPOs that provide increased resistance to said compound in bacteria, plants, or plant parts thereof, including selecting those host bacteria, plants, or plant parts thereof that exhibit resistance to the compound, and suitable selection includes those host bacteria, plants, or plant parts thereof that do not exhibit any PPO deficiency markers. Suitablely, such markers in plants may include stunted growth, wilting, necrosis, discoloration, etc. Suitablely, such markers in bacteria may include stunted growth or death. In one embodiment, the marker is reduced growth compared to unmodified or control bacteria or unmodified or control plants.

[0351] A method for identifying compounds that inhibit PPO enzyme activity is also provided, the method comprising: (a) generating a modified plant or part as described herein; (b) applying a test compound to the plant or part thereof of step (a) and an unmodified reference plant; and (c) selecting a test compound that imparts a reduction in growth to the unmodified reference plant compared to the growth of the modified plant or part thereof.

[0352] In one embodiment, the modified plant or plant part is a plant that has increased resistance to compounds that inhibit PPO enzyme activity as defined in the first aspect of the invention, and may include any characteristics of such plants as enumerated herein.

[0353] Suitablely, the test compound can be any compound that may have or is expected to have inhibitory effects on PPO enzymes in plants. Suitablely, the test compound can involve, be derived from, or be synthesized from compounds as defined herein, and can be a known compound that inhibits PPO enzyme activity (such as a known herbicide compound).

[0354] Suitablely, the test compound may be applied at a test amount, which may be the same as any known effective amount of such herbicide, the suitable amount being defined above.

[0355] In another aspect of the invention, one or more compounds identified by such a method are provided, optionally for use as herbicides. Attached Figure Description

[0356] The invention will now be described with reference to the following figures, in which:

[0357] Figure 1 The plasmid map of the pBin TMV AtPPO1 transformation vector is shown. Example

[0358] Example 1 - Expression and determination of Arabidopsis thaliana PPO1 site saturated variant library in Escherichia coli

[0359] Twist Bioscience synthesized a pET24a plasmid containing a DNA sequence (SEQ ID NO:3) encoding a variant of Arabidopsis thaliana PPO1 (AtPPO1), codon-optimized for expression in *E. coli* under the control of the T7 promoter. This plasmid was used as the basis for a site-saturated variant library (SSVL), which replaces codons at 352 amino acid positions with codons encoding one of 19 other amino acids or removes the codon entirely, thereby producing translational products with deletions at those positions. The 352 mutated positions are listed in Table 1.

[0360] Table 1: Amino acid positions of AtPPO1 with reference to SEQ ID NO 1 mutation

[0361]

[0362]

[0363] SSVL was batch-transformed into *E. coli* BL21(DE3) hemG strain (the hemG gene of which was replaced with a CmR gene conferred resistance to chloramphenicol) via electroporation, and then plated onto LA supplemented with 50 µg / mL kanamycin, 25 µg / mL chloramphenicol, and 20 µg / mL heme. Each batch consisted of all plasmids containing variants at two sites. Colonies from the batch transformation were inoculated into 500 µL of Terrific broth (supplemented with 50 µg / mL kanamycin, 25 µg / mL chloramphenicol, and 20 µg / mL heme) in 96-well plates. The cultures were incubated at 37°C with shaking at 250 rpm for 24 h. The overnight cultures were centrifuged, and the cell pellet was resuspended in 500 µL of Terrific broth. Resuspended cultures were inoculated at a ratio of 1:100 into fresh 96-well plates containing 500 µL of Terrific broth (supplemented with 0.1 mM IPTG, 50 µg / mL kanamycin, 25 µg / mL chloramphenicol, and 6.25 ppm herbicide D or E, or 0.78 ppm herbicide B or DMSO). The assay cultures were grown at 37°C with shaking at 250 rpm for 24 h, with OD600 measured 24 h post-inoculation. Strains grown in DMSO and herbicides were identified as herbicide-resistant, with the percentage of growth inhibition calculated as follows:

[0364] OD600 DMSO - OD600 herbicide / OD600 DMSO x 100

[0365] Plasmids were isolated from herbicide-tolerant strains and sequenced to identify causal mutations in the AtPPO1 gene carried by pET24a in each strain. All identified herbicide-tolerant variants are listed in Table 2.

[0366] Note that in all instances, herbicides A through E are as described above. Table 2: AtPPO1 variants identified as resistant to one or more of herbicides B, D, or E. This table shows the percentage of growth inhibition in the presence of herbicides B, D, or E compared to growth in DMSO.

[0367]

[0368]

[0369] Example 2 - AtPPO1 combined variant library screening.

[0370] A subset of the identified herbicide tolerance mutations from Example 1 were selected and incorporated into a combinatorial variant library (manufactured by TopVest Biosciences). The frequencies of the selected mutations and designs within the combinatorial library are shown in Table 3.

[0371] Table 3: Selection of AtPPO1 mutations for inclusion in combined libraries. The percentage frequency of each mutation within the library is shown.

[0372]

[0373] The combinatorial library was transformed into *E. coli* BL21(DE3) hemG, and selection was made for increased herbicide tolerance (as described in Example 1, except for herbicide concentrations increased to 25 ppm (herbicides B and D) and 50 ppm (herbicide E)). Plasmids were isolated from the herbicide-tolerant strains and sequenced to identify causal mutations in the AtPPO1 gene carried by the pET24 plasmid in each strain. All identified herbicide-tolerant variants are listed in Table 4.

[0374] Table 4: AtPPO1 variants with multiple mutations based on robust growth selection in the presence of herbicides.

[0375]

[0376] Example 3 - Expression and determination of selected Arabidopsis PPO1 variants and percentage inhibition relative to herbicides A through E ratio.

[0377] Topsys Biosciences synthesized a pET24 plasmid containing DNA sequences encoding each identified variant mutant of AtPPO1 derived from Arabidopsis thaliana, codon-optimized for expression in *E. coli* under the control of the T7 promoter. This plasmid was expressed in *E. coli* BL21(DE3) hemG under selection conditions containing 50 µg / mL kanamycin and 25 µg / mL chloramphenicol. Using overnight cultures grown at 37°C, cells were inoculated at a ratio of 1:100 into 150 mL of AIM (AIM-Terrific broth matrix including trace elements, Formedium) in 500 mL shake flasks. The cultures were grown at 37°C, 200 rpm for 3 hours, then overnight at 26°C. Cells were harvested by centrifugation at 600 rpm for 20 minutes at 4°C. Cells were stored at -80°C until extraction. Thaw 0.5–1 g of the cell pellet and resuspend it 1:1 in lysis buffer (20 mM Tris pH 8, 500 mM sodium chloride, 10% glycerol, 1X EDTA-free complete protease inhibitor tablet (Roche)). Sonicate the resuspended 50% for 10–20 cycles (10 seconds sonication, 20 seconds pause). After sonication, add Triton X-100 to the lysate at a final concentration of 0.5%. Centrifuge the lysate at 13,000 rpm for 10 min at 4°C. Store the crude extract (i.e., the supernatant) at -80°C.

[0378] Protein concentration was measured and calculated using absorbance at 280 nm. The extract was diluted 1:4, and 10 μL was analyzed by SDS-PAGE.

[0379] In the fluoresceinogen oxidase assay, the crude extract of the variant was determined in a black 384-well plate with a clear bottom. The total volume of the reaction mixture was 100 μL and contained 100 mM K₂HPO₄ pH 7.2, 1 mM Na₂EDTA, 5 mM MTT, 20% glycerol (v / v), and 0.025% Tween 20 (v / v). The reaction was initiated by adding 1 μM protoporphyrinogen IX to the final assay concentration. Fluorescence was monitored over 30 min using a Tecan microplate reader with excitation at 405 nm, emission at 635 nm, gain of 90, and 15 flashes. In the assay for 1% DMSO and 100 ppm herbicide B, three-fold serial dilutions (10 μL) of the crude extract in 100 mM K₂HPO₄ pH 7.2, 1 mM Na₂EDTA, 5 mM DTT, 20% glycerol (v / v), and 0.05% Tween 20 (v / v) were tested to determine the correct amount of crude extract to add to the assay to observe activity. Then, in the fluoresceinogen oxidase assay, 10 μL of the appropriate crude extract dilution was tested against DMSO and each compound (herbicides A through E) at 10-fold doses (maximum ratio 100 ppm).

[0380] The inhibition percentage was calculated as the percentage of enzyme activity in DMSO in the presence of one of the four herbicide compounds A through E at four concentrations (note that the compounds labeled A through E are identified in the relevant section of the specification above) (Table 5).

[0381] Table 5:

[0382]

[0383] The results showed that, compared with the parental gene AtPPO1 (SEQ ID NO:1) or a previously known PPO1 variant (SEQ ID NO:2), the selected variants exhibited improved tolerance to at least one of the PPO-inhibiting herbicides A to E. In some cases, such as for AtPPO1 S305L Y426V (SEQ ID NO:125), improved herbicide tolerance was observed in all tested herbicides. In other instances, differential tolerance to the tested herbicides was observed; for example, AtPPO1 Y361D V365L (SEQ ID NO:135) showed improved tolerance to some herbicides (i.e., B, C, D, and E) compared to SEQ ID NO:124, but no improvement in tolerance to other herbicides (i.e., herbicide A) was observed.

[0384] TopVest Biosciences synthesized a pET24 plasmid containing a DNA sequence encoding a variant of AtPPO1 derived from Arabidopsis thaliana. This sequence was cTP removed and supplemented with a 6xHis tag and a TEV protease cleavage tag at the N-terminus. Codon optimization was performed for expression in *E. coli* under the control of the T7 promoter. The following variants were synthesized: WTAtPPO1 (SEQ ID NO: 370), AtPPO1 L479M (SEQ ID NO: 371), AtPPO1 L479N (SEQ ID NO: 372), AtPPO1 S305L Y426V (SEQ ID NO: 374), and AtPPO1 S305L Y426V L479M (SEQ ID NO: 373). This plasmid was expressed in *E. coli* BL21 (DE3) under selection conditions containing 50 µg / mL kanamycin. 10 mL of overnight culture grown at 37°C was used to inoculate 1 L of AIM (AIM-Terrific broth matrix including trace elements, Formedia) in a 2 L shake flask. The culture was incubated at 37°C and 200 rpm for 3 hours, then overnight at 26°C. Cells were harvested by centrifugation. 5–15 g of cell pellet was lysed in lysis buffer (20 mM Tris pH 8, 500 mM sodium chloride, 10% glycerol, 1X EDTA-free complete protease inhibitor tablet (Roche), 10 mM imidazole) and resuspended at a 1:1.5 ratio. The resuspended pellet was sonicated at 75% for 10 cycles (30 sec sonication, 40 sec pause). After sonication, Triton X-100 was added to the lysate at a final concentration of 0.5%. The lysate was centrifuged at 20,000 rpm for 25 min at 4°C. The clarified lysate was loaded onto a His GraviTrap (Cytiva) column, washed with 20 mL of lysis buffer, and eluted in elution buffer (20 mM Tris pH 8, 500 mM sodium chloride, 10% glycerol, 200 mM imidazole, 0.03% (v / v) Triton X-100). The eluent was desalted on a PD10 column and 2.5–3.2 mL was collected. Protein concentration was measured and calculated using absorbance at 280 nm. The extract was diluted 1:4, and 10 μL was analyzed by SDS-PAGE.

[0385] The activity of partially purified protoporphyrinogen oxidase was determined using a fluorescence method adapted from that of Shepherd and Dailey (Anal Biochem. [Analytical Chemistry] 2005 344(1) 115-121). The assay was performed in black 384-well plates with transparent bottoms, and the total volume of the reaction mixture was 91 μL. The final assay mixture contained 100 mM K₂HPO₄ pH 7.2, 1 mM Na₂EDTA, 5 mM DTT, 20% glycerol (v / v), 0.05% Tween 20 (v / v), 1.1% DMSO (v / v), 1 μM protoporphyrinogen IX, and 1.5 nM enzyme. The compound was dissolved in DMSO at 1 mM and serially diluted 4-fold to give 8 ratios. 1 μL was added to the assay mixture. This yielded final compound concentrations of 11, 2.7, 0.69, 0.17, 0.04, 0.01, 0.002, and 0.0007 uM. The enzyme and inhibitor were pre-incubated for 5 minutes before adding the substrate to begin the reaction. Fluorescence was monitored over 30 minutes at room temperature using a Tecan Infinite M200PRO microplate reader with excitation at 405 nm, emission at 635 nm, gain of 100, and 15 flashes. During the linear phase of the reaction, the inhibition percentage of each compound at each concentration relative to the uninhibited control was calculated. IC50 was calculated using nonlinear regression with GraphPad Prism 7.05 (Table 6). Each compound was tested in duplicate.

[0386] For all herbicides tested except flumetsulam, AtPPO1 V002 (SEQ ID NO: 373) had a higher IC50 than AtPPO1 V030 (SEQ ID NO: 374). These variants share two mutations, but AtPPO1 V002 (SEQ ID NO: 373) has an additional L479M substitution, while AtPPO V030 (SEQ ID NO: 374) lacks this substitution. One mechanism by which the substitution at L479 can enhance tolerance is by increasing the rate of PPO1 enzyme activity (Table 7).

[0387] Table 6: IC50 (nM) of protoporphyrinogen oxidase variants treated with different PPO inhibitors. < 1.0 indicates below the detection limit.

[0388]

[0389] Table 7 - Activity rates of protoporphyrinogen oxidase variants in vitro.

[0390]

[0391] rfu = relative fluorescence unit

[0392] Example 4 - PPO1 sequence and expression in tobacco plants

[0393] Arabidopsis PPO1 or its orthologs (e.g., SEQ ID NO: 1 and 124-137) or millet PPO1 or its orthologs (e.g., SEQ ID NO: 2 and 138-151) were expressed in transgenic tobacco. The DNA sequences encoding these polypeptides (optimized for tobacco, or optionally codon-optimized according to target crops such as soybean or maize) were prepared synthetically. Each sequence was designed to include a 5' fusion with a TMVΩ 5' leader sequence, and they were side-joined with XhoI at the 5' end and KpnI at the 3' end to facilitate direct cloning into binary vectors suitable for Agrobacterium-based plant transformation.

[0394] In one instance, an expression cassette (containing the TMVΩ5' leader sequence and the target PPO1 coding gene) was excised using XhoI / KpnI and cloned into a similarly digested pBIN 19 (Bevan, Nucleic Acids Res. [Nucleic Acid Research] 12:8711-8721 (1984)) to produce a binary vector, for example, Figure 1 The vector (SEQ ID NO: 152) (after the double-enhanced 35S promoter and before the NOS 3' transcription terminator) was then transformed into *E. coli* DH5α competent cells. *Agrobacterium tumefaciens* LBA4404 was transformed using DNA recovered from this *E. coli*, and the transformed bacteria were selected on a medium containing rifampin and kanamycin. Tobacco tissue was subjected to *Agrobacterium tumefaciens*-mediated transformation using methods well described in the art or as described herein. For example, a mother plate containing a binary vector expressing PPO1 from *Agrobacterium tumefaciens* was used to inoculate 10 ml of LB (L liquid medium) containing 100 mg / L rifampin and 50 mg / L kanamycin (using a single colony). This culture was incubated overnight at 28°C with shaking at 200 rpm. This entire overnight culture was used to inoculate 50 ml of LB containing the same antibiotics. This culture was then incubated again overnight at 28°C with shaking at 200 rpm. The Agrobacterium cells were precipitated by centrifugation at 3000 rpm for 15 minutes and then resuspended in MS (Murashige and Skoog) medium containing 30 g / L sucrose at pH 5.9 until OD (600 nM) = 0.6. The suspension was then aliquoted into 25 ml Petri dishes.

[0395] Young (not fully unfolded) leaves were removed from tobacco shoot cultures propagated clonally via microvessels. The midrib and outer leaf margins were removed and discarded, and the remaining leaves were cut into 1 cm squares. These squares were transferred to an Agrobacterium suspension and allowed to remain for 20 minutes. The explants were then removed, tapped on sterile filter paper to remove excess suspension, and transferred to solid NBM medium (MS medium containing 30 g / L sucrose, 1 mg / L BAP (benzylaminopurine), and 0.1 mg / L NAA (naphthaleneacetic acid), pH 5.9, and fixed with 8 g / L plant agar), with the abaxial surface of each explant in contact with the medium. Approximately 7 explants were transferred per plate, and the plates were then sealed and incubated in a light incubator at 25°C for 16 hours per photoperiod for 3 days.

[0396] The explants were then transferred to NBM medium containing 100 mg / L kanamycin plus antibiotics (200 mg / L termethin and 250 mg / L carbenicillin) to prevent further growth of Agrobacterium. Subcultures were then performed every two weeks on the same medium.

[0397] When shoots began to regenerate from the callus explants, these shoots were transferred to shoot elongation medium (MS medium, 30 g / L sucrose, 8 g / L plant agar, 100 mg / L kanamycin, 200 mg / L termethin, 250 mg / L carbenicillin, pH 5.9). Stable transgenic plants readily rooted within 2 weeks. To provide multiple plants for each event, ultimately allowing for testing of more than one herbicide for each transgenic plant, all rooted shoots were micropropagated to generate 3 or more rooted clones.

[0398] PCR analysis was performed on presumed transgenic plants that were rooting and exhibiting vigorous branching growth on kanamycin-bound media using primers that amplified a 500 bp fragment specific to the target AtPPO1 transgene. Evaluation of this same primer set on untransformed tobacco conclusively showed that these primers did not amplify any sequences from the natural tobacco genome.

[0399] Transformed shoots were divided into 2 or 3 clones and regenerated from kanamycin-resistant callus. The shoots were then rooted on MS agar containing kanamycin. The surviving rooted explants were then allowed to regenerate roots, thus providing approximately 40–50 kanamycin-resistant and PCR-positive events from each event.

[0400] Once rooted, transfer these small plantlets from the agar and pot them in 3-inch round pots containing 50% peat moss and 50% John Innes Soil No. 3 with slow-release fertilizer. Water regularly and establish them in the greenhouse for 8-12 days. Greenhouse conditions are approximately 24°C-27°C during the day; 18°C-21°C at night; and a photoperiod of approximately 14 hours. Adjust the humidity to approximately 65% ​​and use a light intensity of up to 2000 mmol / m² on the worktable. 2 .

[0401] This resulted in transgenic populations of approximately forty tobacco plants containing genes encoding the full-length Arabidopsis PPO1 gene (SEQ ID NO: 1) or its variants (SEQ ID NO: 1 and 124 to 137) or the full-length millet PPO1 gene (SEQ ID NO: 2) or its variants (SEQ ID NO: 138-151). Plants were selected from each population based on similar size and subjected to ELISA or Mass Western blotting to monitor transgenic PPO protein expression levels. The highest-expressing T0 lines were selected and self-pollinated in a normal manner to produce T1 and T2 lines and seeds. Seeds from the highest-expressing lines were tested for germination on agar plates containing a series of concentrations of herbicides that inhibit PPO, as taught in the examples herein, and resistant plant lines were selected for minimal damage to root or leaf growth and morphology at the highest concentrations of herbicides. Compared to wild-type and ineffective isolates with similar growth and treatment, resistant plant lines exhibited a dose-response to the right regarding the herbicidal damage from the PPO1 inhibitor.

[0402] Example 5 - Herbicide tolerance in transgenic tobacco plants expressing heterologous AtPPO1 or heterologous SiPPO1 variants Determination of sexuality.

[0403] To determine whether overexpression of the gene detailed in Example 3 (millet PPO1 (SEQ ID NO: 2 or 138-151) or any one of SEQ ID NO: 1, 2, 4-151, 155-302 or 305-336) confers resistance to compounds that inhibit PPO when expressed in plants, GM tobacco lines were produced and tested with compounds that inhibit PPO. Transgenic tobacco plants expressing the Arabidopsis PPO1 gene and its variants (SEQ ID NO 1 and 124-137) and transgenic tobacco plants expressing the millet PPO1 gene and its variants (SEQ ID NO 2 and 138-151) were produced.

[0404] As described in Example 4, transgenic tobacco populations were generated, each containing 20-30 transgenic events. These lines were cloned and propagated, and one clone / event was sprayed with a PPO herbicide to confirm herbicide resistance.

[0405] Visual assessment of weed damage across the entire population was performed, with herbicide damage scores given at days 7 and 14. A score of 0 indicated no visible damage or stunted growth, while a score of 100 indicated complete plant death. One week prior to spraying the compound that inhibited PPO, 20 transgenic events (i.e., individual transgenic plants) from each GM tobacco line were transplanted into the soil. WT tobacco was included as a control. Table 8 below shows the treatment protocols used.

[0406] Example 5A - Determination of herbicide tolerance in transgenic tobacco plants expressing heterologous AtPPO1 variant

[0407] Data on herbicide tolerance in transgenic tobacco plants were generated based on Example 5 above and are shown in Tables 11-24. Weed damage was visually assessed across the entire population, and herbicide damage scores were given at days 7 and 14. A score of 0 indicated no visible damage or stunted growth, while a score of 100 indicated complete plant death. One week prior to spraying with a compound that inhibits PPO, 20 transgenic events (i.e., individual transgenic plants) from each GM tobacco line were transplanted into the soil. WT tobacco was included as a control. Table 8 below shows the treatment protocols used.

[0408] Table 8: Treatment protocols used for testing PPO inhibitor resistance

[0409]

[0410] Table 9: Plants transformed with Arabidopsis PPO gene variants.

[0411]

[0412] The results are shown in Tables 11 to 24 below. Herbicide damage was assessed in the wild-type Samsun tobacco control population, and the results are shown in Table 10. Wild-type Samsun plants showed significant damage at the assessment times of day 7 and day 14.

[0413] Table 10: Percentage of damage to WT tobacco plants

[0414]

[0415] Table 11: Results of the percentage of damage to tobacco plants containing pBin TMV AtPPO1.

[0416]

[0417] Table 12: Results of the percentage of damage to tobacco plants containing pBin TMV AtPPO1 V022 (mutant V365L G404A L479N).

[0418]

[0419] Table 13: Results of the percentage of damage to tobacco plants containing pBin TMV AtPPO1 V025 (mutant Y426M T461Q L479M).

[0420]

[0421] Table 14: Results of the percentage of damage to tobacco plants containing pBin TMV AtPPO1 V035 (mutant Y361D V365L).

[0422]

[0423] Table 15: Results of the percentage of damage to tobacco plants containing pBin TMV AtPPO1 V055 (mutant S305L V365M).

[0424]

[0425] Table 16: Results of the percentage of damage to tobacco plants containing pBin TMV AtPPO1 V019 (mutant S305L G404A L479N).

[0426]

[0427] Table 17: Results of the percentage of damage to tobacco plants containing pBin TMV AtPPO1 V020 (mutant S305L Y361T V365L T431R L479M).

[0428]

[0429] Table 18: Results of the percentage of damage to tobacco plants containing pBin TMV AtPPO1 V004 (mutant V365L Y426V L479N).

[0430]

[0431] Table 19: Results of the percentage of damage to tobacco plants containing pBin TMV AtPPO1 V036 (mutant S305L G404A Y426V T431R L479N).

[0432]

[0433] Table 20: Results of the percentage of damage to tobacco plants containing pBin TMV AtPPO1 V002 (mutant S305L Y426V L479M).

[0434]

[0435] Table 21: Results of the percentage of damage to tobacco plants containing pBin TMV AtPPO1 V030 (mutant S305L Y426V).

[0436]

[0437] Table 22: Results of the percentage of damage to tobacco plants containing pBin TMV AtPPO1 V052 (mutant S305L Y361D V365M).

[0438]

[0439] Table 23: Results of the percentage of damage to tobacco plants containing pBin TMV AtPPO1 V031 (mutant S305L Y361C Y362F Y426M L479M).

[0440]

[0441] Table 24: Results of the percentage of damage to tobacco plants containing pBin TMV AtPPO1 V018 (mutant S305L Y362F G404A).

[0442]

[0443] Example 6: Converting corn using AtPPO1 or SiPPO1 variants.

[0444] Transgenic maize lines expressing AtPPO1 and variants (SEQ ID NO:1 and 124-137) and SiPPO1 and variants (SEQ ID NO:2 and 138-151) were generated using methods known in the art.

[0445] Transformation of immature corn embryos was carried out essentially as described in the following literature: Negrotto et al. (Plant Cell Reports

[2000] 19: 798-803). In short, Agrobacterium strain LBA4404 (pSB1) containing expression vectors expressing the disclosed AtPPO1 and variants (SEQ ID NO: 1 and 124-137) and SiPPO1 and variants (SEQ ID NO: 2 and 138-151) was grown for 2–4 days at 28°C on YEP (yeast extract (5 g / L), peptone (10 g / L), NaCl (5 g / L), 15 g / L agar, pH 6.8) solid medium. Approximately 0.8 × 10⁻⁶ cells were grown. 9 One Agrobacterium spp. cell was suspended in LS-inf medium supplemented with 100 µM As. The bacteria were pre-induced in this medium for approximately 30–60 minutes.

[0446] Immature embryos from inbred corn lines were removed from 8-12 day old ears and placed in liquid LS-inf + 100 µMAs. These embryos were rinsed once with fresh infection medium. Agrobacterium solution was then added, and the embryos were vortexed for 30 seconds and allowed to settle with the bacteria for 5 minutes. The embryos were then transferred scutellum-upward to LSA medium and incubated in the dark for two to three days. Subsequently, approximately 20 to 25 embryos per petri plate were transferred to LSDc medium supplemented with cefotaxime (250 mg / L) and silver nitrate (1.6 mg / L) and incubated in the dark at approximately 28°C for 10 days.

[0447] Immature embryos producing embryogenic callus were transferred to LSD1M0.5S medium. Cultures were selected on this medium for approximately 6 weeks, followed by subculturing at about 3 weeks. Surviving callus tissue was transferred to Reg1 medium supplemented with mannose. After culturing under light (16-hour light / 8-hour dark), green tissue was transferred to Reg2 medium without growth regulators and incubated for approximately 1–2 weeks. These plantlets were then transferred to Magenta GA-7 boxes (Magenta Corp., Chicago, Illinois) containing Reg3 medium and grown under light. After approximately 2–3 weeks, the presence of the disclosed PPO gene in the plants was tested by PCR. Positive plants from the PCR assay were transferred to a greenhouse for further evaluation.

[0448] Plants were treated with herbicides that inhibit PPO to confirm herbicide resistance.

[0449] Example 7: Converting soybeans using AtPPO1 or SiPPO1 variants.

[0450] Transgenic soybean lines expressing AtPPO1 and variants (SEQ ID NO:1 and 124-137) and SiPPO1 and variants (SEQ ID NO:2 and 138-151) were produced.

[0451] Soybean plant material can be suitably transformed and fertile plants can be regenerated by a variety of methods well known to those skilled in the art. For example, fertile, morphologically normal transgenic soybean plants can be obtained by: 1) generating somatic embryogenic tissue from, for example, immature cotyledons, hypocotyls, or other suitable tissues; 2) transformation by particle bombardment or Agrobacterium infection; and 3) regenerating the plants. In one example, as described in U.S. Patent No. 5,024,944, cotyledonary tissue is removed from an immature embryo of soybean, optionally the hypocotyl is removed, and the material is cultured in a hormone-containing medium to form somatic embryogenic plant material. This material is transformed using, for example, direct DNA methods, DNA-coated micro-bullet bombardment, or Agrobacterium infection, cultured on a suitable selection medium, and optionally regenerated into fertile transgenic soybean plants in the continuous presence of a selector. The selector can be an antibiotic such as kanamycin, hygromycin, or a herbicide, or alternatively, selection can be based on the expression of a visible marker gene such as GUS. Target tissues for transformation include meristems, somatic clonal embryogenic tissues, and flowers or flower-forming tissues. Other examples of soybean transformation include physical DNA delivery methods, such as particle bombardment (see, for example, Finer & McMullen, In Vitro Cell Dev. Biol, 1991, 27P:175-182; McCabe et al., Bio / technology, 1998, 6:923-926), tentacles (Khalafalla et al., African J. of Biotechnology, 2006, 5:1594-1599), aerosol soybean injection (US Patent No. 7,001,754), or delivery methods mediated by Agrobacterium (Hinchee et al., Bio / Technology, 1988, 6:915-922; US Patent No. 7,002,058; US Patent Application Publications 20040034889 and 20080229447; Paz et al., Plant Cell). Report [Plant Cell Communications], 2006, 25:206-213).

[0452] Transgenic soybean plants can be produced using any available transformation method with binary vectors containing AtPPO1 and variants (SEQ ID NO: 1 and 124-137) or SiPPO1 and variants (SEQ ID NO: 2 and 138-151). Optionally, the PPO gene can provide a means of selecting and identifying transgenic tissues. For example, a vector can be used to transform immature seed targets to directly produce transgenic PPO soybean plants using a PPO inhibitor as a selector. The PPO gene can be present in polynucleotides alongside other sequences that provide additional means of selecting / identifying transformed tissues, including, for example, known genes providing resistance to kanamycin, hygromycin, glufosinate, flufenoxuron, or glyphosate. Different binary vectors containing PAT or EPSPS selective marker genes are known in the art (see, for example, U.S. Patent Application Publication No. 20080229447). Alternatively, the selective marker sequences can be present on separate polynucleotides and methods such as co-transformation or co-selection can be used. Scoring marker genes, such as GUS, can also be used to identify transformed tissues.

[0453] TO plants were removed from tissue culture and placed in a greenhouse. In the greenhouse, they were transplanted into 2" square pots with 5-10 g / gal soil into water-saturated soil mixed with 1% granular MARATHON® (Olympic Horticultural Products, Co., Mainland, Pennsylvania) in REDI-EARTH® Plug and Seedling Mix (Sun Gro Horticulture, Bellevue, Washington, or Fafard Germinating Mix). These plants were covered with a humidity dome and placed in a Conviron chamber (Pembina, North Dakota) with the following conditions: 24°C daytime; 20°C nighttime; photoperiod of 16-23 hours light to 1-8 hours dark; 80% relative humidity.

[0454] After the plants are established in the soil and new growth is observed (approximately 1-2 weeks), the plants are sampled and tested for the presence of the desired transgene using appropriate probes or promoters for the PPO gene via TAQMAN® analysis. Positive plants are transplanted into 4" square pots filled with Fafard #3 soil. Sierra 17-6-12 slow-release fertilizer is incorporated into the soil at the recommended ratio. These plants are then re-established in a standard greenhouse for acclimatization (approximately 1 week). The environmental conditions are: 27°C daytime; 21°C nighttime; 14-hour light period (with supplemental light); ambient humidity. After acclimatization (approximately 1 week), these plants are sampled and the presence and copy number of the inserted transgene are tested in detail. These transgenic soybean plants are grown to maturity for Tl seed production.

[0455] Tl plants were allowed to grow, and the presence of the PPO gene, as revealed by PCR testing, was confirmed. Positive plants from the PCR assay were then transferred to a greenhouse for further evaluation.

[0456] Following TAQMAN® analysis, homozygous plants were grown for seed production. Transgenic seeds and progeny plants were then used to further evaluate their herbicide tolerance and molecular characteristics.

[0457] Plants were treated with herbicides that inhibit PPO to confirm herbicide resistance.

[0458] Example 8: Producing transgenic maize and soybean plants expressing heterologous AtPPO1 and SiPPO1 variants

[0459] Corn and soybean were converted using the AtPPO1 and SiPPO1 variants disclosed herein using the conversion methods described in Examples 6 and 7.

[0460] At least six events / PPO1 variants shown in Tables 25 and 26 were selected to advance the T1 screening. For each event, 36–54 seeds were sown per event. On day 10 post-sowing, leaf tissue samples were taken from all successfully germinating seeds for TAQMAN® as described in Example 7, and their zygoticity was determined. Chi-square analysis was performed on all zygotic data to determine the segregation pattern for each event. The null hypothesis for the chi-square was set at a null ratio of 1:2:1 for the heterozygous: homozygous type. A p-value cutoff of <= 0.05 was used to reject the null hypothesis.

[0461] Table 25: PPO1 variants expressed in maize

[0462]

[0463] Table 26: PPO1 variants expressed in soybean

[0464] Table of Specific Implementation Methods

[0465] Table 27 - Modified PPO motifs

[0466] sequence

[0467] Arabidopsis thaliana PPO1 (containing a transport peptide) (SEQ ID NO:1)

[0468] MELSLLRPTTQSLLPSSKPNLRLNVYKPLRLRC SVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKL TDLPPFLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRM LPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSL FPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0469] Millet PPO1 (containing a transport peptide) (SEQ ID NO:2)

[0470] MVAAAMATAPSAGVPPLRGTRGPARFRIRGVSVRCAAVAGGAAEAPASAGARVSADCVVVGGGISGLCTAQALATKHGVGDVLVTEARARPGGNITTVERDPEGYLWEEGPNSFQPSDPVLTMAVDSGLKDDLVFGDPNAPRFVLWEGKLRPVPSKPADLPFDFDLMSIPGKLRAGFGIRPPPPGREESVEEFVRRNLGAEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWRLEEAGGSIIGGTIKTIQERGKNPKPPRDPRLPTPKGQTVASFRKGLAMLP NAITSSLGSKVKLSWKLTSITKSDGMGYVLVYETPEGVVSVQAKSVIMTIPSYVASDILRPLSSDAADALSRFYYPPVAAVTISYPKEAIRKECLIDGELQFGGQLHPRSQGVETLGTIYSSSLFPNRAPAGRVLLLNYIGGATNTGIVSKSASELVEAVDRDLRKMLINPSAVDPLVLGVRVWPQAIPQFLVGHLDLLEAAKSSLDRGGYDGLFLGGNYVAGVALGRCVEGAYESASQISDFLTKYAYK

[0471] pET24A AtPPO1(SEQ ID NO:3)

[0472]

[0473] (Contains transport peptides)

[0474] Arabidopsis thaliana PPO1 G64A (SEQ ID NO:4)

[0475] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGAGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0476] Arabidopsis thaliana PPO1 V88I (SEQ ID NO:5)

[0477] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIITEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0478] Arabidopsis thaliana PPO1 E111D (SEQ ID NO:6)

[0479] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEDGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0480] Arabidopsis thaliana PPO1 E111F (SEQ ID NO:7)

[0481] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEFGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0482] Arabidopsis thaliana PPO1 V127I (SEQ ID NO:8)

[0483] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVIDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0484] Arabidopsis thaliana PPO1 V127L (SEQ ID NO:9)

[0485] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVLDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0486] Arabidopsis thaliana PPO1 P154Y (SEQ ID NO:10)

[0487] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRYVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0488] Arabidopsis thaliana PPO1 K173H (SEQ ID NO:11)

[0489] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGHIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0490] Arabidopsis thaliana PPO1 A176L (SEQ ID NO:12)

[0491] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRLGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0492] Arabidopsis thaliana PPO1 V198W (SEQ ID NO:13)

[0493] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFWRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0494] Arabidopsis thaliana PPO1 V206G (SEQ ID NO:14)

[0495] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEGFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0496] Arabidopsis thaliana PPO1 F207Y (SEQ ID NO:15)

[0497] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVYERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0498] Arabidopsis thaliana PPO1 E212Y (SEQ ID NO:16)

[0499] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIYPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0500] Arabidopsis thaliana PPO1 F214Y (SEQ ID NO:17)

[0501] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPYCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0502] Arabidopsis thaliana PPO1 V218K (SEQ ID NO:18)

[0503] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGKYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0504] Arabidopsis thaliana PPO1 Y219S (SEQ ID NO:19)

[0505] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVSAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0506] Arabidopsis thaliana PPO1 A220C (SEQ ID NO:20)

[0507] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYCGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0508] Arabidopsis thaliana PPO1 P271C (SEQ ID NO:21)

[0509] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKCQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0510] Arabidopsis thaliana PPO1 Q272H (SEQ ID NO:22)

[0511] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPHGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0512] Arabidopsis thaliana PPO1 Q272I (SEQ ID NO:23)

[0513] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPIGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0514] Arabidopsis thaliana PPO1 Q272T (SEQ ID NO:24)

[0515] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPTGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0516] Arabidopsis thaliana PPO1 K281C (SEQ ID NO:25)

[0517] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRCGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0518] Arabidopsis thaliana PPO1 K281E (SEQ ID NO:26)

[0519] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFREGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0520] Arabidopsis thaliana PPO1 K281N (SEQ ID NO:27)

[0521] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRNGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0522] Arabidopsis thaliana PPO1 R284G (SEQ ID NO:28)

[0523] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLGMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0524] Arabidopsis thaliana PPO1 S305L (SEQ ID NO:29)

[0525] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLLGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0526] Arabidopsis thaliana PPO1 L360C (SEQ ID NO:30)

[0527] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKCYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0528] Arabidopsis thaliana PPO1 Y361D (SEQ ID NO:31)

[0529] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLDYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0530] Arabidopsis thaliana PPO1 Y361F (SEQ ID NO:32)

[0531] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLFYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0532] Arabidopsis thaliana PPO1 Y361P (SEQ ID NO:33)

[0533] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLPYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0534] Arabidopsis thaliana PPO1 Y361Q (SEQ ID NO:34)

[0535] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLQYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0536] Arabidopsis thaliana PPO1 Y361R (SEQ ID NO:35)

[0537] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYRPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0538] Arabidopsis thaliana PPO1 Y361T (SEQ ID NO:36)

[0539] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLTYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0540] Arabidopsis thaliana PPO1 Y362F (SEQ ID NO:37)

[0541] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYFPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0542] Arabidopsis thaliana PPO1 Y365L (SEQ ID NO:38)

[0543] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPLAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0544] Arabidopsis thaliana PPO1 Y365M (SEQ ID NO:39)

[0545] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPMAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0546] Arabidopsis thaliana PPO1 G404A (SEQ ID NO:40)

[0547] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLATIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0548] Arabidopsis thaliana PPO1 P413G (SEQ ID NO:41)

[0549] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFGNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0550] Arabidopsis thaliana PPO1 P418M (SEQ ID NO:42)

[0551] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPMGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0552] Arabidopsis thaliana PPO1 L424V (SEQ ID NO:43)

[0553] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLVNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0554] Arabidopsis thaliana PPO1 Y426C (SEQ ID NO:44)

[0555] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNCIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0556] Arabidopsis thaliana PPO1 Y426L (SEQ ID NO:45)

[0557] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNLIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0558] Arabidopsis thaliana PPO1 Y426M (SEQ ID NO:46)

[0559] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNMIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0560] Arabidopsis thaliana PPO1 Y426T (SEQ ID NO:47)

[0561] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNTIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0562] Arabidopsis thaliana PPO1 Y426V (SEQ ID NO:48)

[0563] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNVIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0564] Arabidopsis thaliana PPO1 T431R (SEQ ID NO:49)

[0565] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSRNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0566] Arabidopsis thaliana PPO1 V447C (SEQ ID NO:50)

[0567] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEACDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0568] Arabidopsis thaliana PPO1 V447I (SEQ ID NO:51)

[0569] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAIDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0570] Arabidopsis thaliana PPO1 D448H (SEQ ID NO:52)

[0571] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVHRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0572] Arabidopsis thaliana PPO1 D448L (SEQ ID NO:53)

[0573] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVLRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0574] Arabidopsis thaliana PPO1 D448N (SEQ ID NO:54)

[0575] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVNRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0576] Arabidopsis thaliana PPO1 R449K (SEQ ID NO:55)

[0577] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDKDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0578] Arabidopsis thaliana PPO1 T461Q (SEQ ID NO:56)

[0579] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSQDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0580] Arabidopsis thaliana PPO1 F478R (SEQ ID NO:57)

[0581] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQRLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0582] Arabidopsis thaliana PPO1 L479M (SEQ ID NO:58)

[0583] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFMVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0584] Arabidopsis thaliana PPO1 L479N (SEQ ID NO:59)

[0585] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFNVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRCVEGAYETAIEVNNFMSRYAYK

[0586] ​​​MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVANVALGRCVEGAYETAIEVNNFMSRYAYK

[0588] Arabidopsis thaliana PPO1 V511L (SEQ ID NO:61)

[0589] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGLALGRCVEGAYETAIEVNNFMSRYAYK

[0590] Arabidopsis thaliana PPO1 V511N (SEQ ID NO:62)

[0591] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGNALGRCVEGAYETAIEVNNFMSRYAYK

[0592] Arabidopsis thaliana PPO1 C516Q (SEQ ID NO:63)

[0593] MELSLLRPTTQSLLPSFSKPNLRLNVYKPLRLRCSVAGGPTVGSSKIEGGGGTTITTDCVIVGGGISGLCIAQALATKHPDAAPNLIVTEAKDRVGGNIITREENGFLWEEGPNSFQPSDPMLTMVVDSGLKDDLVLGDPTAPRFVLWNGKLRPVPSKLTDLPFFDLMSIGGKIRAGFGALGIRPSPPGREESVEEFVRRNLGDEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWKLEQNGGSIIGGTFKAIQERKNAPKAERDPRLPKPQGQTVGSFRKGLRMLPEAISARLGSKVKLSWKLSGITKLESGGYNLTYETPDGLVSVQSKSVVMTVPSHVASGLLRPLSESAANALSKLYYPPVAAVSISYPKEAIRTECLIDGELKGFGQLHPRTQGVETLGTIYSSSLFPNRAPPGRILLLNYIGGSTNTGILSKSEGELVEAVDRDLRKMLIKPNSTDPLKLGVRVWPQAIPQFLVGHFDILDTAKSSLTSSGYEGLFLGGNYVAGVALGRQVEGAYETAIEVNNFMSRYAYK

[0594] Foxtail millet PPO1 G62A (SEQ ID NO:64)

[0595] MVAAAMATAPSAGVPPLRGTRGPARFRIRGVSVRCAAVAGGAAEAPASAGARVSADCVVVGAGISGLCTAQALATKHGVGDVLVTEARARPGGNITTVERPDEGYLWEEGPNSFQPSDPVLTMAVDSGLKDDLVFGDPNAPRFVLWEGKLRPVPSKPADLPFFDLMSIPGKLRAGFGALGIRPPPPGREESVEEFVRRNLGAEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWRLEEAGGSIIGGTIKTIQERGKNPKPPRDPRLPTPKGQTVASFRKGLAMLPNAITSSLGSKVKLSWKLTSITKSDGMGYVLVYETPEGVVSVQAKSVIMTIPSYVASDILRPLSSDAADALSRFYYPPVAAVTISYPKEAIRKECLIDGELQGFGQLHPRSQGVETLGTIYSSSLFPNRAPAGRVLLLNYIGGATNTGIVSKSASELVEAVDRDLRKMLINPSAVDPLVLGVRVWPQAIPQFLVGHLDLLEAAKSSLDRGGYDGLFLGGNYVAGVALGRCVEGAYESASQISDFLTKYAYK

[0596] Foxtail millet PPO1 V84I (SEQ ID NO:65)

[0597] MVAAAMATAPSAGVPPLRGTRGPARFRIRGVSVRCAAVAGGAAEAPASAGARVSADCVVVGGGISGLCTAQALATKHGVGDVLITEARARPGGNITTVERPDEGYLWEEGPNSFQPSDPVLTMAVDSGLKDDLVFGDPNAPRFVLWEGKLRPVPSKPADLPFFDLMSIPGKLRAGFGALGIRPPPPGREESVEEFVRRNLGAEVFERLIEPFCSGVYAGDPSKLSMKAAFGKVWRLEEAGGSIIGGTIKTIQERGKNPKPPRDPRLPTPKGQTVASFRKGLAMLPNAITSSLGSKVKLSWKLTSITKSDGMGYVLVYETPEGVVSVQAKSVIMTIPSYVASDILRPLSSDAADALSRFYYPPVAAVTISYPKEAIRKECLIDGELQGFGQLHPRSQGVETLGTIYSSSLFPNRAPAGRVLLLNYIGGATNTGIVSKSASELVEAVDRDLRKMLINPSAVDPLVLGVRVWPQAIPQFLVGHLDLLEAAKSSLDRGGYDGLFLGGNYVAGVALGRCVEGAYESASQISDFLTKYAYK<0001——324><0001——325><0001——326>Foxtail millet PPO1 E109D (SEQ ID NO:66)<0001——327><0001——328> It should be noted that the tags , ,

[0598] , ,

[0599] seem to be in a ...

Claims

1. A modified protoporphyrinogen oxidase (PPO) or a functional fragment thereof, wherein the modified protoporphyrinogen oxidase or the functional fragment thereof contains at least one mutation at one or more amino acid residues selected from residues 479, 365 and / or 362 or their corresponding residues selected from SEQ ID NO:

1.

2. The modified PPO enzyme or its functional fragment according to claim 1, wherein the modified protoporphyrinogen oxidase or its functional fragment comprises the following motif: (G / P / S); (D / K / N / R / S / T); (A / S); (A / E / G / K / Q / V / T); (D / E); P; (F / L / R / S); (A / T / V / K); (L / T / V); (G / S); V; (K / R); V; W; (P / R); (K / Q / R); A; I; P; Q; F; (M / N); (I / V); G (SEQ ID NO:354); or AIPQF[M / N][I / V]G (SEQ ID NO: 356).

3. The modified PPO enzyme or its functional fragment according to claim 1 or 2, wherein the modified PPO enzyme or its functional fragment comprises a combination of mutations at the following residues: (a) 365, 426 and 479 of SEQ ID NO:1, or the corresponding residues thereof; optionally, said mutation comprises a substitution of 365L, 426V and 479N of SEQ ID NO:1, or the corresponding substitutions thereof; (b) 305, 426, and 479 of SEQ ID NO:1, or their corresponding residues; optionally, said mutation comprises a substitution of 305L, 426V, and 479M of SEQ ID NO:1, or their corresponding substitutions; or (c) 305, 361, 362, 426 and 479 of SEQ ID NO:1, or their corresponding residues; optionally, said mutation comprises a substitution of 305L, 361C, 362F, 426M and 479M of SEQ ID NO:1, or their corresponding substitution.

4. The modified PPO enzyme or its functional fragment according to any one of claims 1 to 3, wherein the modified PPO enzyme or its functional fragment comprises an amino acid sequence having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 98%, or at least 99% sequence identity: SEQ ID NO: any one of 58, 59, 126, 127, 130, 131, 132, 134, 136, 137, 209, 210, 277, 278, 281, 282, 283, 285, 287, 288, 118, 119, 140, 141, 144, 145, 146, 148, 150, 151, 269, 270, 291, 292, 295, 296, 297, 299, 301, or 302; or Any one of SEQ ID NO 126, 131, 134, 140, 145, 148, 277, 282, 285, 291, 296 or 299.

5. A modified protoporphyrinogen oxidase (PPO) or a functional fragment thereof, wherein the modified protoporphyrinogen oxidase or the functional fragment thereof comprises a mutation at amino acid residues 305 and 426 of SEQ ID NO:1 or their corresponding residues, wherein the mutation is a substitution of 305L and 426V.

6. The modified PPO enzyme or its functional fragment according to any one of claims 1 to 5, wherein the modified PPO enzyme or its functional fragment is a PPO1 enzyme; optionally, The modified PPO enzyme or its functional fragment exhibits increased resistance to compounds that inhibit PPO enzyme relative to the control PPO enzyme and / or a decreased percentage of inhibition relative to the control PPO enzyme in response to compounds that inhibit PPO enzyme; further optionally... The increased resistance to the compound includes an increase of at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 times compared to an unmodified reference plant or its parts; further optionally... The control PPO enzyme is either an unmodified PPO enzyme or a modified PPO enzyme according to SEQ ID NO:

124.

7. The modified PPO enzyme or its functional fragment according to any one of claims 1, 5, and 6, wherein the modified PPO enzyme or its functional fragment comprises: (a) An amino acid sequence having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 1, and at least one mutation at one or more amino acid residues selected from residues 362, 365, and / or 479 of SEQ ID NO: 1 or their corresponding residues; or (b) An amino acid sequence having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 2, and at least one mutation at one or more amino acid residues selected from residues 360, 363, and / or 477 of SEQ ID NO: 2 or their corresponding residues; or (c) An amino acid sequence having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 153, and at least one mutation at one or more amino acid residues selected from residues 328, 331, and / or 445 of SEQ ID NO: 153 or their corresponding residues; or (d) An amino acid sequence having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 154, and at least one mutation at one or more amino acid residues selected from residues 325, 328, and / or 442 of SEQ ID NO: 154 or their corresponding residues.

8. The modified PPO enzyme or a functional fragment thereof as described in any one of the following claims: (i) any one of claims 1, 6, and 7, wherein the modified PPO enzyme or a functional fragment thereof further comprises one or more additional mutations at one or more amino acid residues selected from residues 305, 361, 404, 426, 431, and / or 461 or their corresponding residues selected from SEQ ID NO: 1; or (ii) any one of claims 5 to 7, wherein the modified PPO enzyme or a functional fragment thereof further comprises one or more additional mutations at one or more amino acid residues selected from residues 361, 362, 365, 404, 431, 461 and / or 479 or their corresponding residues selected from SEQ ID NO: 1; optionally, in: (a) The mutation at residue 305 of SEQ ID NO: 1 or at its corresponding residue contains a substitution to leucine; (b) The mutation at residue 361 of SEQ ID NO: 1 or at its corresponding residue contains a substitution to cysteine, aspartic acid, glutamine or threonine; (c) The mutation at residue 404 of SEQ ID NO: 1 or at its corresponding residue involves a substitution to alanine; (d) The mutation at residue 426 of SEQ ID NO: 1 or its corresponding residue contains a substitution of leucine, cysteine, methionine, threonine or valine. (e) A mutation at residue 431 of SEQ ID NO: 1 or its corresponding residue involves a substitution to alanine, phenylalanine, or arginine; and / or (f) The mutation at residue 461 of SEQ ID NO: 1 or at its corresponding residue contains a substitution to glutamine.

9. The modified PPO enzyme or a functional fragment thereof as described in any one of the following claims: (i) any one of claims 1 and 6 to 7 and claim 8 (i), wherein (a) The mutation at residue 362 of SEQ ID NO: 1 or at the residue corresponding thereto contains a substitution to cysteine ​​or phenylalanine; (b) The mutation at residue 365 of SEQ ID NO: 1 or its corresponding residue comprises a substitution to methionine or leucine; and / or (c) The mutation at residue 479 of SEQ ID NO: 1 or its corresponding residue comprises a substitution to methionine or asparagine; or (ii) Claim 8 (ii), wherein: (a) The mutation at residue 362 of SEQ ID NO: 1 or the residue thereon contains a substitution to cysteine ​​or phenylalanine; (b) The mutation at residue 365 of SEQ ID NO: 1 or its corresponding residue comprises a substitution to methionine or leucine; and / or (c) The mutation at residue 479 of SEQ ID NO: 1 or its corresponding residue comprises a substitution to methionine or asparagine.

10. The modified PPO enzyme or functional fragment thereof according to any one of claims 1 to 9, wherein the modified PPO enzyme or functional fragment thereof comprises a combination of mutations at the following residues: (a) 365, 426 and 479 of SEQ ID NO:1, or their corresponding residues; (b) SEQ ID NO:1 residues 305, 404, 426, 431 and 479, or their corresponding residues; (c) 305 and 365 of SEQ ID NO:1, or their corresponding residues; (d) SEQ ID NO:1 residues 305, 362 and 404, or their corresponding residues; (e) SEQ ID NO:1 residues 305, 361, 365, 431 and 479, or their corresponding residues; (f) SEQ ID NO:1 residues 305, 426 and 479, or their corresponding residues; (g) SEQ ID NO:1 residues 426, 461 and 479, or their corresponding residues; (h) SEQ ID NO:1 305, 361 and 365, or their corresponding residues; (i) residues 305, 361, 362, 426 and 479 of SEQ ID NO:1, or their corresponding residues; (j) 361 and 365 of SEQ ID NO:1, or their corresponding residues; (k) residues 365, 404, and 479 of SEQ ID NO:1, or their corresponding residues; or (l) SEQ ID NO:1, residues 305, 404 and 479, or their corresponding residues.

11. The modified PPO enzyme or a functional fragment thereof as described in any one of the following claims: (a) Any one of claims 1 and 6 to 10, wherein the modified PPO enzyme or a functional fragment thereof comprises or consists of a sequence according to SEQ ID NO: 188-190, 209, 210, 248-250, 269, 270, 277-288 or 291-302; or (b) Any one of claims 5 to 10, wherein the modified PPO enzyme or a functional fragment thereof comprises or consists of the sequence according to SEQ ID NO: 276 or 290.

12. The modified PPO enzyme or a functional fragment thereof according to any one of claims 1 and 6 to 11 or claims 5 to 11, wherein the modified PPO enzyme further comprises a transport peptide; optionally, The transport peptides described herein comprise mitochondrial transport peptides and / or chloroplast transport peptides; further optionally... The modified PPO enzyme comprises a sequence having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 98%, or at least 99% sequence identity with any of the sequences according to SEQ ID NO: 1, 2, 4-151 or 305-320. Further optionally, the modified PPO enzyme comprises or consists of a sequence according to SEQ ID NO: 37-39, 58, 59, 97-99, 118, 119, 125-137 or 139-151.

13. A nucleic acid comprising a polynucleotide encoding a functional fragment of a modified PPO enzyme according to any of the preceding claims; or A recombinant vector comprising the nucleic acid.

14. A plant or a part thereof, said plant or part thereof comprising a modified PPO enzyme or a functional fragment thereof according to any one of claims 1 to 12, or a nucleic acid or recombinant vector according to claim 13; optionally, The plant or its parts thereof exhibit increased resistance to compounds that inhibit PPO enzymes relative to control plants and / or a decreased percentage of inhibition relative to control plants in response to compounds that inhibit PPO enzymes; further optionally The control plants are either wild-type plants or plants containing the modified PPO enzyme according to SEQ ID NO:

124.

15. A method for producing the plant or a portion thereof according to claim 14, the method comprising: Modify the plant or a portion thereof to include the PPO enzyme according to any one of claims 1 to 12; Optionally, modifying the plant or a portion thereof includes transforming the plant or a portion thereof with a nucleic acid or recombinant vector according to claim 10.

16. A method for controlling unwanted vegetation in the vicinity of a plant or a portion thereof, or at the site of growth of said plant or a portion thereof, the method comprising applying an effective amount of at least one PPO-inhibiting herbicide to the vicinity of the plant, at the site of growth of said plant, or to the plant or a portion thereof, wherein said plant or a portion thereof comprises the plant or a portion thereof according to claim 14, wherein said effective amount of said PPO-inhibiting herbicide controls unwanted vegetation in the vicinity or at the site.

17. Use of a compound that inhibits PPO enzyme in combination with the plant or a portion thereof as described in claim 14.

18. The modified PPO enzyme according to any one of claims 6 to 12, the plant or part thereof according to claim 14, or the method for controlling undesirable vegetation according to claim 16, or the use according to claim 17, wherein the compound is a herbicide selected from the group consisting of: flupyribac-methyl, cyprodinil, cyclopyridaben, flupyribac-methyl (herbicide A), flupyribac-methyl, propyzoxystrobin, flusulfanilamide, ethoxyfluazuron, pyrazosulfuron, pyrazosulfuron (herbicide E), mesotrione, flupyribac-methyl, trifluralin (herbicide B); 3-(2-chloro-4-fluoro-5-(3-methyl-2,6-dioxo-4-trifluoromethyl) Ethyl 2-[[3-[[3-chloro-5-fluoro-6-[3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]-2-pyridyl]oxy]ethyl acetate; (5S)-3-[2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thio-1,3,5-triazin-1-yl)-4-fluoro-phenyl]-5-methyl-4H-isooxazol-5-carboxylate (herbicide D); pyridin-2-ylmethyl-[(3-(2-chloro-4-fluoro-5-[3-methyl- 2,6-Dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenoxy)pyridin-2-yl)oxy]acetate, 2-methoxyethyl-[(3-(2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenoxy)pyridin-2-yl)oxy]acetate, 2-methoxyethyl-[(3-(2-cyano-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydro-pyrimidin-1(2H)-yl]phenoxy)pyridin-2-yl)oxy]acetate and cyanomethyl-[(3-(2-) -bromo-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenoxy)pyridin-2-yl)oxy]acetate; 3-[2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1(2H)-pyrimidinyl]-4-fluorophenyl]-3a,4,5,6-tetrahydro-6-methyl-6aH-cyclopentane[d]isoxazole-6a-carboxylic acid methyl ester; 2-[2-[2-bromo-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy]phenoxy]-2-methoxy-acetic acid methyl ester;(2-ethoxy-2-oxo-ethyl)1-[2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy]cyclopropane carbamate, enantiomers of said compounds (including mixtures rich in enantiomers), and / or their agrochemically acceptable salts and / or esters.

Citation Information

Patent Citations

  • Plant cells resistant to glutamine synthetase inhibitors, made by genetic engineering

    EP0242246A1

  • HPPD variants and methods of use

    EP2453012A1

  • Enhanced disease resistance of maize to northern corn leaf blight by a QTL on chromosome 4

    EP3839073A1

  • Herbicide tolerance genes and methods of use thereof

    US10023874B2

  • Plants having increased tolerance to herbicides

    US10100329B2